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SUMMARY
1. Two cyclic nucleotide phosphodiesterase (PDE) activities were 
identified in pig aortic endothelial cell (PAEC) homogenates , a 
cyclic GMP- stimulated PDE (Type II) which hydrolyses both cyclic 
AMP and cyclic GMP and a cyclic AMP- specific PDE (Type IV). The 
role of these PDE isozymes pres e n t  in PAEC was evaluated by 
examining the effects of selective PDE inhibitors on cyclic AMP 
and cyclic GMP content.
2. Inhibitors of the calcium/ calmodulin- dependent PDE (Type I) 
and of the cyclic GMP- inhibited PDE (Type III), M & B 22948 and 
SK & F 94120, respectively, only weakly inhibited the two PDE 
isozymes. In contrast, dipyridamole and trequinsin, two non- 
selective PDE inhibitors, p o t e n t l y  inhibited both isozymes, 
whereas rolipram, selectively inhibited the cyclic AMP- specific 
PDE .
3. Incubation of intact cells with the non- selective PDE inhibi­
tors , dipyridamole (25pM) and trequinsin (25pM), induced large 
i n c r eases in i n t r a c e l l u l a r  c y c l i c  GMP content, w h i c h  were 
completely blocked by the addition of haemoglobin (lOpM). The 
selective cyclic AMP PDE inhibitor, rolipram (25pM), was without 
effect on the cyclic GMP content.
4. D i p y r i d a m o l e  (25pM) e n h a n c e d  the increase in cyclic GMP 
content induced by the nitrovasodilator and stimulant of soluble 
guanylate cyclase, sodium nitroprusside (lpM).
5. Atriopeptin II (0.1-100nM), which activates particulate guany­
late cyclase, i n c r e a s e d  the c y c l i c  GMP c o n t e n t  in a 
c o n c e n t r a t i o n -  d e p e n d e n t  m anner. D i p y r i d a m o l e  (25pM) and 
trequinsin (25pM), but not rolipram (25pM), enhanced the increase
ii
in cyclic GMP content induced by atriopeptin II (lOnM).
6. The non- selective PDE inhibitor, d i p y r i d a m o l e  increased 
cyclic AMP content at lOOpM but not at 25pM. The selective cyclic 
AMP PDE inhibitor, rolipram (25pM) induced, a large increase in 
cyclic AMP content.
7. Dipyridamole (25pM and lOOpM) enhanced the increase in cyclic 
AMP c o n t e n t  s t i m u l a t e d  by the p- a d r e n o c e p t o r  agonist, 
isoprenaline (25pM), or the a c t i v a t o r  of adenylate cyclase, 
forskolin (lOpM). Furthermore, rolipram (25pM) enhanced the 
increase in cyclic AMP content induced by forskolin (30pM).
8. These results suggest that the cyclic GMP- stimulated PDE 
present in PAEC regulates the cyclic GMP content and the cyclic 
AMP PDE regulates the cyclic AMP c o n t e n t . Whether or not the 
cyclic GMP- stimulated PDE also contributes to the regulation of 
the cyclic AMP content could not be determined.
9. The effects of stimulation of protein kinase C and of cyclic 
nucleotides on proliferation of PAEC in culture was investigated.
10. Phorbol 12- myristate 13- acetate (P M A . O.lnM-lpM), which 
activates protein kinase C, inhibited proliferation in a concen­
tration- dependent manner. No early stimulation of proliferation 
was seen with PMA (0.3pM). The inactive phorbol ester, 4a- phor­
bol- 12,13- didecanoate (0.3pM), lacked the ability of PMA to 
inhibit proliferation of PAEC.
11. S t a u r o s p o r i n e  (lOnM and lOOnM) inhibited serum- induced 
proliferation of PAEC but had no effect on the antiproliferative 
effects of PMA (0.3pM).
12. PMA- induced inhibition of proliferation appeared not to be
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due to stimulated production of destructive oxygen- derived free 
radicals since it was u n a f f e c t e d  by the radical scavangers, 
superoxide dismutase (30 units/ ml) and catalase (30 units/ ml), 
vitamin E (30pM), or butylated hydroxytoluene (30pM). The anti­
proliferative actions of paraquat (lOpM), an agent which gener­
ates free radicals intracellularly, was, in contrast, inhibited 
by vitamin E (30pM) or butylated hydroxytoluene (30pM) but not by 
the extracellular radical scavangers, superoxide dismutase (30 
units/ ml) and catalase (30 units/ ml).
13. Neither dibutyryl cyclic AMP (30pM), nor 8 bromo cyclic GMP 
(30pM) had any effect on the ability of PMA (0.3pM) to inhibit 
proliferation of PAEC.
14. Dibutyryl cyclic AMP (30pM) inhibited proliferation, but 8 
bromo cyclic GMP (30pM) had no effect. Four other stimuli known 
to increase PAEC cyclic GMP content by stimulating particulate or 
soluble guanylate cyclase, atriopeptin II (lOnM), bradykinin 
(O.lpM), sodium n i t r o p r u s s i d e  (lpM) and glyceryl trinitrate 
(lpM), were also without effect on proliferation.
15 . Two agents known to inhibit soluble guanylate cyclase and 
lower intracellular cyclic GMP content, haemoglobin (lOpM) and 
methylene blue (lOpM), each inhibited proliferation of PAEC.
16. The inhibitory effect of haemoglobin (lOpM) was mediated by 
inhibition of soluble guanylate cyclase since it was reversed by 
agents known to increase cyclic GMP content i.e. atriopeptin II 
(lOnM), 8 bromo cyclic GMP (30pM) and sodium nitroprusside (lpM). 
The inhibitory effect of methylene blue (lOpM) was not reversed 
by these agents.
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17. L- NMMA (300pM), which blocks the synthesis of nitric oxide 
by inhibiting nitric oxide synthase, inhibited proliferation of 
PAEC. This appeared to be a non- specific effect, however, since 
the inactive D- enantiomer, D- NMMA (300pM) also inhibited 
proliferation.
18. The non- selective PDE inhibitor, dipyridamole (25pM), inhib­
ited p r o l i f e r a t i o n  of PAEC. The a n t i p r o l i f e r a t i v e  effect of 
d i pyridamole was not b l o c k e d  by the addition of haemoglobin 
(lOpM) and therefore probably resulted from elevation of cyclic 
AMP and not cyclic GMP content.
19. These results suggest that protein kinase C, cyclic AMP and 
cyclic GMP have powerful effects on the proliferation of PAEC.
20. The role of protein kinase C and cyclic nucleotides in con­
trolling the proliferation of rat aortic smooth muscle cells (rat 
A S M C ) in culture was investigated.
21. Serum (2-20%) s t i m u l a t e d  p r o l i f e r a t i o n  of rat ASMC in a 
concentration- dependent manner.
22. PMA (0.3pM), which activates protein kinase C, had no effect 
on the p r o l i f e r a t i o n  of rat ASMC grown in a range of serum 
concentrations (4-20%).
23. Phenylephrine (O.lpM-lmM), a x- adrenoceptor agonist, stimu­
lated proliferation in a concentration- dependent manner, whereas 
the selective - and p 2- a d r e n o c e p t o r  agonist, dobutamine 
(lOpM) and salbutamol (lOpM), respectively, inhibited prolifera­
tion .
24.Dibutyryl cyclic AMP (30pM-lmM) inhibited proliferation in a
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concentration- dependent manner. Furthermore, forskolin (lpM- 
lOOpM), which activates adenylate cyclase, inhibited prolifera­
tion in a concentration- dependent manner. The inactive isomer, 
dideoxy forskolin (lpM-30pM), lacked the ability of forskolin to 
inhibit proliferation of rat ASMC.
25. Forskolin- induced inhibiton of proliferation appeared to be 
media t e d  via an increase in cyclic AMP content since it was 
potentiated by the selective cyclic AMP PDE inhibitor, rolipram 
(3 0pM).
26. Histamine (lpM-lmM) inhibited proliferation in a concentra­
tion- dependent manner. The histamine (lOpM)- induced inhibition 
of proliferation appeared to be mediated via H 2~ receptors since 
the H 2- antagonist, cimetidine (lOpM), blocked its antiprolifera­
tive effects.
27. 8 bromo cyclic GMP (I m M ), glyceryl trin i t r a t e  (ImM) and 
sodium nitroprussside (0.ImM-ImM) inhibited proliferation of rat 
ASMC in a c o n c e n t r a t i o n -  d e p e n d e n t  manner. In contrast, 
atriopeptin II (O.lpM) had no effect on proliferation.
28. The sodium nitroprusside- induced inhibiton of proliferation 
appeared to be mediated by a mechanism independent of the activa­
tion of soluble guanylate cyclase, since haemoglobin (20pM) was 
w i t h o u t  effect. F u r t h e r m o r e ,  M & B 22948 (30pM) f a i l e d  to 
potentiate the antiproliferative effect of sodium nitroprusside 
(O.lmM-lmM). It is likely that the inhibition of proliferation 
resulted from a cytotoxic actions since sodium nitroprusside 
(O.lmM-lmM) stimulated uptake of trypan blue.
29. The inhibitory effect of sodium nitroprusside (O.lmM-lmM) was 
not mediated through the production of cyanide since
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me t h a e m o g l o b i n  (5pM), w h ich binds cyanide avidly, failed to 
reverse the antiproliferative effect.
30. These results suggest that cyclic AMP powerfully inhibits the 
p r o l i f e r a t i o n  of rat ASMC. This inhibition of pr o l i f e r a t i o n  
induced by n i t r o v a s o d i l a t o r s  appears to reflect a cytotoxic 
action w h i c h  oc c u r s  i n d e p e n d e n t l y  of g u a n y l a t e  cycl a s e  
stimulation.
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INTRODUCTION
.1. VASCULAR CELL BIOLOGY
dentification of the hormonal factors and intracellular pathways 
hat control the migration and proliferation of vascular endothe- 
ial and smooth muscle cells is important since dysfunction of 
oth cell types is observed in several cardiovascular diseases 
Hansson & Bonjers, 1986; Nilsson, 1986; Ross, 1986b; Schwartz et 
1. , 1986). A example of such a disease is atherosclerosis.
.2. ATHEROSCLEROSIS
he term atherosclerosis was originally devised to describe a 
egenerative process involving the progressive hardening of the 
lood vessel wall. Today's description of this disease is more 
omplex: a fatty streak is observed to be present in the early
evelopment of atherosclerosis. Furthermore, these lesions are 
onsidered to be the precursor for the more advanced state of 
his disease. The fatty streak is characterized by the presence 
f smooth muscle cells, T- lymphocytes and macrophages. These 
ells are located at a subendothelial level upon an extracellular 
atrix composed of lipids, collagen, elastin and proteoglycans, 
he predominant cell type found here is the macrophage which 
eadily accumulates lipids and takes on the appearance of foam 
ells .
he fibrous plaque represents the more advanced state of the 
isease. These plaques are found to have a cellular core 
ontaining smooth muscle cells, macrophages and T- lymphocytes, 
hich is capped by a layer of smooth muscle cells, macrophages 
nd T- lymphocytes in a dense m atrix of connective tissue, 
urther d e g e n e r a t i o n  of the plaque can occur as the disease 
rogresses and this includes calcification and ulceration (Bocun
1
et a l . , 1986; Small, 1986; Munro et al., 1987; Munro & Cotran,
1988).
1.2.1. Pathogenesis of atherosclerosis
In 1976, Ross & Glomset proposed the 'response-to-injury' model 
which stated that injury (mechanical, LDL, homocysteine, immuno­
logical) to and subsequent denudation of the endothelium was the 
initiating event for the disease. Injury to the endothelium may 
involve the loss of either individual cells or in extreme damage, 
loss of large areas of the endothelium. The endothelial cells 
respond by either spreading, or by the proliferation and migra­
tion of neighbouring endothelial cells to re- endothelialize the 
denuded area.
formally the e n d o t h e l i u m  is an intact m o n o l a y e r  w h i c h  is 
lonthrombogenic and secretes various antithrombotic substances, 
Eor example, e n d o t h e l i u m -  d e r i v e d  r e l a x i n g  f a c t o r  and 
prostacyclin, which prevent the adhesion of platelets to the 
arterial wall. Damage to the endothelial cell monolayer may 
promote the adhesion and aggregation of platelets to the arterial 
fall thereby allowing the platelets to release the contents of 
iheir a- granules. This includes several factors which are chemo- 
:actic and mitogenic for the underlying smooth muscle cells.
lodification of this earlier 'response-to-injury' model is neces­
sary since several studies have indicated that endothelial denu- 
lation or platelet adhesion is neither necessary nor sufficient 
:o explain a t h e r o s c l e r o s i s  (Schwartz & Reidy, 1987; Munro & 
'otran, 1988; Hansson & Bondjers, 1986). Recently, the involve­
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ment of other cells of the immune system, in particular mono­
cytes/ macrophages has been proposed (reviewed in Hansson et a l .,
1989) .
The revised hypothesis is that formation of the fatty streak and 
the more advanced fibrous plaque can occur via two pathways: the 
first h i g h l i g h t e d  in m o d e l s  of e x p e r i m e n t a l l y  indu c e d  
hypercholesterolemia. In animals which have been fed a high fat 
diet it was demonstrated that alterations in the viscosity of the 
plasma m e m b r a n e  o ccurs . This i n c r e a s e s  the a t t a c h m e n t  of 
monocytes to the endothelium (Alderson et a l ., 1986). Further­
more, macrophages enhance this process of adhesion of monocytes 
to the arterial wall by the localised release of interleukin-1 
(Bevilacqua et a l . , 1985 ). After attachment, these cells move
between the endothelial cells and become localized in the suben­
dothelium. This is obser v e d  to be the earliest event in the 
formation of a fatty streak. The monocytes become activated and 
secrete numerous chemoattractants and mitogens, such as trans­
forming growth factor p, tumour necrosis factor a and interleu- 
kin-1, which maybe sufficient for stimulation of smooth muscle 
accumulation in the arterial intima (Libby et a l . , 1988; Raines
at a l ., 1989; Majack et a l ., 1990). The opportunity for platelets 
zo attach to the endothelium increases thereby allowing the loca­
lised release of the contents of the a- granules. Furthermore, it 
las been shown that macrophages can damage neighbouring endothe- 
Lial cells by the formation of toxic free radicals. Thus, en- 
lothelial injury could result from any or all of three sources, 
lamely, the endothelial cells themselves, macrophages or plate­
lets .
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The second revised hypothesis for development of atherosclerosis 
involves stimulation of the endothelium to release growth fac­
tors. This too is an example of a non- denud i n g  injury. The 
release of these factors induces smooth muscle migration and 
proliferation, and further growth factor release by the stimu­
lated smooth muscle cells themselves. Figure 1 describes the 
development of an advanced intimal lesion of atherosclerosis by 
the different pathways outlined above.
1.2.2. P r o d u c t i o n  of growth factors by cells implicated in 
atherosclerosis
There is a multidude of different growth promoting and growth 
inhibitory factors secreted by the various cell types present in 
the atherosclerotic lesion (endothelial cells, smooth muscle 
cells, monocytes-macrophages and platelets) (Bowen-Pope et a l . , 
1985; Ross, 1986a; Klagburn & Edelman, 1989). The effects of 
these growth factors upon the cells located within the arterial 
wall is important in the development of atherosclerosis. Table 1 
summarizes only four of these growth factors secreted by the 
different cell types: platelet- derived growth factor, fibroblast 
growth factor, transforming growth factor p and epidermal growth 
factor. All of these growth factors are present in serum. Fibro­
blast growth factor is the primary mitogen responsible for the 
migration and proliferation of endothelial cells whereas all four 
of the growth factors have been observed to be mitogenic for 
smooth muscle cells in culture.
The following introductory chapters will discuss the effect of 
these growth factors upon the migration and proliferation of
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"Injury"
(mechanical, LDL,
homocysteine,
immunological)
/
Figure 1: S c h e m a t i c  d i a g r a m  of the R e s p o n s e s  to I n j u r y
Hypothesis. Advanced intimal lesions of atherosclerosis may occur 
by at least two p a t h w a y s . Th e  p a t h w a y  d e m o n s t r a t e d  by the 
clockwise arrows to the right has been observed in experimentally 
induced hypercholesterolemia. Injury to the endothelium (A) may 
induce growth factor release (short arrow). Monocytes attach to 
endothelium (B) and release growth factors. Subendothelial cell 
migration of monocytes (C) occurs and this leads to the formation 
of the fatty streak and release of growth factors such as PDGF 
(short arrow). The appearance of fibrous plaque occurs through 
the release of growth factors from macrophages or endothelial 
cells or both (long arrow from C to F). M a c r o p h a g e s  m a y  also 
stimulate or injure surrounding endothelial cells. The loss of 
endothelial cells a l l o w s  the a t t a c h m e n t  of p l a t e l e t s  to the 
arterial wall (D). This allows the localised release of growth 
factors from platelets. Some of the smooth muscle cells in the 
lesion (F) m a y  r e l e a s e  g r o w t h  f a c t o r s  s u c h  as P D G F  ( s h o r t 
arrows). An alternative pathway for the development of advanced 
lesions of atherosclerosis is shown by the arrows from A to E to 
F. In this case, the e n d o t h e l i u m  m a y  be i n j u r e d  but r e m a i n s  
intact. Increased proliferation of endothelial cells may result 
in i n c r e a s e d  g r o w t h  f a c t o r  r e l e a s e  by the e n d o t h e l i a l  cells 
them s e l v e s  (A). T h i s  m a y  s t i m u l a t e  the m i g r a t i o n  an d  
proliferation of the u n d e r l y i n g  smooth mu s c l e  cells from the 
media into the intimal. This is accompanied by the endogenous 
p r o d u c t i o n  of P D G F  by the s m o o t h  m u s c l e  c e l l s  (E) . T h e s e  
interactions could then lead to the for m a t i o n  of the fibrous 
plaque and f u r t h e r  l e s i o n  p r o g r e s s i o n  (F). This d i a g r a m  is 
reproduced from New Eng. J. Med., 314, 488-500, 1986.
vascular cells. T h e y  w i l l  a l s o  h i g h l i g h t  the i n t r a c e l l u l a r  
messengers and pathways that are utilised to commit these cells 
to intiate DNA synthesis.
Table 1: Production of growth factors by cells associated with 
atherosclerosis.
CELL PDGF FGF TGFft EGF
Platelets + - + +
Monocytes-Macrophages + + + +
Endothelial cells + + + +
Smooth muscle cells + + + -
1.3. PLATELET- DERIVED GROWTH FACTOR (PDGF)
PDGF is a dimeric polypeptide with a relative molecular mass of 
32000 daltons and was initially purified from platelets (Anton- 
iades, 1981). The predominant form of PDGF released by a- gran­
ules in platelets is a heterodimer consisting of an A chain and a 
B chain, but A-A and B-B homodimers are also produced by other 
cell types (Antoniades, 1981). There is about a 60% sequence 
homology between A and B chains (Heldin & Westermark, 1987). PDGF 
is the main mitogenic component found in serum and is known to be 
a potent mitogen for a diverse array of cells including cells of 
mesenchymal origin (Kohler & Lipton, 1974; Ross et a l . , 1974;
Seppa et a l ., 1982; Diliberto et a l . , 1990).
PDGF has been implicated in the abnormal proliferation of vascu­
lar cells that o c c u r s  in the d e v e l o p m e n t  of a t h e r o s c l e r o s i s  
(Ross, 1986b). The effect of PDGF is discussed below.
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1.3.1. Effect of PDGF on endothelial cell proliferation
With the exception of cells from the microvasculature (Bar et 
al., 1989), endothelial cells exhibit a growth independence from 
PDGF by being able to grow e q u a l l y  well in serum- or plasma- 
supplemented medium (Kazlauskas & DiCorleto, 1985). Even though 
vascular endothelial cells do not respond mitogenically to PDGF, 
they synthesize and secrete PDGF or a PDGF- like material (Di­
Corleto & Bowen-Pope, 1983; Vlodavsky et a l ., 1987). It is possi­
ble, therefore, that the endothelial cell layer is involved in 
the m o d ulation of events (migration and pro l i f e r a t i o n )  via a 
paracrine action on adjacent smooth muscle cells in the vascular 
w al l .
1.3.2. Effect of PDGF on smooth muscle cell proliferation
Unlike endothelial cells which exhibit a growth- independence
from PDGF in culture, smooth muscle cell growth depends upon the
presence of platelet factors as observed by Fager et al. (1988).
In this study, human aortic smooth muscle cells were observed not
to grow in the absence of PDGF or when an antiserum to PDGF was
added to the culture medium. PDGF is a potent mitogen for the
vascular smooth muscle cells derived from aortas of many other
species including bovine (Banskota et al., 1989), rat (Tomita et
al . , 1987; Takagi et a l . , 1988; Abell et a l . , 1989; Kihara et
a l . , 1989; M a j a c k  et a l ., 1990), and r a b b i t  ( Kariya et al.,
1987a).
PDGF is produced and secreted not only by platelets, activated 
monocytes and endothelial cells, but by the smooth muscle cells 
themselves (Sjolund et a l . , 1988). The production and secretion
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of a PDGF- like material was observed in cultured aortic smooth 
muscle cells d e r i v e d  fro m  rat pups but not f r o m  3 m o n t h  old 
animals (Seifert et a l . , 1984). Even though these latter cells
did not produce or secrete PDGF, they were found to possess cell 
surface r e c e p t o r s  for it thus m a k i n g  t h e m  r e s p o n s i v e  to the 
mitogen. Furthermore, Walker et a l . (1986) reported that smooth
muscle cells from the arterial intima produced higher levels of 
PDGF in cul t u r e  w h e n  c o m p a r e d  to m e d i a l  s m o o t h  m u s c l e  cells 
cultured from control uninjured a r t e r i e s .
1.3.3. Mechanism of PDGF- induced signal transduction 
The mechanism of PDGF induced signal transduction has been inves­
tigated in several cell types. After binding, PDGF is rapidly 
internalized and degraded (Bowen-Pope & Ross, 1982). This trig­
gers several biochemical changes that lead individually or col­
lectively to various changes in cellular physiology and to commit 
the cell to the initiation of DNA synthesis.
These r e s p o n s e s  i n c l u d e  r e c e p t o r -  m e d i a t e d  t y r o s i n e  k i n a s e  
phosphorylation of cellular and nuclear proteins (Cooper et a l . , 
1982; Fields et al., 1990 ), increases in i n t r a c e l l u l a r  pH by 
activation of N a +/ H + e x c h a n g e  and i n c r e a s e  in c y t o s o l i c  C a 2+ 
(Ives & Daniel, 1987; T ucker et a l ., 1989; D i l i b e r t o  et al.,
1990). On this last point, in rat aortic smooth muscle cells it 
was found that calcium a n t a g o n i s t s  and c a l m o d u l i n  inhibitors 
blocked the PDGF- induced m i t o g e n i c  response (Tomita et a l . ,
1987). F u r t h e r m o r e ,  a c t i v a t i o n  by P D G F  i n d u c e s  c y t o s k e l e t a l  
changes (Bo c k u s  & S t i l e s ,  1984) a n d  h y d r o l y s i s  of 
p h o s p h a t i d y i n o s i t o l  thus g e n e r a t i n g  the s e c o n d  m e s s e n g e r s
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diacyglycerol and inositol trisphosphate (Tsuda et al. , 1986).
Addition of phorbol esters or a PKC inhibitor, H7 , to rabbit and 
rat aortic s m o o t h  m u s c l e  c e lls r e p o r t e d l y  b l o c k s  the PDoF- 
induced mitogenic response (Kariya et a l . , 1987a; Takagi et a l . ,
1988), whereas another investigation found that inhibition of PKC 
failed to suppress the DNA synthesis induced by PDGF in rat aorta 
smooth muscle cells (Kihara et a l ., 1989).
Increased intracellular cyclic AMP concentrations and expression 
of the proto- oncogenes, c-fos and c-myc (Kelly et a l . , 1983;
Rozengurt et al., 1983a; Armelin et a l . , 1984; Kruijer et a l . , 
1984; Coughlin et a l . , 1985; Banskota et a l . , 1989; Williams,
1989; Diliberto et a l ., 1990) have also been observed in response 
to PDGF.
1.4. HEPARIN- BINDING GROWTH FACTOR (H B G F )
The main member of this family is the fibroblast growth factors 
(F G F ) . Acidic and basic FGF share a strong sequence h o m o l o g y  
(55%) and have similiar molecular mass (18000 daltons) but differ 
on isoelectric points and chromosome position (G o s p o d a r o w i c z ,
1989) .
1.4.1. Effect of HBGF on endothelial cells
HBGF are the best characterized and most potent of the endotheli­
al cell mitogens and depending on type, a difference in potency 
can be observed: acidic FGF is approximately 30- to 100- fold 
less potent than that of basic FGF (G o s p a d o r o w i c z , 1989). Both
factors induce en d o t h e l i a l  cell p r o l i feration, m i g r a t i o n  and 
increased production of the enzyme, protease, in culture and are
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found to be angiogenic in v i v o .
1.4.2. Effect of HBGF-I on endothelial cell proliferation
HBGF-I is a family of acidic p o l y p e p t i d e s  that stimulate the 
proliferation of endothelial cells in vitro (Schreiber et a l . / 
1985; Gospodarowicz et a l . , 1986; Herbert et a l . y 1988; Hoshi et
al., 1988a; 1988b). The main member of this family is acidic FGF 
but others include endothelial cell growth factor, brain- derived 
growth fa c t o r  I and eye- d e r i v e d  g r o w t h  f a c t o r  II. V a s c u l a r  
e n d othelial cells have been shown not to e x p r e s s  or p r o d u c e  
active HBGF-I (Schweigerer et a l . , 1987b; Winkles et a l . , 1987;
Bikfalvi et al., 1990).
All these growth factors share similiar chemical and physical 
characteristics: molecular mass, amino acid composition, isoelec­
tric point (pi 5-6) and possess the ability to strongly bind to 
heparin.
1.4.3. Effect of HBGF-I on smooth muscle cell proliferation 
Unlike vascular e n dothelial cells w h i c h  were o b s e r v e d  not to 
actively produce or secrete HBGF-I, human aortic and umbilical 
vein smooth muscle cells were seen to express the HBGF-I mRNA 
transcipt (Winkles et a l . , 1987 ). HBGF-I has been found to be 
mitogenic for smooth muscle cells (Mioh & Chen, 1987; Winkles et 
al., 1987; Hoshi et a l ., 1988a).
1.4.4. Mechanism of HBGF-I- induced signal transduction
It has been shown that in capillary endothelial cells the binding 
of HBGF-I to its receptor is followed by rapid internalization
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(Friesel & Macaig, 1988). Upon internalization, HBGF-I induces 
several cellular responses.
In m u r i n e  3T3 f i b r o b l a s t s ,  the r e s p o n s e  i n c l u d e s  t y r o s i n e  
p h o s p h o r y l a t i o n  of c e l l u l a r  p r o t e i n s  (Huang & Huang, 1986). 
Addition of purified HBGF-I to quiescent Chinese hamster lung 
fibroblasts leads to the reinitiation of DNA synthesis without 
activation of p h o s p h a t i d y l i n o s i t o l  h y d r o l y s i s  or i n c r e a s e d  
cytosolic calcium concentrations (Magnaldo et a l . , 1986). This
report is in agreement with Tucker et al (1989) who showed that 
an increase in c y t o s o l i c  c a l c i u m  was not n e c e s s a r y  for FGF- 
induced mitogenesis in Balb/ c3T3 cells.
In human aortic endothelial and smooth muscle cells, HBGF-I was 
found to s t i m u l a t e  the a c t i v i t y  of a d e n y l a t e  cycla s e ,  and a 
concurrent rise in cyclic AMP content was observed (Mioh & Chen, 
1987; 1989). Recent reports indicate that HBGF-I increases the 
cellular levels of several proto- oncogenes: c-fos, c-jun amd c- 
myc in human umbilical vein endothelial cells (Gay & Winkles, 
1990 ; Lampugnoni et a l . , 1990 ). These ce l l u l a r  onc o g e n e s  are
known to e n c o d e  for D N A  b i n d i n g  p r o t e i n s  w h i c h  f u n c t i o n  as 
transcriptional activators and therefore maybe involved in the 
mitogenic response to HBGF-I.
1-4.5. HBGF-II
The main growth factor in this group is basic FGF. As discussed 
earlier, basic FGF possesses 55% sequence homology with acidic 
FGF but differs on isoelectric point and position on chromosomes 
(G o s p o d a r o w i c z , 1989 ). B a s i c  FGF was i n i t i a l l y  i s o l a t e d  and
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purified from s e v e r a l  d i s t i n c t  tissues, i n c l u d i n g  c u l t u r e d  
pituitary follicular cells, brain, and placenta (Ferrara et a l . , 
1987; Moscatelli et a l ., 1986).
1.4.6. Effect of HBGF-II on endothelial cell proliferation 
Basic FGF is a potent mitogen for vascular endothelial cells. 
This mitogenic activity is not species dependent nor is it d e ­
pendent upon vascular origin of endothelial cells unlike PDGF 
which is mitogenic only for microvascular endothelial cells (Bar 
et a l ., 1989). Bovine aortic and c a p i l l a r y  e n d o t h e l i a l  cells
(Gospodarowizc et a l .,1978; 1986; S c h w e i g e r e r  et a l ., 1987a;
1987b; Herbert et al., 1988; Sato & Rifkin, 1988; Presta et a l . , 
1989a, 1989b; De Cristan et a l . , 1990 ), human u m b i l i c a l  vein
endothelial cells (Gospodarowizc et a l . , 1978; Hasegawa et a l . ,
1988; Herbert et a l . , 1988) and rat carotid artery endothelial
cells (Lindner et a l . , 1990) are known to respond mitogenically
to basic FGF.
In contrast to HBGF-I, it is known that v a s c u l a r  e n d o t h e l i a l  
cells e x p r e s s ,  s y n t h e s i z e  a n d  s e c r e t e  t h e i r  ow n  b a s i c  FG F 
(Schweigerer et a l ., 1987b; Vlodavsky et al., 1987; Winkles et
al. , 1987 ; Sato & Rifkin, 1988; Presta et a l ., 1989b; Bikfalvi et 
al. , 1990) and are capable of responding to basic FGF through the 
interaction of the m i t o g e n  w i t h  hig h  a f f i n i t y  cell s u r f a c e  
receptors (Ne u f i e l d  & G o s p o d a r o w i c z , 1988; B i k f a l v i  et al.,
1989).
1.4.7. Effect of HBGF-II on smooth muscle cell proliferation 
Basic FGF is a mitogen for vascular smooth muscle cells and this
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mitogenic activity has been observed in bovine aortic (Gospoda- 
rowicz et a l . , 1981) and rat aortic smooth muscle cells (Kihara
et a l ., 1989; Majack et a l ., 1990).
1.4.8. M e c h a n i s m  of s e c r e t i o n  of H B G F - I  and b a s i c  FGF fro m  
vascular cells
It is proposed that HBGF-I and basic FGF act in an aut o c r i n e  
manner to control smooth m u s c l e  and e n d o t h e l i a l  cell growth, 
respectively, despite both HBGF-I and basic FGF lacking the 
classical signal sequences required for secretion (Abraham et 
a l . , 1986a; 1986b). This is consi s t e n t  wit h  the f inding that
cultured endothelial cells that synthesize basic FGF appear to 
release little or none into the s u r r o u n d i n g  b a t h i n g  m e d i u m  
(Vlodavsky et a l ., 1987).
Whether or not basic FGF was s e c r e t e d  remai n e d  u n k n o w n  until 
recently when it was shown that it binds to the endothelial cell- 
derived glycosaminoglycan, heparan sulphate, a major structural 
component of the underlying basement membrane, and is secreted as 
a complex. These complexes of basic FGF and heparan sulphates 
then become integrated into the extracellular matrix (Saksela & 
Rifkin, 1990; B a i r d  & Ling, 1987). F u r t h e r m o r e ,  at a r e a s  of 
r egro w t h  a f t e r  e n d o t h e l i a l  c e l l  i n j u r y ,  s e c r e t i o n  of the 
p r o teolytic enzymes, p r o t e a s e  and c o l l a g e n a s e ,  d e g r a d e s  the 
basement m e m b r a n e  t h e r e b y  r e l e a s i n g  the c o m p l e x e d  b a s i c  FGF 
(Saksela & Rifkin, 1990). The released basic FGF induces growth 
and migration of surrounding endothelial cells thereby promoting 
the restoration of the endothelial cell layer.
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This scheme may indicate that basic FGF has a potential role as a 
growth r e g u l a t o r  of e n d o t h e l i a l  cells in the a r t e r i a l  w a l l  
(reviewed by K l a g s b r u n  & E d e l m a n ,  1989). It is p o s s i b l e ,  
therefore, that the release of HBGF-I from smooth muscle cells 
occurs through a similiar mechanism by complexing with heparan- 
related glycosaminoglycans.
1.4.9. Mechanism of HBGF-II- induced signal transduction 
Basic FGF has been shown to interact with specific cell- surface 
receptors in human capillary and umbilical vein endothelial cells 
and this is followed by rapid internalization (Neufeld & Gospoda- 
rowicz, 1988; B i k f a l v i  et a l ., 1989). This t r i g g e r s  s e v e r a l
biochemical cha n g e s  l e a d i n g  i n d i v i d u a l l y  or c o l l e c t i v e l y  to 
commit the cell to initiation of DNA synthesis.
The signal transduction pathway utilised by basic FGF has been 
investigated in a number of cell systems. There is, however, no 
clear u n d e r s t a n d i n g  of the p r i m a r y  t r a n s d u c i n g  m e c h a n i s m  
involved. Unlike with PDGF, increases in cytosolic calcium are 
not n e c e s s a r y  for m i t o g e n e s i s  in B a l b /  c3T3 f i b r o b l a s t s  
stimulated with basic FGF (Tucker et al., 1989). Activation of 
the calcium, p h o s p h o l i p i d  d e p e n d e n t  kinase, p r o t e i n  kinase C 
(PKC) and increases in cyclic AMP are not consistently observed. 
In Swiss 3T3 fibroblasts, basic FGF at mitogenic concentrations 
activates protein kinase C (Blackshear et a l . , 1985; Moscatelli
et a l ■i 1986), whereas as in hamster fibroblasts the basic FGF- 
receptor s i g n a l l i n g  p a t h w a y  was f o u n d  to be i n d e p e n d e n t  of 
phospholipase C- activated phosphatidylinositol hydrolysis or 
protein kinase C activation (Magnaldo et al., 1986).
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in rat a o r t i c  s m o o t h  m u s c l e  c ells, b o v i n e  c e r e b r a l  c o r t e x  
capillary endothelial cells, normal and transformed foetal bovine 
aortic e n d o t h e l i a l  cells, a c t i v a t i o n  of p r o t e i n  k i n a s e  C is 
likely to be responsible for the chemotactic and mitogenic activ­
ity of basic FGF. This is suggested since pretreatment of the 
cells with H7 or staurosporine (protein kinase C inhibitors) or 
prolonged pretreatment with phorbol esters, abolishes the chemo 
tactic and mitogenic activity of basic FGF in these cells (Kihara 
et a l . , 1989; Presta et a l ., 1989a; 1989b; Daviet et a l . , 1990). 
Increased expression of the proto-oncogenes, c-fos and c-myc, 
have been observed in response to basic FGF (Lampugnani et ■ #
1990) .
1.4.10. Additional members of FGF family
Additional members of the FGF family have recently been identi­
fied: int-2, hst/k53 and FGF-5 ( Yoshida et a l . , 1987 ; Zhan et
a l ., 1988). All three proteins share considerable sequence homol­
ogy (between 35 and 55%) with acidic and basic FGF. One major 
structural difference is the presence of a hydrophobic leader 
sequence that facilitates secretion (Delli- Bovi et a l ., 1988)
and therefore permits access of to the plasma membrane receptors 
thus closing the autocrine loop. The targets of these gr o w t h  
factors are not yet fully characterized.
1.5. EPIDERMAL GROWTH FACTOR (E G F )
EGF is a p o l y p e p t i d e  w i t h  a r e l a t i v e  m o l e c u l a r  m a s s  of 6000 
daltons and was first discovered because of its presence in high 
concentrations within the submaxilary glands of mice (Savage & 
Cohen, 1972). It is n o w  k n o w n  t h a t  p l a t e l e t s ,  m o n o c y t e s -
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macrophages and endothelial cells produce and release EGF (Bowen 
Pope et a l ., 1985 ; Assoian et a l . , 1984).
1.5.1. Effect of EGF on endothelial cell proliferation
EGF has been shown to have differing effects upon the prolifera­
tion of endothelial cells in culture: stimulation of prolifera­
tion was observed in human aortic and umbilical vein endothelial 
cells (Gospodarowicz et a l . , 1978; Hoshi et a l . , 1988a) and in a 
transformed foetal bovine aortic endothelial cell line (Presta et 
al., 1989a). In contrast, no effect was observed in bovine aor­
tic, bovine umbilical vein or foetal bovine aortic endothelial 
cells. These cells w e r e  s h o w n  to lack the r e c e p t o r s  for EGF 
(Gospodarowicz et a l ., 1978).
1.5.2. Effect of EGF on smooth muscle cell proliferation
EGF is a mitogen for vascular smooth muscle cells including those 
from bovine aorta, human aorta and umbilical vein, and rat aorta 
(Gospodarowicz et a l . , 1981; Owen, 1985; Tomita et a l . , 1987 ;
Hoshi et a l ., 1988a; Takagi et a l ., 1988).
1-5.3. Mechanism of EGF- induced signal transduction 
The signal transduction pathway utilised by EGF has been investi­
gated in a number of cell types. There is, however, no clear 
understanding of the primary transducing mechanisms involved.
After binding EGF triggers receptor- mediated tyrosine kinase 
phosphorylation of cellular substrates including its own receptor 
(Cooper et a l . , 1982; Margolis et a l ., 1989). Pretreatment of NIH 
3T3 cells with a protein tyrosine kinase inhibitor abolished the
15
mitogenic activity of EGF (Margolis et a l . , 1989). Stimulation of 
Na+/ H + antiport activity, of amino acid and glucose transport 
and of increased c-myc e x p r e s s i o n  have also been o b s e r v e d  in 
response to EGF (Tsuda et a l . , 1986 ). Phosphatidylinositol h y ­
drolysis is not consistently observed upon stimulation by E G F . In 
human foreskin fibroblasts and A431 human epidermoid cells, a 
phosphatidylinositol hydrolysis was observed (Sawyer & Cohen, 
1981; M e i s e n h e l d e r  et a l ., 1989; T h o m p s o n  et a l ., 1989). In
contrast in Swiss 3T3 cells there was no hydrolysis of phosphat­
idylinositol in response to EGF (Tsuda et a l . , 1986). F u r t h e r ­
more, addition of calcium antagonists, calmodulin inhibitors, 
phorbol esters, or a PKC inh i b i t o r  b l o c k e d  the EGF- i nduced 
stimulation of D N A  s y t h e s i s  in rat and b o v i n e  a o r t i c  s m o o t h  
muscle cells (Owen, 1985 ; Tomita et a l . , 1987; Takagi et a l . ,
1988).
1.6. INTERACTIONS OF GROWTH FACTORS AND VASCULAR CELL PROLIFERA­
TION
It is apparent that the control of vascular cell proliferation
requires complex interactions between growth factors. Control
may be mainly under the influence of a specific growth factor
whose actions is then modified by others. Several substances have
been i d e n t i f i e d  that are k n o w n  to m o d u l a t e  p r o l i f e r a t i o n  of
endothelial cells in response to FGF, or of smooth muscle cells
in response to serum. These include heparin, transforming growth
factor p, tumour necrosis factor and interleukin-1. Several of
these factors are released by the numerous cell types present
within the atherosclerotic lesions (Table 2), and are discussed 
below.
16
Table 2: Production of heparin, transforming growth factor p,
tumour necrosis factor a and interleukin- 1 by cells associated 
with atherosclerosis.
CELL HEPARIN TGFfi TNFa IL-1
Platelets +
Monocytes- Macrophages - + + +
Endothelial cells + + - +
Smooth Muscle cells + + +
1.6.1. Effect of heparin on endothelial cell prolferation 
Heparin and its related glycosaminoglycan, heparan sulphate, have 
been shown to have differing effects on endothelial cell growth: 
stimulation of growth was observed in human umbilical vein e n ­
dothelial cells, inhibition of growth was o b s e r v e d  in b ovine 
capillary and human omental microvascular endothelial cells, and 
no effect was observed in human umbilical vein endothelial cells 
(Gospodarowicz et a l . , 1986; Gospodarowicz & Cheng, 1986; Bik- 
falvi et a l . , 1988; Herbert et al., 1988 ). In b ovine aortic,
human capillary and umbilical vein endothelial cells, HBGF-I was 
seen to b e c o m e  mor e  p o t e n t  in the p r e s e n c e  of hepar i n ,  thus 
making it as potent as basic F G F . It was s u g g e s t e d  that this 
reflected the ability of heparin to stabilize the tertiary struc­
ture of acidic FGF (Schreiber et al., 1985; Gospodarowicz et al., 
1986; Herbert et a l ., 1988). In contrast, in the p r e s e n c e  of
heparin, basic FGF had an either an antiproliferative effect or 
no effect on human umbilical vein endothelial cell growth (Her­
bert et a l . , 1988; Hasegawa et al., 1988).
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1.6.2. Effect of heparin on smooth muscle cell proliferation
Heparin and its related glycosaminoglycan, heparan sulphate, have 
been shown to have an inhibitory effect on the proliferation of 
vascular smooth muscle c e l l s . This inhibition is not species 
dependent nor is it dependent upon vascular origin of the smooth 
muscle cells: heparin i n h ibited the serum-, P D G F - , HBGF- and
phorbol ester- induced growth of bovine and human aortic (Clowes 
& Karnowsky, 1977; R eilly et a l . , 1988; Hoshi et a l . , 1988a;
Castellot et a l ., 1989), rat aortic (Hoover et a l . , 1980; Guyton 
et_al., 1980; Castellot et a l . , 1989), rabbit aortic (Herbert & 
Maffrand, 1989) and human saphenous vein smooth m u s c l e  cells 
(Castellot et a l ., 1989).
Heparin was found to inhibit the mitogenic response to growth
factors which utilise the activation of protein kinase C as a
m e c h a n i s m  of s i g n a l  t r a n s d u c t i o n .  T h e  s t i m u l a t i o n  of
P^olifera tion by EGF is indepe n d e n t  of a c t i v a t i o n  of p r o t e i n
kinase C and is therefore insensitive to heparin (Castellot et
al. , 1989). A possible mechanism by which heparin inhibits growth
of smooth muscle cells is by its ability to selectively inhibit
the e x p r e s s i o n  of the p r o t o -  o n c o c g e n e s ,  c- fos and c- xnyc,
induced by a protein kinase C dependent pathway (Castellot et 
al., 1989).
Furthermore, production of an antiproliferative heparan sulphate 
y bovine a o r t i c  s m o o t h  m u s c l e  cells has b e e n  d e m o n s t r a t e d  
(Fritze et a l . , 1985 ). This suggests that smooth muscle cells
themselves can control their own growth.
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1.6.3. Effect of transforming growth factor p (TGFp) on endothe­
lial cell proliferation
TGFp is a polypeptide with a relative molecular mass of 25000 
daltons which is secreted by platelets, monocytes- macrophages, 
endothelial cells and medial smooth muscle cells (Assoian et a l ., 
1984; Sarzani et a l . , 1989; A n t o n e l l i -  O rlidge et a l . , 1989;
Assoian & Sporn, 1986).
TGFp has b e e n  s h o w n  to act as a b i f u n c t i o n a l  r e g u l a t o r  of 
endothelial cell growth. TGF p  i n h i b i t s  the g r o w t h  of b o v i n e  
aortic and a d r e n a l  c o r t e x  c a p i l l a r y  a n d  h u m a n  a r t e r i a l  
endothelial cells i n d u c e d  by s e r u m  and b a s i c  or a c i d i c  FGF 
(Frater-Schroder et a l . , 1986; Baird & Durkin, 1986; Hoshi et
al., 1988a; Bell & Madri, 1989; Mioh & Chen, 1989). In contrast 
to bovine aortic and adrenal cortex capillary endothelial cells, 
TGFp is mitogenic for bovine corneal endothelial cells and has a 
synergistic effect on the mitogenic action of basic FGF (Plouet & 
Gospodarowizc, 1989).
1.6.4. Effect of TGFp on smooth muscle cell proliferation 
TGFp has been shown to act as a bifunctional regulator of smooth 
muscle cell growth. TGFp potentiated the mitogenicity of serum, 
PDGF-BB and basic FGF in cultures of quiescent, confluent smooth 
muscle cells, whereas in sparse, p r o l i f e r a t i n g  s mooth m u s c l e  
cells, it inhibited growth induced by these stimuli (Hoshi et 
al. , 1988a; Majack et a l ., 1990).
jLL615_. Mechanism of TGFp- induced signal transduction
TGFp has been shown to display a variety of activities: decreased
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synthesis of the proteases, collagenase and plasminogen activa­
tor, elevated synthesis of inhibitors of both collagenase and 
plasminogen activator, and the induction of matrix macromolecule 
synthesis (Saksela & Rifkin, 1990). These actions would tend to 
decrease the amount of com p l e x e d  basic FGF re l e a s e d  from the 
subendothelium extracellular matrix, but in bovine corneal e n ­
dothelial cells TGFp exerted its mitogenic effect via the i n ­
creased intracellular content of basic FGF (Plouet & Gospodaro­
wicz , 1989).
TGFp has been observed to decrease the migration of bovine aortic 
endothelial cells, whereas it stimulates the migration of bovine 
aortic smooth muscle cells (Bell & Madri, 1989).
Addition of TGFp to HBGF-I stimulated human adult endothelial 
cells induced a reduction in the intracellular cyclic AMP content 
by decreasing adenylate cyclase activity (Mioh & Chen, 1989). It 
is l i k e l y  tha t  t h e r e f o r e  t h a t  T G F p  e x e r t s  its e f f e c t s  on 
proliferation at least partially through modulation of cyclic 
AMP content.
1.6.6. Tumour necrosis factor a (TN F a )
TNFa is released from monocytes- macrophages and smooth muscle 
cells (Warner & Libby, 1989) and has been reported to have sever­
al actions on endothelial cells: increased neutrophil adhesion,
induction of pro-coaggulant activity, cytoskeletal rearrangement, 
and stimulated production of PDGF, prostacyclin, interleukin-1 
and granulocyte- monocyte- colony stimulating factor (GM-CSF) 
(Bevilacqua et a l . , 1986; Nawroth et a l . , 1986; Hajjar et al.,
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1987; Endo et a l ., 1988; Cotran & Pober, 1989). Furthermore, TNFa 
induces the expression of interleukin-1 by smooth muscle cells 
(Warner & Libby, 1989). TNFa is known to inhibit the prolifera­
tion of human umbilical vein endothelial cells grown in serum and 
of capillary endothelial cells stimulated to grow with basic FGF 
(Schweigerer et a l ., 1987a; Shimada et a l ., 1990).
1.6.7. Effect of Interleukin-1 (IL-1) on endothelial cell p rolif­
eration
IL-1 is a cytokine which is involved in enabling endothelial 
cells to partic i p a t e  a c t i v e l y  in immune and i n f l a m m a t o r y  r e ­
sponses (Cotran & Pober, 1989; Martin et a l ., 1988a).
IL-1 was found to inhibit thy m i d i n e  i n c o r p o r a t i o n  into human 
umbilical vein endothelial cells (Cozzolino et a l . , 1990). IL-1
is secreted not only by activated macrophages, but by endothelial 
cells themselves. Endothelial cells respond following the binding 
of IL-1 to cell- surface receptors, thus indicating that IL-1 
may have an autocrine role in controlling endothelial cell growth 
(Cozzolino et a l . , 1990). IL-1 inhibits endothelial growth in
response to basic FGF (Cozzolino et a l ., 1990).
1.6.8. Effect of IL-1 on smooth muscle cell proliferation
IL-1 has been shown to act as a growth factor for vascular smooth 
muscle cells (Libby et a l ., 1988; R a i n e s  et a 1 ., 1989). The
mitogenic activity of IL-1 was found to be associated with in­
creased expression and secretion of PDGF from the smooth muscle 
cells themselves. This was demonstrated by the observation that 
addition of antibodies against PDGF completely blocked the mito-
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genic response to IL-1 (Raines et a l . , 1989).
1.7.1. INTERACTIONS BETWEEN ENDOTHELIAL CELLS AND SMOOTH MUSCLE 
CELLS
As introduced earlier, smooth muscle cell migration and prolifer­
ation plays an important role in the formation of an atheroscle­
rotic lesion. Upon re- endothelialization of the endothelial cell 
monolayer there is some indication that regression of the intimal 
thickening occurs (Ross, 1986b). This would suggest that vascular 
endothelial cells produce and secrete growth inhibitors for the 
underlying smooth muscle cells. Several studies have indicated 
that endothelial cells not only produce growth inhibitory s u b ­
stances, but under certain conditions also growth stimulatory 
substances, and chemotactic factors for smooth muscle cells.
Endothelial cells are known to produce and secrete a PDGF or a 
PDGF- like substance which is a potent mitogen for smooth muscle 
cells (DiCorleto & Bowen- Pope, 1983; Vlodavsky et al., 1987; 
Staiano- Coico et a l . , 1988). Other growth promoting substances 
have been detected in the conditioned medium of bovine aortic 
endothelial cells (Wang et a l ., 1981).
On the o t h e r  hand, the c o n d i t i o n e d  m e d i u m  f r o m  c o n f l u e n t  
monolayers of e i t h e r  b o v i n e  a o r t i c  or h u m a n  u m b l i l i c a l  v e i n  
endothelial cells have been found to contain a growth inhibitory 
substance for actively dividing smooth muscle cells (Castellot et 
al-/ 1981; 1982; Willems et a l . , 1982; Herbert & Maffrand, 1989).
is possible that endothelial cells secrete factors which are 
not only mitogenic but are chemotactic for the underlying smooth
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muscle cells. A c h e m o t a c t i c  f a c t o r  has bee n  d e t e c t e d  in the 
conditioned medium from confluent monolayers of bovine aortic 
endothelial cells (Autio et a l . , 1989).
Such interactions between endothelial cells and smooth muscle 
cells might contribute to the p r o l i f e r a t i o n  and m i g r a t i o n  of 
smooth muscle cells into the intima during the development of 
atherosclerosis.
1.7.2. Endothelin
Recently it has been demonstrated that various endothelial cells 
possess the ability to synthesize and release a vasoconstrictor 
peptide now r e c ognised as e n d o t h e l i n  (ET). These include pig 
aortic (Yanagisawa et al., 1988) and bovine adrenal cortex capil­
lary and aortic (Hexum et al., 1990; Vigne et al., 1990) endothe­
lial cells. It has been shown, however, that not all endothelial 
cells possess the ability to produce E T . One such cell type is 
bovine brain capillary endothelial cells (Vigne et a l ., 1990).
The release of ET by endothelial cells in culture occurs sponta­
neously, but can also be stimulated by a variety of substances 
including IL-1 ( Y o s h i z u m i  et a l ., 1990), TGFp, P D G F  an d  EG F
(Resink et a l ., 1990a), t h r o m b i n  and the p h o r b o l  ester, T P A
(Emori et a l . , 1989). The primary sources of IL-1 and thrombin in 
the arterial wall are monocytes and platelets, respectively. It 
has been demonstrated that an important complication in athero­
sclerosis is the increased v a s o c o n s t r i c t e d  state of a f f e c t e d  
arteries• A recent study indicated that the ET- induced vasocon­
strictor response was potentiated in atherosclerotic arteries
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(Lopez et al., 1990). Furthermore, a recent report has d e m o n ­
strated that cyclic GMP- elevating agents such as atrial natriu­
retic peptide and the n i t r o v a s o d i l a t o r , sodium n i t r o p r u s s i d e , 
reduce basal and stimulated ET production from human umbilical 
vein endothelial cells (Saijunmaa et a l ., 1990).
Several studies have suggested a possible role for ET in vascular 
endothelial cell proliferation. ET was observed to stimulate DNA 
synthesis in bovine brain capillary endothelial cells with great­
er potency than basic FGF. These cells were found to possess a 
large n u m b e r  of hig h  a f f i n i t y  cell s u r f a c e  r e c e p t o r s  for ET 
(Vigne et a l . , 1990). A second study confirmed the growth promot­
ing action of ET (Takagi et a l ., 1990). Here it was reported that 
serum- induced proliferation of human umbilcal vein endothelial 
cells was inhibited by anti- ET antibodies. Furthermore, ET has 
been shown to stimulate proliferation of rat aortic smooth muscle 
cells in culture (Komuro et al., 1988; Bobik et al., 1990).
1.7.3. Mechanism of ET- induced signal transduction 
The m e c h a n i s m  by w h i c h  ET i n d u c e s  v a s o c o n s t r i c t i o n  and DN A  
synthesis has been investigated in vascular cells . ET has been 
shown to i n t e r a c t  w i t h  hig h  a f f i n i t y  s p e c i f i c  cell- s u r f a c e  
receptors on endothelial (Vigne et al., 1990) and smooth muscle 
cells (Hirata et a l ., 1988; Resink et al., 1990c). The signalling 
pathways involved include intracellular alkalinization, activa­
tion of S6- kinase, activation of phopsholipase C, which stimu­
lates the formation of the second messengers, inositol trisphos- 
phate and diacyglycerol, and mobilization of intracellular calci­
um (Komuro et a l ., 1988; Resink et a l . , 1988; 1990b; Griendling
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et al., 1989; Vigne et a l ., 1990). Increased expression of the
proto-oncogenes, c-fos and c-myc, have been observed in response 
to ET (Komuro et a l ., 1988; Bobik et a l . , 1990 ).
1.8. NEW ANGIOGENIC FACTORS
Acidic and basic FGF are known to be angiogenic in v i v o , that is 
they stimulate the migration and proliferation of endothelial 
cells, but evidence suggests that other factors may have a role 
in triggering a n g i o g e n e s i s . Firstly, FGF lacks the hydrophobic 
signal sequence that governs secretion, but if a factor is to be 
angiogenic, it must be able to diffuse freely. Secondly, basic 
FGF is synthesized by the endothelial cells themselves, so if 
oasic FGF is present in and around the endothelial cells at all 
times but in spite of this the cells are quiescent, then the 
possibility exists that other factors may initiate angiogenesis. 
Recent work has identified and characterized several new angio­
genic factors. These include
1.8.1. Platelet-derived endothelial cell growth factor (PD-ECGF) 
This is a platelet- derived endothelial cell mitogen, distinct 
from PDGF that has recently been identified and characterized 
(Miyazano et a l ., 1987; Miyazano & Heldin, 1989). PD-ECGF is a 
single polypeptide with a relative molecular mass of 45000 dal- 
tons.
It has been shown to stimulate migration and proliferation of 
porcine aortic endothelial cells in culture and angiogenesis in 
(Ishikawa et a l . , 1989). The mitogenic activity of PD-ECGF
has been examined on a diverse array of cell types and was found
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to be m i t o g e n i c  o n l y  for v a s c u l a r  e n d o t h e l i a l  cells. T h i s  
mitogenic activity was not species dependent nor dependent upon 
the vascular origin of the cells (Ishikawa et a l ., 1989).
1.8.2. Vascular endothelial cell growth factor(VEGF)
This is a family of mitogens recently characterized from the 
conditioned culture media of either rat glioma cells (Conn et 
a l ., 1990a), or of bovine folliculo stellate cells (Ferrara &
Henzel, 1989; Gospodarowicz et a l . , 1989; Plouet et a l . , 1989).
These m i t o g e n s  a p p e a r  to be m e m b e r s  of a d i s t i n c t  f a m i l y  of 
growth factors which have been characterized as dimeric polypep­
tides with a relative m o l e c u l a r  mass of 45-46000 d altons and 
exhibit s e q u e n c e  h o m o l o g y  to the h u m a n  P D G F  A and B c h a i n s  
(Tischer et a l . , 1989; Conn et a l ., 1990b).
VEGF possesses the ability to bind to heparin and like basic FGF, 
is complexed with heparan sulphates in the basement membrane. The 
mitogenic activity of VEGF has been examined on a diverse array 
of cell types and was found to be mitogenic only for vascular 
endothelial cells (Plouet et a l . , 1989; Gospodarowicz et a l . ,
1989; Ferrara & Henzel, 1989). This mitogenic activity is not 
dependent on species nor is it dependent upon the vascular origin 
of the endothelial cells. This is in contrast to PDGF which is 
mitogenic o n l y  for e n d o t h e l i a l  c e l l s  d e r i v e d  f r o m  the 
microvasculature (Bar et a l ., 1989).
Although P D-ECGF and VEGF have the same appar e n t  u nique cell 
specificity and similiar molecular mass, the two mitogens differ 
by a 20- fold d i f f e r e n c e  in p o t e n c y  (VEGF is the mor e  p otent
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mitogen) and by their secondary structure (PD-ECGF is a single 
polypeptide whereas VEGF is a dimer).
1.8.3. Vascular permeability fact o r (V P F )
VPF was isolated and purified from the conditioned medium of a 
guinea pig line 10 tumour cells (Senger et a l ., 1990). VPF has
been c h a r a c t e r i z e d  as a d i m e r i c  p o l y p e p t i d e  w i t h  a r e l a t i v e  
molecular mass of 40000 daltons and was originally described as a 
p e rmeability f a c t o r  since it p r o m o t e d  the l e a k a g e  of pl asm a  
fluids and proteins across the endothelial cell layer (Senger et 
al., 1990).
R ecently V P F  w a s  f o u n d  to be a n g i o g e n i c  w h e n  i n j e c t e d  
intradermally into guinea pigs and to be m i t o g e n i c  for human 
umbilical vein endothelial cells and bovine aortic and adrenal 
capillary endothelial cells in culture (Connolly et a l . , 1989;
Ferrara & Henzel, 1989).
Recent w o r k  has i n d i c a t e d  that VP F  p o s s e s s e s  i d e n t i c a l  N H 2~ 
terminal sequences to VEGF. Therefore, VPF might be considered to 
be an additional member of the mitogenic family of VEGF (Connolly 
et a l . , 1989; Ferrara & Henzel, 1989).
1.9. PROTEIN KINASE C (PKC) AND CELLULAR PROLIFERATION 
PKC was first reported in 1977 as a proteolytically- activated 
protein kinase located in many tissues with no obvious role in 
signal transduction (Inoue et al., 1977). Later it was shown that 
it was a calcium- activated, phospholipid- dependent enzyme which 
was firmly linked to signal transduction (Nishizuka, 1984). PKC
27
is widely distributed in many tissues and organs of mammals and 
is involved in mediating an intracellular signal that triggers 
various cellular responses including those elicited by the growth 
factors PDGF and basic FGF.
PKC is transiently activated by diacylglycerol, which is one of 
two s e c o n d  m e s s e n g e r s  p r o d u c e d  by the d e g r a d a t i o n  of 
phosphatidylinositol bisphosphate in response to stimulation of 
ph ospholipase C (Bell, 1986). The o t h e r  m e s s e n g e r ,  i n o s i t o l  
trisphosphate, activates the release of calcium stored in the 
endoplasmic reticulum (Putney, 1987; Rana & Hokin, 1990). More 
recent w o r k  has d i s c o v e r e d  an a l t e r n a t i v e  s o u r c e  of 
uiacylglycerol. This occurs via the degradation of phosphatidy- 
choline by phospholipase C or D to yield phosphatidic acid which 
is further degraded to diacyglycerol by phosphatidic acid phosp- 
hohydrolase (Pelech & Vance, 1989).
1.9.1. Molecular Heterogenity and Structure
PKC is a single polypeptide chain with an approximate molecular 
mass of 77000 daltons and is composed of two functionally differ­
ent domains: a hydrophobic domain that binds to the plasma m e m ­
brane and h y drophilic domain that contains the c a t a l y t i c a l l y  
active centre.
Initially four species emerged from the screening of a variety of 
complementary DNA libraries: a, pi, pil and gamma. The enzymes 
with pi- and pil -  s e q u e n c e s  are d e r i v e d  f r o m  a s i n g l e  R N A  
transcript by a l t e r n a t i v e  s p l i c i n g ,  w i t h  pil b e i n g  the m o s t  
abundant. Each of the four PKC subspecies consists of a single
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polypeptide with four conserved (Cl- C4) and five variable (VI- 
V 5 ) regions. The amino- terminal containing the Cl and C2 regions 
is the regulatory domain and interacts with calcium, phospholipid 
and either endogenous diacyglycerol or exogenous phorbol e s t e r s . 
The Cl region consists of a tandem repeat of cysteine- rich zinc- 
finger like sequences which seem to be essential for binding of 
phorbol esters implying its involv e m e n t  in the m e m b r a n e -  PKC 
interaction (Ono et a l . , 1989b). C2 m a y  be n e c e s s a r y  for the
calcium sensitivity of the enzyme (Ono et a l . , 1988; 1989a). The
carboxyl- terminal containing the C3 and C4 regions show sequence 
homology with many other protein kinases (reviewed in Nishizuka, 
1988). C3 c o n t a i n s  the c a t a l y t i c  s i t e  of the e n z y m e .  M o r e  
recently at least three other subspecies have been identified: 6 , 
g and £. These subspecies have a common structure closely related 
to, but c l e a r l y  d i s t i n c t  f r o m  the four s u b s p e c i e s  d e s c r i b e d  
above. T h e s e  a d d i t i o n a l  m e m b e r s  l a c k  the C2 r e g i o n  of the 
regulatory domain and the requirement of calcium for enzymatic 
activity. It has been suggested that these subspecies of PKC may 
be responsible for the large diversity of responses observed upon 
activation of these enzymes (Coussens et al., 1986; Nishizuka, 
1988; Farago & Nishizuka, 1990).
1-9.2. Phorbol esters
Phorbol esters are potent tumour promoters that were originally 
isolated from the oil of Euphorbiacea Croton tiglium and identi­
fied by Van Duuren & Orris (1965) and H e c k e r  (1968). Phor b o l  
esters are now known to activ a t e  PKC by i n t e r a c t i n g  w i t h  the 
enzyme at the same site as diacyglycerol (Ashendel, 1985).
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Structural analysis indicates that the phorbol ester, phorbol 12- 
myristate 13-acetate, has a diacyglycerol- like structure which 
enables it to substitute for the endogenous activator at extreme­
ly low c o n c e n trations. There is an approximate correlation b e ­
tween the ability of the i n d ividual phor b o l  ester to p r o m o t e  
tumours and to activate the enzyme (Castagna et a l ., 1982).
1.9.3. Function of PKC
Upon a c t i v a t i o n  of PK C  by e i t h e r  p h o r b o l  e s t e r s  or by 
diacyglycerol, a rapid translocation of the enzyme occurs from 
the soluble to the particulate fraction without any change in PKC 
activity. This is a s s o c i a t e d  wit h  their role in c e l l u l a r  r e ­
sponses (Blackshear, 1988). P r o l o n g e d  t r e a t m e n t  w i t h  p h o r b o l  
esters leads to a decrease or a down- regulation in PKC activity 
which is dist i n g u i s h a b l e  from the rapid t r a n s l o c a t i o n  of the 
enzyme.
Activation of PKC and s u b s e q u e n t  p h o s p h o r y l a t i o n  of p r o t e i n s  
(Takai et a l . , 1985; Kuroki & Chida, 1988) has been found to be 
involved in s e v e r a l  c e l l u l a r  r e s p o n s e s :  m o d u l a t i o n  of ion
conductance (Nishizuka, 1986); down- r e g u l a t i o n  of r e c eptors 
(Hoshi et a l . , 1988b); stimulation of gene expression (Colotta et 
al. , 1988; Murphy et a l ., 1988; Reuse et a l . , 1990); stimulation 
of protein synthesis (Brostrom et a l . , 1987); stimulated release 
of enzymes and growth factors (Nishizuka, 1986; M urphy et a l . ,
1988) and interference in progression of the cell cycle (Fukumoto 
£t_al. # 1988). These diverse functions may well involve activaion 
of the different PKC subspecies as described earlier (Coussens et 
^1. , 1986; Nishizuka, 1988; Farago & Nishizuka, 1990).
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In a d d i t i o n  to t h e s e  s t i m u l a t o r y  a c t i o n s  of P K C  t h e r e  is 
accumulating evidence to indicate that PKC provides an inhibitory 
control of cell s i g n a l l i n g .  It has b e e n  r e p o r t e d  t h a t  PKC 
inhibits calcium mobilization by blocking the receptor- mediated 
hydrolysis of inositol phospholipid and hence the production of 
diacyglycerol and inositol trisphosphate (Nishizuka, 1988). This 
inhibitory role of PKC m a y  be e x t e n d e d  to i n c l u d e  c e l l u l a r  
proliferation.
1.9.4. Effect of phorbol esters on cellular proliferation 
Phorbol esters, through activation of PKC have been shown to have 
a dualistic effect on DNA synthesis and proliferation in a varie­
ty of cell types examined. A stimulation of proliferation was 
observed in Swiss 3T3 cells (Collins & Rozengurt, 1982), lympho­
cytes (Kaibuchi et a l . , 1985 ), thyroid cells (Bachrach et a l . ,
1985 ), primary adrenocortical cells (Menapace et a l . , 1987 ) and
an interleukin-1 dependent T cell line (Goto et a l . , 1988).
In contrast, an inhibition of proliferation was observed in human 
lung carcinoma (Gescher & Reed, 1985), human melanoma (Huberman 
et a l . , 1979 ), human epithelial (Mckay et al., 1983 ) and human 
breast cancer cells (Osborne et al., 1981).
1-9.5. Effect of phorbol esters on endothelial cell proliferation 
Activation of PKC by phorbol esters has been shown to have di f ­
fering actions on the proliferation of endothelial cells from 
identical or from different sources in culture: inhibition of
proliferation of human aortic endothelial cells (Hoshi et al., 
1988b) and bovine adrenal capillary endothelial cells (Doctrow &
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Folkman, 1987); stimulation of proliferation of bovine cerebral 
cortex capillary endothelial cells (Daviet et__al. , 1989; 1990),
human umbilical vein endothelial cells (Dupuy et a l . , 1989), and
of a t r a n s f o r m e d  f oetal b o v i n e  a o r t i c  e n d o t h e l i a l  cell line 
(Presta et al., 1989a) and had no effect on p r o l i f e r a t i o n  of 
foetal bovine aortic endothelial cells (Presta e t a l . , 1989a),
human omental m i c r o v a s c u l a r  e n d o t h e l i a l  cells (Dupuy et a l . ,
1989), bovine aortic endothelial cells (Doctrow & Folkman, 1987) 
and bovine adrenal capillary endothelial cells (Morris et a l . , 
1988) .
In pig a o r t i c  e n d o t h e l i a l  ce l l s ,  p h o r b o l  e s t e r s  h a v e  b e e n  
reported to p r o d u c e  an i n i t i a l  s t i m u l a t i o n  of p r o l i f e r a t i o n  
followed within hours by an inhibition (Uratsuji & DiCorleto,
1988). In this latter study the presence of multiple subspecies 
of PKC was demonstrated in endothelial cells. It is possible that 
each of these subspecies of PKC has a different role in regulat­
ing the proliferation of endothelial cells.
1.9.6. Effect of phorbol esters on smooth muscle cell prolifera­
tion
Activation of PKC by phorbol esters has been shown to have d i f ­
fering actions on the proliferation of smooth muscle cells from 
identical or from different sources in culture. A stimulation of 
proliferation has been reported for smooth muscle cells obtained 
from bovine pulmonary artery and aorta (Dempsey et a l . , 1990;
Doctrow & Folkman, 1987), rat aorta (Owen, 1985) and rabbit aorta 
(Kariya et a l ., 1987a).
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In contrast, an inhibition of proliferation has been observed for 
smooth muscle cells obtained from rat aorta (Kihara et a l ., 1989) 
and in rabbit a o rta (Kariya et a l ., 1987b; F u k u m o t o  et a l .,
1988) .
One study demonstrated the ability of PMA to stimulate or inhibit 
the proliferation of rabbit aortic smooth muscle cells when the 
cells were either grown in plasma- derived serum or whole blood 
serum, respectively (Kawahara et a l ., 1988). The dualistic action 
of PMA on rabbit aortic smooth mu s c l e  cells was s u g g e s t e d  to 
reflect the ability of phorbol esters to either down- regulate 
growth f a c t o r  r e c e p t o r s  (Owen, 1985), or to r e f l e c t  the 
activation of the numerous PKC isozymes present in smooth muscle 
cells (Kawahara et al., 1988).
1.9.7. Inhibitors of PKC
Much of our knowledge of the actions of PKC has been obtained by 
the use of activators of this enzyme such as phorbol esters. The 
role of PKC in cellular physiology has been further elucidated, 
however, by the recent development of potent inhibitors of PKC 
such as, s t a u r o s p o r i n e , a microbial alkaloid (Tamaoki et a l . , 
1986) .
Staurosporine b l o c k s  p h o r b o l  e s t e r -  and b a s i c  FGF- i n d u c e d  
growth of bovine cerebral c ortex c a p i l l a r y  e n d o t h e l i a l  cells 
(Daviet et a l , 1989; 1990) and serum- and phorbol ester- induced 
growth of rabbit and rat aortic smooth muscle cells (Matsumato & 
Sasaki, 1989; Takagi et a l . , 1988),and, phorbol ester- and PDGF- 
induced growth of NIH/3T3 fibroblasts (Fields et al. , 1990).
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Inhibitiors of protein kinase C are therefore powerful tools with 
which to investigate the role of this e n z y m e  in c e l l u l a r 
responses.
1.10. CYCLIC NUCLEOTIDES AND CELLULAR PROLIFERATION 
Prior to 1968, there was little interest in the possibility that 
cyclic nucleotides were involved in cell proliferation. This lack 
of interest was altered following the observations of several 
groups (Burk, 1968; Ryan & Heidrick, 1968; MacManus & Whitfield, 
1969). These studies demonstrated that addition of either cyclic 
AMP itself or cyclic AMP phosphodiesterase inhibitors inhibited 
the growth of BHK 21/13 hamster cells, HeLa cells and rat thymic 
lymphocytes. This led to extensive research into the possibility 
that cyclic AMP, and s u b s e q u e n t l y  c y c l i c  G M P , had a role in 
cellular proliferation.
1.10.1. Role of cyclic AMP in cellular proliferation 
Early observations indicated that cultu r e d  f i b r o b l a s t s  made 
quiescent by serum d e p r i v a t i o n  p o s s e s s e d  a m a r k e d l y  e l e v a t e d  
cyclic AMP c o n t e n t  w h i c h  fell u p o n  r e l e a s e  f r o m  q u i e s c e n c e  
(Anderson et a l . , 1973; Kram et a l . , 1973; Moens et a l . , 1975).
In other extensive studies cyclic AMP analogues or agents that 
cause an elevation in intracellular cyclic AMP content were found 
to have either a growth inhibitory or stimulatory effect (re­
viewed in Pastan et a l ., 1975): stimulation of proliferation was 
observed in mammary epithelial cells (Yang et a l ., 1980), hepato- 
cytes (McGowan et a l . , 1981) and Swiss 3T3 fibroblasts (Rozengurt 
®t__al. f 1983b; O'Neill et a l . , 1985 ) whereas an antiproliferative
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effect was observed in normal fibroblasts (Hollenberg & Cuatreca- 
sas, 1975) and B-lymphocytes (Muraguchi et a l . , 1984). A recent
study indicates that forskolin, which stimulates adenylate c y ­
clase (Seaman & Daly, 1981) inhibits the growth- promoting effect 
of PDGF in cultures of human foreskin fibroblasts (Heldin et a l .,
1989) .
1.10.2. Role of cyclic GMP in cellular proliferation
In contrast to cyclic AMP described above, cultured 3T3 f i b r o ­
blasts made quiescent by serum deprivation contained low levels 
of cyclic GMP which rose drammatically when the cells were r e ­
leased from q u i e s c e n c e  (Moens et al., 1975; R u d l a n d  et a l ., 
1974). More recently, atrial natruretic factor which elevates 
cyclic GMP content has been observed to have inhibit rat glomeru­
lar mesangial cell growth in culture (Johnson et a l . , 1988).
1.10.3. Cyclic n u c leotide g e n e r a t i o n  in v a s c u l a r  e n d o t h e l i a l  
cells
In several studies, atrial natriuretic peptides and nitrovasodi- 
lators, which stimulate particulate and soluble guanylate c y ­
clase, respectively, have been shown to elevate cyclic GMP con­
tent in endothelial cells cultured from bovine and pig aorta and 
human umbilical vein (Brotherton, 1986; Leitman & Murad, 1986; 
Schini et a l . , 1988; Martin et a l ., 1988b). The vasoactive agents 
histamine, angiotensin II, acetylcholine and phenylephrine have 
been shown to elevate cyclic GMP content in endothelial cells 
cultured from rabbit aorta (Buonassi & Venter, 1976).
Adenosine and its analogues, forskolin, p- adrenoceptor agonists
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and v a s o a c t i v e  ag e n t s  w h i c h  are k n o w n  to a c t i v a t e  a d e n y l a t e  
cyclase have been o b s e r v e d  to e l e v a t e  c y c l i c  A M P  c o n t e n t  in 
endothelial cells cultured from bovine pulmonary artery , bovine, 
rabbit, and pig aorta (Buonassi & Venter, 1976; Goldman et__al. , 
1983; Makarski , 1981; Brotherton & Hoak, 1982; Legrand et a l . ,
1989; 1990; Martin et a l . , 1988b).
All these studies indicate that adenylate cyclase and particulate 
and soluble guanylate cyclase are present in vascular endothelial 
cells.
1.10.4. Role of cyclic nucleotides in endothelial cell prolifera­
tion
It has been reported that cyclic AMP has differing actions on the 
proliferation of e n d o t h e l i a l  cells from d i f f e r e n t  sources in 
culture: adenosine, w h i c h  is known to increase i n t r a c e l l u l a r  
cyclic AMP content (Goldman et a l ., 1983), was found to stimulate 
proliferation of bovine aortic and coronary micro v a s c u l a r  e n ­
dothelial cells (Meininger et a l . , 1988; Meininger & Granger,
1990), foetal bovine aortic endothelial cells (Presta et a l . , 
1989a), and human dermal microvascular endothelial cells (Davison 
& Karasek, 1981). In contrast, an inhibition of growth was r e ­
ported for bovine aortic and rat cerebrovascular endothelial 
cells (Leitman et a l ., 1986; Kempski et a l ., 1987).
In contrast to cyclic AMP, the role of cyclic GMP in endothelial 
cell proliferation has not been extensively investigated. One 
study indicated that a slight inhibition of proliferation was 
observed when bovine aortic endothelial cells were treated with
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membrane permeant analogues of cyclic GMP (Leitman et a l . , 1986).
1.10.5. Role of cyclic nucleotides in smooth muscle cell prolif­
eration
There is a c c u m u l a t i n g  e v i d e n c e  t h a t  c y c l i c  A M P  is the 
intracellular mediator of vasorelaxation induced by prostacyclin 
and adenosine, w h e r e a s ,  c y c l i c  GMP is the m e d i a t o r  for 
endothelium- derived relaxing factor (EDRF), atrial natriuretic 
factor and sodium nitroprusside (Rapoport & Murad, 1983; Lincoln 
& Fisher-Simpson, 1984; Itoh et al., 1985; Kurtz, 1987; Grace et 
al., 1988).
Recent reports indicate that as well as possessing vasorelaxant 
properties, aden o s i n e ,  a t r i a l  n a t r i u r e t i c  f a c t o r  and s o d i u m  
nitroprusside inhibit the proliferation of smooth muscle cell in 
culture. Elevation of cyclic AMP content by various treatments 
(adenosine and its analogues, forskolin, cyclic AMP phosphodies­
terase (PDE) inhibitors, p- adrenoceptor agonists and cyclic AMP 
analogues) has an inhibitory action on proliferation of smooth 
muscle cells from d i f f e r e n t  sources in culture i n c l u d i n g  rat 
cerebrovascular (Kempski et a l . , 1987), rat aortic, human aortic 
and rabbit aortic (Nilsson & Olsson, 1984; Jonzon et a l . , 1985; 
Tertov et a l . , 1984; Fukumoto et a l ., 1988; Nakaki et a l ., 1990).
Elevation of cyclic GMP content by various treatments (nitrova- 
sodilators, atrial natriuretic factor and the cyclic GMP a n a ­
logue, 8 bromo cyclic GMP) inhibits the proliferation of rat and 
rabbit aortic smooth muscle cells stimulated to grow by serum and 
PDGF (Abell et a l . , 1989; Kariya et al., 1989; Garg & Hassid,
1989). Garg & Hassid (1989) proposed that nitric oxide (NO), the
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active principle generated by nitrovasodilators, is the ultimate 
effector of the i n h i b i t i o n  of g r o w t h  obs e r v e d .  T h e y  f u r t h e r  
proposed that EDRF, now identified as nitric oxide (Palmer et 
a l . , 1987 ), is an e n d o genous r e g u l a t o r  of smooth m u s c l e  cell 
growth within the arterial wall.
1.11. ENDOTHELIUM- DERIVED RELAXING FACTOR (EDRF)
The vascular endothelium is important in controlling vascular 
homeostasis by secreting a variety of substances such as endothe­
lin and p r o s t a c y c l i n .  It als o  p r o d u c e s  and s e c r e t e s  a n o t h e r  
powerful v a s o d i l a t o r ,  e n d o t h e l i u m -  d e r i v e d  r e l a x i n g  f a c t o r  
(EDRF)(Furchgott & Zawadzki, 1980).
The actions of EDRF were first described by Furchgott & Zawadzki 
(1980) who reported that a c e t y l c h o l i n e  induced r e l a x a t i o n  of 
rabbit aortic preparations only when the endothelium was present. 
Further studies showed that endothelial cells release this factor 
spontaneously or in response to a variety of stimuli including 
vasoactive agents or increased blood flow or shear stress (Pohl 
et_al., 1986; Rubanyi et al., 1986; Buga et al., 1991). Recent 
research has shown that s mooth mus c l e  cells grown in c ulture 
synthesize a v a s oactive substance(s) that interacts w i t h  the 
endothelium to stimulate the production of EDRF (Warren et a l . ,
1990) .
It was not until 1987 that Palmer et a l . (1987 ) identified EDRF
as nitric oxide (NO) by a chemiluminescence techniques. Nitric 
oxide is a small lipophilic molecule that can readily permeate 
biological m e m branes.
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1.11.1. Biosynthesis of EDRF
In the last few years the biosynthetic pathway of EDRF has been 
elucidated. L- arginine was found to be the physiological precur­
sor for basal and stimulated nitric oxide formation (Palmer et 
al., 1988b; Schmidt et a l . , 1988). Nitric oxide is formed from
the terminal guanidino group(s) of L- arginine by the enzyme 
nitric oxide synthase. This r e a c t i o n  is s t e r e o s e l e c t i v e  and 
specific since D- arginine and other basic amino acids cannot act 
as a substrate for this enzyme (Palmer et a l . , 1988a). Figure 2
illustrates the biosynthetic pathway of EDRF.
The nitric oxide synthesized by vascular endothelial cells rapid­
ly diffuses out to the underlying smooth muscle cells or nearby 
platelets in the lumen of the blood vessel where its actions are 
mediated by stimulation of soluble guanylate cyclase. Stimulation 
of this enzyme results from the b i n d i n g  of nit r i c  oxide to a 
ferrous haem moiety (Craven & De Rubertis, 1978). The associated 
rise in cellular cyclic GMP content mediates the actions of EDRF 
(Rapoport & Murad, 1983; Miilsch et al . , 1987; M a r t i n  et a l . ,
1988b).
Endothelial c e l l s  c o n t a i n  s o l u b l e  g u a n y l a t e  c y c l a s e  a n d  a 
consequence of this is that they are themselves sensitive to the 
EDRF they produce (Martin et a l . , 1988b). The effects of EDRF on 
endothelial function are, however, unknown. It has been shown 
recently that the endothelial cell is not the only cell with the 
capacity to produce and release nitric oxide (NO): macro p h a g e s , 
neutrophils, smooth muscle cells, central and peripheral neurons 
have all been shown to release this sub s t a n c e  (Hibbs et a l . ,
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Figure 2: Schematic diagram of the biosynthesis of EDRF. EDRF, 
now identified as nitric oxide (NO) (Palmer e ^ _ a l . , 1987),
formed from the terminal guanidino nitrogen(s) of L 9 
the enzyme nitric oxide synthase (NO synthase). This reaction 
be inhibited by NG- monomethyl L- arginine (L-NMMA) or N 
L- arginine (NG- NOARG) . NO is readily degraded to nitrite (N02 ) 
and nitrate (N03‘) ions by superoxide radicals (02 ). Superoxide 
dismutase (SOD) inhibits this breakdown.
1987a; Gillespie et a l . , 1989; Mehta et a l . , 1990; Wood et a l • /
1990; Garthwaite, 1990). These findings suggest that nitric  
oxide is a widespread messenger molecule in intercellular commu­
nication .
1.11.2. Role of EDRF in atherosclerosis
The endothelial cell layer lining the vascular wall is normally 
confluent and possesses both anticoagulant and antithrombotic 
properties. It has been found that EDRF can influence platelet 
function; for example, it inhibits platelet aggregation, induces 
platelet disaggregation and inhibits platelet adhesion to the 
vascular e n d o t h e l i u m  ( R a d o m s k i  et al . , 1987a; 1987b; 1987c;
Hawkins et a l . , 1988; Sneddon & Vane, 1988).
Since EDRF has these antithrombotic properties, its loss might 
aggravate the atherosclerotic process by allowing the adhesion of 
platelets to the vessel wall. This could promote the localised 
release of platelet- derived mitogens such as PDGF.
In aortas from humans and animals with atherosclerosis, it has 
been found that endo t h e l i u m -  d e p e n d e n t  v a s o d i l a t i o n  m e d i a t e d  
through EDRF is impaired (Cox et a l ., 1989; Freiman et a l ., 1986; 
Guerra et a l . , 1989; Nabel et a l ., 1990 ). It was proposed that
this early state of atherosclerosis may be associated with an 
impaired ability of the endothelial cells to produce EDRF. In 
e x p e r i m e n t a l l y  i n d u c e d  a t h e r o s c l e r o s i s  r e s u l t i n g  f r o m  
hypercholesterolemia, high levels of low density lipoproteins 
(LDL) are p r o d u c e d .  T h i s  no t  o n l y  p r o m o t e s  a t t a c h m e n t  of 
monocytes to the endothelium (Alderson et a l ., 1986) but leads to
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inactivation of EDRF after its release from the endothelial cells 
(Galle et a l ., 1991).
Furthermore, EDRF, n o w  i d e n t i f i e d  as n i t r i c  oxide, has bee n  
proposed to be an endogenous growth regulator for smooth muscle 
cells present within the arterial wall (Garg & Hassid, 1989). The 
impaired release of nitric oxide could, therefore, promote the 
abnormal proliferation of smooth muscle cells which is observed 
during the development of atherosclerosis.
1.12. Aim
The aim of this part of the study was to investigate the effects 
of cyclic nucleotides and the activation of protein kinase C on 
proliferation of pig aortic e n d o t h e l i a l  cells and rat aortic  
smooth muscle cells in culture.
2.1. CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
The transdu c t i o n  s i g n a l s  in r e s p o n s e  to a c t i v a t i o n  of cell-
surface receptors by an extracellular stimulus involves a series
of rapid i n t r a c e l l u l a r  e v e n t s  w h i c h  t r a n s l a t e s  the e x t e r n a l
signal into specific cellular responses. One exception is the
activation of soluble guanylate cyclase where the receptor is not
on the cell surface but on the soluble enzyme itself (Craven & De
Rubertis, 1978). The extracellularly generated signals give rise
to intracellularly generated second messengers such as calcium,
diacyglycerol, cyclic AMP and cyclic GMP which then change cell
function through p h o s p h o r y l a t i o n  of di s t i n c t  target p r o t e i n s
(Lincoln & Corbin, 1983; Corbin et a l ., 1988; Tremblay et a l ., 
1988) .
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Cyclic nucleotide activity is terminated by degradation and this 
was originally thought to occur by a single enzymatic activity. 
It was the o b s e r v a t i o n s  of T h o m p s o n  & A p p l e m a n  (1971) w h i c h  
showed that degradation and therefore inactivation of cyclic AMP 
and cyclic GMP is c a t a l y s e d  by not one but a large g r o u p  of 
different cyclic nu c l e o t i d e -  p h o s p h o d i e s t e r a s e s  (PDEs). PDEs 
terminate the actions of cyclic nucleotides by catalysing their 
hydrolysis to the respective nucleoside 5 '-monophosphate.
2.1.1. Nomenclature of PDE families
Many groups have defined different forms of PDE on the basis of 
the order of elution from a DEAE- Trisacyl chromatography column, 
utilising names such as peak I, II, III, or IV, often modified 
with regard to their substrate specificity (cyclic AMP or cyclic 
GMP), kinetic properties (KM and V MAX), sensitivity to calcium/ 
calmodulin and response to selective PDE inhibitors. Unfortunate­
ly many of these peaks of activity contain multiple activites and 
the order of elution of isozymes from DEAE varies with species, 
tissue, pH and eluting salt (reviewed in Beavo, 1988).
Beavo & Reifsnyder (1990) recently proposed a new classification 
of PDE isozymes b a s e d  upo n  the p r i m a r y  p r o t e i n  and its c D N A 
sequence information. They identified at least five distinct but 
related families coding for cyclic nucleotide PDE in m a m m a l s . 
Table 3 indicates the nomenclature of the PDE isozymes.
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Table 3 : Nomenclature of PDE- isozymes 
Family
I Ca2+-- calmodulin- dependent family PDE 
II cGMP- stimulated family PDE 
III cGMP- inhibited family PDE 
IV cAMP- specific family PDE
V cGMP- specific family PDE
Moreover most of t hese f a m i l i e s  c o n t a i n  two or m o r e  c l o s e l y  
related subspecies. Members of one family share between 20 and 
2b% sequence h o m o l o g y  w i t h  m e m b e r s  of another. M u c h  of this 
homology is found to occur in the C- terminal part of the PDE 
which is known to be par t  of the c a t a l y t i c  domain. The d a t a  
currently available suggest that most of the individual subfamily
members are encoded by different but highly homologous genes (70-
90% sequence homology). Many of these subfamilies have multiple 
members that are likely to be products of alternative mRNA splic­
ing .
2_-1.2. Identification and localization of PDE isozymes 
It is likely that identification of the cellular and subcellular 
distribution of each PDE isozyme will aid the d e v e l o p m e n t  of 
selective inhibitors as therapeutic agents for specific diseases. 
From extensive studies, it is becoming apparent that there is a 
variation in the distribution and substrate specificity of PDE 
isozymes in numerous tissues and c e l l s .
From the use of a n t i b o d i e s  a g a i n s t  the c a l c i u m /  c a l m o d u l i n  
dependent PDE, it was found that this isozyme is present in high
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concentrations in the dendrites of the Purkinje cells and in the 
cortical pyramidal cells in rat brains (Kincaid et a l . , 1987 ).
The substrate s p e c i f i c i t y  was h igher for cyclic AMP than for 
cyclic GMP. Human blood platelets were found to contain three PDE 
activities: a c a l m o d u l i n -  i n d e p e n d e n t  PD E  (I) w h i c h
preferentially hydrolyses cyclic GMP, a cyclic GMP-stimulated PDE 
(II), and a cyclic AMP PDE (IV) (Hidaka & Asano, 1976; Weishaar 
et al., 1986). In c o n t r a s t ,  h u m a n  b l o o d  m o n o c y t e s  w e r e  
demonstrated to contain only a soluble high affinity cyclic AMP 
PDE (IV) (Thompson et a l . , 1980). In adipocytes the predominant
isozyme is the c y c l i c  G M P -  i n h i b i t e d  P D E  (III) (Elks & 
Manganiello, 1984). The distribution of the cyclic GMP- specific 
PDE (V) is b e s t  c h a r a c t e r i z e d  in the r e t i n a .  The h i g h e s t  
concentrations are found in the outer s e g m e n t s . Recent research 
has indicated that there are separate isozymes in the rod and cone 
photoreceptor outer segments (Hurwitz et a l . , 1985 ).
2.1.3. Selective inhibitors
The development of drugs which have the ability to inhibit selec­
tively individual PDE isozymes could provide valuable tools with 
which to examine cyclic nucleotide regulated cellular processes. 
Butcher & Sutherland (1962) indicated that methylxanthines such 
as caffeine and theoph y l i n e  i n h i b i t e d  cyclic AMP hydrolysis. 
Further research has led to the development of a number of selec­
tive inhibitors. These inhibitors have proven useful in charac­
terizing the intracellular roles of the different molecular forms 
°f PDE, but there is no inhibitor known to distinguish between 
members of the same isozyme family. The inhibitory profile of 
several of these selective PDE inhibitors as well as several non-
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selective inhibitors is summarized in Table 4
Table 4: Selective and non- s 
PDE isozyme families.
INHIBITOR
Selective Inhibitors 
M & B 22948 
SK & F 94120 
IBMX
ROLIPRAM
Non- Selective Inhibitors 
DIPYRIDAMOLE
TREQUINSIN
lective inhibitors of the different
PDE- ISOZYME FAMILY
Ca2+/ CaM dependent PDE (I)
Cyclic GMP- inhibited PDE (III) 
Ca2+/ CaM dependent PDE (I)
Cyclic AMP- specific PDE (IV)
Cyclic GMP- syimulated PDE (II) 
Cyclic AMP- specific PDE (IV) 
Cyclic GMP- stimulated PDE (II) 
Cyclic AMP- specific PDE (IV)
There is substantial interest in the use of selective PDE inhibi­
tors as therapeutic agents in diseases. In one such study, selec­
tive PDE inhibitors were proposed to represent a new approach to 
the treatment of asthma. In this scheme bronchodilatation can be 
brought about through selective inhibitors of the PDE isozymes 
present in bronchial smooth muscle thus avoiding the side effects 
encountered with non- selective PDE inhibitors (Torphy, 1988).
2.2. AIM
The aim of this part of the project was to investigate the e f ­
fects of selective and non- selective inhibitors of PDE isozymes 
on accumulation of cyclic AMP and cyclic GMP in intact pig aortic 
endothelial cells.
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MATERIALS AND METHODS
3.1. ENDOTHELIAL CELLS
3 .1 .1. Endothelial cell culture
Pig aortae were o b t a i n e d  fro m  a local aba t t o i r .  Less tha n  5 
minutes after removal from animal, the aorta was flushed with 
sterile saline (0.9% w/v, Baxter, UK) containing benzyl penicil­
lin (100U/ ml) and streptomycin (lOOpg/ ml) to remove any remain­
ing blood. The aortae were then tied off at the larger thoracic 
end using string and cannulated at the smaller abdominal end with 
a 60 ml syringe containing the same saline solution. Saline was 
infused into the lumen before the vessels were transported to the 
laboratory, which took 30 minutes.
In a laminar flow hood (Flow), the in t e r c o s t a l  a rteries were 
cleared of remaining connective and fatty tissues and ligated 
ensuring that no fluid leakage occured. Any remaining saline was 
removed and 10-15 ml of sterile collagenase solution (Type II, 
Sigma, 0.2% in Dulbecco's modified Eagle's M edium (DM E M ) ) was 
introduced into the lumen. The aorta was then incubated at 3 7 °C 
for 25 minutes. After incubation, the collagenase solution now 
containing detached endothelial cells was removed and the aorta 
gently massaged to loosen any remaining endothelial cells from 
their basement mem b r a n e .  The c o l l a g e n a s e  s o l u t i o n  was t h e n  
H u s h e d  in and out several times to d i s l o d g e  these r e m a i n i n g  
cells from the vessel wall. The resultant cell suspension was 
Placed in a sterile centrifuge tube (50 ml, Falcon). 20 ml of 
sterile saline was then introduced into the aorta to remove any 
remaining cells and this suspension was combined with the first.
The cell suspension was then centrifuged at 200 g for 4
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minutes at 10°C (IEC Centra 8R centrifuge) , the supernatant was 
discarded and the cell pellet resuspended in 20 ml of DMEM sup­
plemented with foetal calf serum (10%), newborn calf serum (10%), 
glutamine (4 mM) , benzyl penicillin (100U/ ml) and streptomycin 
(lOOpg/ ml): this is subsequently referred to as normal serum- 
supplemented DMEM in the text. The cell suspension was centrifuged 
as before, the supernatant was d i s c a r d e d  and the cell pellet  
resuspended in 5 ml of normal serum- supplemented DMEM. Cells 
were seeded initially into 80 c m 2 tissue culture flasks (Nunc) 
and normal serum- supplemented DMEM was added to give a final 
volume of 20 ml.
The cells were then grown at 37 °C under an atmosphere of 5% C02 
in air in an incubator (Flow C 02 incubator model 220). The normal 
serum- supplemented DMEM was aspirated off every 2 or 3 days, the 
cells were then was h e d  wit h  2 x 20 ml of sterile saline, and 
fresh culture medium was added. Cells normally grew to confluence 
within 6-8 days. F i g u r e  3 s h o w s  the m o r p h o l o g y  of f r e s h l y  
isolated and confluent pig aortic endothelial cells in culture.
3.1.2. Characterization of pig aortic endothelial cells
Cells were characterized as endothelial cells by their growth as
a strict monolayer with a typical cobblestone morphology.
Furthermore, we have previously reported their ability to secrete 
prostacyclin and endothelium-derived relaxing factor (Martin et 
• / 1988b), and fluoresce w h e n  inc u b a t e d  w i t h  the sel e c t i v e  
marker, acetylated low- density lipoprotein labelled with 1 ,1 ' 
dioctadecyl-3,3,3' ,3'-tetramethyl-indocarbocyanine perchorate
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Figure 3: Phase contrast micrographs of pig aortic endothelial 
cells. 24 hours and 4 days a f t e r  i s o l a t i o n  fro m  pi g  a o r t a  by 
collagenase treatment. Endothelial cells were isolated as small 
clumps, but divided and multiplied to form a strict monolayer of 
cobblestone morphology.
(Voyta et a l . , 1984)
3.2 PROLIFERATION STUDIES 
3.2.1. Haemocytometric Studies
Once the pig aortic endothelial cells (PAEC) reached confluence, 
the normal serum- supplemented DMEM was removed by aspiration and 
the cells washed with 2 x 10 ml of sterile saline. 10 ml trypsin 
(0.05%)/ EDTA (0.02%) solution (Flow) was then added, and the 
flask incubated at 3 7 °C until the cells became detached (usually 
around 5 minutes). 2-3 ml of n e w b o r n  calf serum was added to 
inactivate the trypsin/ EDTA solution. The resultant cell suspen­
sion was placed in a sterile centrifuge tube (50 ml, Falcon) and 
centrifuged, at 200 g for 4 minutes at 10 °C (IEC Centra 8R
centrifuge ) . The supernatant was discarded and the cell pellet 
resuspended in 20 ml of normal serum- supplemented DMEM. The cell 
suspension was then centrifuged as before, but this time the cell 
pellet was resuspended in 10 ml of normal serum- supplemented 
DMEM. A 1 ml aliquot of the cell suspension was removed and cell 
density d e t e r m i n e d  by the use of a h a e m o c y t o m e t e r . The cell 
suspension was subsequently diluted to a final density of 4.5 - 
6.0 x 105 cells/ ml with normal serum- supplemented DMEM.
^0r Pr°liferation studies , PAEC were seeded at a d e n s i t y  of 
aPproximately l - 1.5 x 104 cells / c m2 in 2 ml of normal serum-
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supplemented DMEM in six- well plates (9.6 c m2,Nunc). The effects 
of various drug treatments on proliferation were examined with 
time. All drugs were added twice d a ily with the e x c e ption of 
methylene blue w h i c h  was added once daily. The normal serum- 
supplemented DMEM was removed by aspiration every 2 or 3 days, 
the cells were washed with 2 x 2 ml of sterile saline, and fresh 
culture medium added.
At various time points as indicated in the Results, the culture 
medium was removed by aspiration and cells washed with 2 x 2 ml 
of sterile saline. 1 ml of trypsin (0.05%)/ EDTA (0.02%) solution 
(Flow) was added. Cells were incubated at 3 7 °C until they became 
detached (usually around 5 minutes). 0.5 ml of newborn calf serum 
was added to inactivate the trypsin/ EDTA solution. The resultant 
cell suspension was transferred to eppendorf tubes and the cell 
density determined by haemocytometry .
3.2.2. [3h]-Thymidine Incorporation Studies
These were conducted in some experiments to hopefully obtain a 
more sensitive index of proliferation than could be obtained by 
haemocytometry .
Once the primary cultures of PAEC had grown to confluence in a 80 
cm flask, the normal serum- supplemented DMEM was removed by 
aspiration and the cells washed with 2 x 10 ml of sterile saline. 
iO ml of trypsin (0.05%)/ EDTA (0.02%) solution (Flow) was added. 
Ihe flask was then i n c u b a t e d  at 37°C u n til the cells b e c a m e  
^tached (usually around 5 minutes). 2-3 ml of newborn calf serum 
Was ai3ded to inactivate the trypsin/ EDTA solution and the re-
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sultant cell suspension was transferred to a sterile centrifuge 
tube (50 ml, Falcon) and centrifuged at 200 g for 4 minutes
at 10°C (IEC Centra 8R centrifuge] . The supernatant was discarded 
and the cell pellet resuspended in 20 ml of normal serum- supple­
mented DMEM. The cell suspension was then centrifuged as before, 
the supernatant was discarded and the cell pellet resuspended in 
10 ml of normal serum- s u p p l e m e n t e d  DMEM. A 1 ml aliquot was
removed and cell density determined by haemocytometry . The cell
suspension was diluted to a final density of 6-8 x 105 cells/ ml 
with normal serum- supplemented DMEM.
PAEC were seeded at a d e n s i t y  of a p p r o x i m a t e l y  1. 5-2.0 x 1 04 
cells/ cm2 in six- well plates (9.6 c m 2 , Nunc). The cells were 
grown in normal serum- supplemented DMEM for 24 hours. The normal 
serum- supplemented DMEM was removed by aspiration, the cells 
washed with 2 x 2 ml of sterile saline, and 2 ml of serum- free 
DMEM supplemented with glutamine (4 m M ) , benzyl penicillin (100U/ 
ml) and streptomycin (100pg/ ml) was added: this is subsequently 
referred to as ser u m -  free D M E M  in the text. The cells w e r e  
incubated for a further 24 hours and at the end of this period, 
the serum- free DMEM was removed by aspiration. Cells were then 
challenged with drugs in DMEM supplemented with various concen­
trations of s e r u m  a n d  t h e n  p u l s e d  w i t h  a m i x t u r e  of [3H]-  
thymidine (2pCi/ well) and unlabelled thymidine (lpM) at 3 7 °C for
various times as indicated in the R e s u l t s .
the end of the incubation period, the cells were washed with 3 
x 2 ml of 5% ice-cold trichloroacetic acid and solubilized in 0.5 
^  of 0.25M ice-cold NaOH. The cells were then scraped off the
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multiwell plates and h a r v e s t e d  into s c i n t i l l a t i o n  vials. Any 
remaining cells were recovered by the addition of a second volume 
of 0.5 ml of NaOH and this extract was combined with the first. 5 
ml of Ecoscint (Natural Diagnostics) was added to each vial fol­
lowed by vortex mixing. The radioactivity in each vial was count­
ed for 5 minutes using a Liquid Scintillation Counter (Packard 
2000CA) . The results were converted from c.p.m. to d.p.m. using 
an external standard.
3.3. SMOOTH MUSCLE CELLS
3.3.1. Smooth muscle cell culture
Vascular smooth muscle cells were harvested from the enzymatical­
ly dissociated aortae of Sprague- Dawley rats using a modifica­
tion of the method described by Chamley- Campbell et a l . (1979).
Briefly, Sprague-Dawley rats (200-300g) were killed, and under 
sterile conditions, the aorta was dissected out and placed in a 
petri dish containing 2-3 ml of DMEM. The aorta was cleared of 
fat, adventitial tissue and any remaining blood. The aorta was 
incubated for 5 minutes at 3 7 °C in a sterile tube (15 ml, Falcon) 
containing 5 ml of DMEM containing collagenase (Type II, Sigma, 
0.125%) and elastase (Type II, Sigma, 0.025%). The aorta was then 
transferred to fresh DMEM and any remaining fat and adventitia 
was removed. The aorta was then cut into 1-2 mm sections with 
scissors and incubated at 37 °C in fresh DMEM-enzyme solution for 
2 3 hours. The mixture was drawn through a sterile glass pipette 
to aid dispersal of cells.
Ths resultant cell suspension of rat aortic smooth muscle cells
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was then centrifuged at 200 g for 4 minutes at 10°C (IEC
Centra 8Rcentrifuge) . The supernatant was discarded and the cell 
pellet resuspended in 10 ml of normal serum- supplemented DMEM. 
The cell suspension was centrifuged as before, the supernatant 
discarded and the cell pe l l e t  r e s u s p e n d e d  in 10 ml of normal 
serum- supplemented DMEM. The rat aortic smooth muscle cells (Rat 
ASMC) were seeded initially into a 25 c m2 tissue culture flasks 
(Nunc) and grown at 3 7 °C under an atmosphere of 5% C 0 2 in air. 
The normal serum- supplemented DMEM was removed by aspiration 
every 2 or 3 days. The cells were then washed with 2 x 10 ml of 
sterile saline and fresh culture medium added.
When primary cultures of rat A S M C  a t t a i n e d  confl u e n c e  (10-14 
days), the c u l t u r e  m e d i u m  was a s p i r a t e d  off, the cells w e r e  
washed with 2 x 2 ml of s t e r i l e  s a l i n e  and 5 ml of t r y p s i n  
(0.05%)/ EDTA (0.02%) solution (Flow) was added. The flask of rat 
ASMC was i n c u b a t e d  at 37 °C u n t i l  the cells b e c a m e  d e t a c h e d  
(usually around 5 minutes). 1 ml of newborn calf serum was added 
to inactivate the trypsin/ EDTA solution and the resultant cell 
suspension was p l a c e d  in a sterile' centrifuge t u b e  (15 ml, 
Falcon). The cell suspension was then centrifuged at 200 g 
for 4 minutes at 10°C (IEC Centra 8R Centrifuge)i the supernatant 
was discarded and the cell pellet resuspended in 10 ml of normal 
serum- supplemented DMEM. The cell suspension was centrifuged as 
before, the supernatant was discarded, and the cell pellet resus- 
pended once again in 10 ml of nomal serum- supplemented DMEM. The 
Cell suspension was seeded into 80 c m 2 tissue culture flasks 
(Nunc) . Normal serum- supplemented DMEM was added to give a final 
volume of 20 ml pe r  flask. F i g u r e  4 shows the m o r p h o l o g y  of
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Figure 4: Phase contrast micr o g r a p h  of subcultured rat aortic 
smooth muscle cells.
subconfluent secondary cultures of ASMC in culture.
3.3.2. Characterization of rat aortic smooth muscle cells 
Characterization of the cells as smooth muscle cells was estab­
lished by the following criteria: the cells grew in the typical 
'hill and valley' pattern and were shown to fluoresce with antis­
mooth muscle actin antibodies (Chamley et a l . , 1977).
3.4. PROLIFERATION STUDIES
3.4.1. Haemocytometeric Studies
When secondary cultures of rat ASMC grew to confluence in 80 c m2 
flasks, the normal serum- supplemented DMEM was removed by aspi­
ration and the cells washed with 2 x 20 ml of sterile saline. 10 
ml of trypsin (0.05%)/ EDTA (0.02%) solution (Flow) was added and 
the flasks were incubated at 3 7 °C until the cells became detached 
(usually around 5 minutes). 2-3 ml of n ewborn calf serum was 
added to inactivate the trypsin/ EDTA solution and the resultant 
cell suspension was placed in a sterile centrifuge tube (50 ml, 
Falcon) . The cell suspension was then centrifuged at 200 g 
for 4 minutes at 1 0 °C (IEC Centra 8R Centrifuge), the supernatant 
discarded and the cell pel l e t  r e s u s p e n d e d  in 20 ml of normal 
serum- supplemented DMEM. The cell suspension was then centrifuged 
as before, the su p e r n a t a n t  was d i s c a r d e d  and the cell p ellet 
resuspended once again in 10 ml of normal serum- supplemented 
DMEM. A 1 ml aliquot of cell s u s p e n s i o n  was r emoved and cell 
density counted by h a e m o c y t o m e t e r y . The cell s u s p e n s i o n  was 
diluted to a final density of 4 .5-6 x 105 cells/ ml with normal 
serum- supplemented DMEM.
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For proliferation studies, rat ASMC were seeded at a density of 
approximately 1.25-1.5 x 104 cells/ c m2 in six- well plates (9.6 
cm2, Nunc). The rat A S M C  w e r e  e i t h e r  g r o w n  in n o r m a l  s erum-  
supplemented DMEM or DMEM supplemented with foetal calf serum 
(5%), newborn calf serum (5%), glutamine (4 mM) , benzyl penicil­
lin (100U/ ml) and streptomycin (lOOpg/ ml): this is subsequently 
referred to as 10% serum- supplemented DMEM in the text. The ef­
fects of various drug treatments on proliferation were examined 
with time. All drugs were added twice daily after an initial 
period of 24 hours to a l l o w  the rat A S M C  to p l a t e  down. The 
normal serum- supplemented DMEM, or the 10% serum- supplemented 
DMEM was removed by aspiration every 2 or 3 d a y s . The cells were 
then washed with 2 x 2 ml of sterile saline, and fresh culture 
medium added.
At the various time points indicated in the Results, the culture 
medium was removed by aspiration, cells were washed with 2 x 2 ml 
of sterile s aline and 1 ml of t r y p s i n  (0.05%)/ E D T A  (0.02%) 
solution (Flow) was added. Cells were incubated at 3 7 °C until the 
cells became detached (usually around 5 minutes). 0.5 ml of new­
born calf serum was added to inactivate the trypsin/ EDTA solu­
tion. The resultant cell suspension was transferred to eppendorf 
tubes. A lOpl aliquot of cell suspension was removed and counted 
ky haemocytometry • Rat ASMC between the 3rd and 15th passage 
were used in experiments described in the R e s u l t s .
 ^ r
tj_il__MEASUREMENT OF ENDOTHELIAL CELL CYCLIC NUCLEOTIDE CONTENT
j-ijjj^ P r e p a r a t i o n  of endothelial cell monolayers
Primary cultures of PAEC were isolated as described in 3.1.1.
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except that all the cells harvested from each aorta were resus­
pended in 30 ml of normal serum- supplemented DMEM. 1 ml of cell 
suspension was then added into 5 multiwell dishes, each contain­
ing 6 wells (9.6 c m 2 , Nunc). A further 1 ml of normal serum- 
supplemented DMEM was added to give a final volume of 2 ml per 
well.
Cells were then grown at 3 7 °C under an atmosphere of 5% C 02 in 
air in an incubator (Flow C02 incubator model 220). The culture 
medium was removed every 2-3 days by aspiration, the cells were 
washed with 2 x 2 ml of sterile saline and then fresh culture 
medium added. Cells were used for experimentation when confluent 
(attained within 7 days).
3.5.2. Experimental procedure
Following removal of the tissue culture medium by aspiration, the 
endothelial cells were washed with 2 x 2 ml of warmed (37°C) and 
gassed Kreb's solution containing (mM) : NaCl 118, KCl 4.8, CaCl2
2.5, MgS04 1.2, K H2P 04 1.2, N a H C 03 24 and glucose 11; and then 
incubated in 2 ml of Kreb's solution at 3 7 °C under an atmosphere 
of 5% C02 in air for at least 60 minutes.
At the appropriate time, drugs were added, the Kreb's bathing 
solution was q u i c k l y  removed, and the cells were i m m e d i a t e l y  
extracted with 0.5 ml of ice cold 6% trichloroacetic acid (TCA). 
The cells w e r e  t h e n  s c r a p e d  off the m u l t i w e l l  p l a t e s  a n d  
harvested. Any remaining cells were recovered by the addition of 
a second volume of 0.5 ml TCA, and this extract was combined with 
the first. The e x t r a c t  w a s  centrifuged at 10000 g
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(MicroCentaur MSE) for 2 minutes and the pellet and supernatant 
were separated.
The supernatant, and in some e x p e r i m e n t s  w h e n  i n d i c a t e d  the 
Kreb's bathing solution, were stored for subsequent measurement 
of cyclic nucleotide content. The DNA content of the pellet was 
determined so tha t  the c y c l i c  n u c l e o t i d e  c o n t e n t  c o u l d  be 
expressed in pmol or fmol pg DNA-1.
3.5.3. Preparation of trichloroacetic acid extracts for radioim- 
munoassay
The TCA extracts were neutralised to pH 5.5-6.0 by adding 2 ml of 
0.5M tri-n-octylamine in freon (1,1,2,t r i c h l o r o t r i f l u r o e t h a n e ) 
and vortex mixing for 90 seconds. The upper aqueous layer was 
removed using a glass Pasteur pipette ensuring that no contamina­
tion from the lower layer occured. The pH of the aqueous layer 
was checked with Whatman pH paper. The cyclic AMP and cyclic GMP 
content of the aqueous layer was determined by radioimmunoassay 
using New England Nuclear kits (Dupont).
3.6. RADIOIMMUNOASSAY
jj-j.l. Principles of the cyclic AMP and cyclic GMP radioimmunoas­
say
The radioimmunoassays (RIA) for cyclic AMP and cyclic GMP were 
based on the basic principle of RIA first described by Yalow and 
Berson (I960): this consists of competition between radioactive 
and non-radioactive antigen for a fixed number of antibody bind-
lng sites. This i n t e r a c t i o n  is r e p r e s e n t e d  s c h e m a t i c a l l y  in
Figure 5 .
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Figure 5: S c h e m a t i c  r e p r e s e n t a t i o n  of the p n n c i p
radioimmunoassay (R IA ). RIA is  based on the competition between 
radiolabelled a n d  u n l a b e l l e d  a n t i g e n  for a f i x e d  n u m b e r  
antibody binding sites. Increasing amounts of unlabelled antigen
4- antibody and radiolabelled
in the presence of fixed amounts o
antigen, produce a decreasing amount of radiolabelled antigen 
bound to antibody. T h i s  r e l a t i o n s h i p  can be e x p r e s  
standard curve after seperation of bound from free rad 
antigen, and a m o u n t s  of u n l a b e l l e d  a n t i g e n  d e t e r m
interpolation from the curve.
If increasing amounts of unlabelled antigen (i.e. in standards or 
unknown samples) and a fixed amount of labelled antigen (i.e. 
tracer) are allowed to react with a constant amount of antibody, 
a decreasing amount of labelled antigen is bound to the antibody. 
This relationship can be expressed as a standard curve and the 
amount of unlabelled antigen in a sample can be determined by 
interpolation from this curve.
3.6.2. RIA for cyclic GMP
Determination of cyclic GMP was adapted from the procedure of 
Steiner et a l . (1972), using New England Nuclear RIA kits (Du­
pont). Steiner et a l . ( 1972 ) reported that cyclic nucleotides
substituted at the 2 '-a-position had a higher affinity for the 
antibody and thus displaced the [ 125I ]-labelled derivative better 
than the u n s u b s t i t u t e d  cyclic nucleotide. Thus standards and 
samples were acetylated with acetic anhydride to give 2 '-a-acetyl 
cyclic GMP t h e r e b y  i n c r e a s i n g  the s e n s i t i v i t y  of the a s s a y  
(Harper & Brooker, 1975). The labelled antigen was a succinyl 
tyrosine-[ 125i ]-methyl ester derivative of cyclic GMP.
separation of bound from free antigen was achieved by the use of 
a pre-reacted primary and secondary antibody complex. The primary 
antibody was prepared in rabbits against a succinyl cyclic GMP 
albumin conjugate, w h ile the s econd a n t i b o d y  was p r e p a r e d  in 
sheep against rabbit globulin. W i t h  this p r e - r e a c t e d  system, 
pipetting and incubation times were reduced compared to the usual 
sequential double antibody assay and no second incubation was 
inquired. After a single overnight incubation at 4°C, 1 ml of 
Propan-l-ol was added to aid precipitation, the tubes were centi-
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fuged, the supernatants discarded, and the radioactivity in the 
precipitates counted.
3.6.3. Chemicals for RIA 
3 .6.3.1. Cyclic GMP antiserum complex
One vial of lyophilized pre-reacted ,first and second antibody was 
supplied. It was reconstituted with 21 ml of distilled water. The 
resulting solution, in 0.1M sodium phosphate buffer with 0.05% 
thimerosal, pH 6.2, contained sufficient antibody to bind approx­
imately 50-60% of the labelled antigen in the absence of u n l a ­
belled antigen when used as directed later. The reconstituted 
antiserum complex was stable for at least two months when stored 
at 2-8°C.
3.6.3.2. Succinyl cyclic GMP tyrosine methyl ester-[125I] 
(ScGMP-TME-[125I] )
Two vials of concentrated tracer were supplied. Each vial con­
tained approximately 28KBq (0.7 5pCi) on the calibration date in 1 
ml of p r o p a n - l - o l :w a t e r  s o l u t i o n  (1:1). The c o n c e n t r a t e  was 
stable for at least 2 months when stored at 2- 8 °C.
j_-6.3. 3. Normal rabbit serum
The normal rabbit serum was used to m e a s u r e  the n o n - s p e c i f i c  
binding obtained using non-immune serum. Two vials of lyphilized 
normal rabbit serum were supplied. 5 ml of distilled water was 
added to one vial of S c G M P - T M E - [ 125I ] concentrate, and to one 
Vlal lyophilised normal rabbit serum. The entire contents of 
the reconstituted n o r m a l  r a b b i t  s e r u m  via l  was a d d e d  to the 
diluted ScGMP-TME-[ 125I ] vial and the resulting solution mixed
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well. The resulting solution (appro x i m a t e l y  11 ml) c o n t ained 
ScGMP-TME-[ 125I ] (0.068pCi/ ml), 1.0% normal rabbit serum, and
0.05M sodium acetate buffer, p H 6 .2.
3 .6 . 3.4. Acetic anhydride and triethylamine
A mixture of these two solutions was used to acetylate cyclic GMP 
in the samples in order to increase the sensitivity of the assay. 
One vial of acetic anhydride and triethylamine was supplied. They 
were allowed to equilibrate to room temperature before use. When 
protected from moisture these chemicals were stable for at least 
two months. Immediately prior to use, one volume of acetic anhy­
dride was mixed wit h  two vol u m e s  of triethylamine; the exact 
volume of each was dependent upon the number of samples to be 
acetylated.
3.6. 3. 5. Cyclic GMP standard
This was the unlabelled antigen. One vial of lyophilized standard 
was supplied. It was reconstituted with exactly 20 ml of d i s ­
tilled water and contained 2000 pmol/ ml in 0.05M sodium acetate 
buffer, pH 6.2. The cyclic GMP standard had been calibrated spec- 
trophotometrically by the manufacturer using the molar absorption 
coefficient for GMP, e = 13.7 x l 0 3/mol/cm at 252 nm, pH 7.0. The 
reconstituted standard was stable for at least two months when 
stored at 2-8°C.
3^ 6.4. Preparation of standard curve and assay of neutralized
£^ll__extracts
A series of 3.5 cm p l a s t i c  tubes (Sarstedt) was n u m b e r e d  for 
identification and the standard cyclic GMP stock solution (2000
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pmol/ ml) diluted with sodium acetate buffer, pH 6.2 to a concen­
tration of 100 pmol/ ml. Further serial dilutions with sodium 
acetate buffer were made to p r e p a r e  the fo l l o w i n g  cyclic GMP 
standards for assay: 0.025. 0.05, 0.1, 0.25, 0.5, 1.0, 2.5 and
5.0 pmol/ ml. All standards were run in duplicate.
Tubes 1 and 2 were used to measure "total counts", tubes 3 and 4 
were "blanks" and tubes 5 and 6 were used to measure the " ’O'
standard". 50pl of e a c h  s t a n d a r d  s o l u t i o n  (in d u p l i c a t e )  or
sample was added to the appropriately labelled tube. All tubes
except for "total counts" and "blank" received 5pl of the acety- 
lation mixture ensuring that the reagents were added directly to 
the solution and were immediately vortex mixed for 2 seconds. All 
tubes received 50pl of [125I] tracer solution, and 50pl of anti­
serum complex was added to all tubes except for "total counts" 
and "blanks". All tubes were vortex mixed for 5 seconds, covered 
with aluminium foil and equilibrated overnight (16-18 hours) at 
4°C.
Following overnight incubation at 4°C, 1 ml of ice cold propan-1- 
ol was added to each tube except for "total counts". This aided 
the precipitation of the antigen-antibody complex. The tubes were
vortex mixed and spun at 2000 g for 30 minutes at 4°C (Damon IEC
Centrifuge). The supernatants were removed by aspiration (except 
tor the "total counts"). All tubes were counted for 1 minute in a 
gamma counter (Packard Cobra Auto g a m m a ) .
Analysis of radioactivity 
Analysis of the radioactivity in tubes (counting and background
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reduction) was performed by an IBM-compatible computer with a 
defined RIA protocol. This allowed the user to define the nature 
of the sample (i.e.total counts, blanks, standards, unknowns and 
the number of replicates) and the count time. The standard curve 
was plotted with the charcteristics of a Bound Fraction RIA curve 
with a negative slope (spline f i t t e d ) . The concentration for each 
unknown sample was calculated by interpolation from the standard 
curve and the value printed. Table 5 and Figure 6 represents a 
typical standard curve obtained for an acetylated cyclic GMP RIA.
3.6.6. RIA for cyclic AMP
Determination of cyclic AMP, like that of cyclic GMP, was adapted 
from the procedure of Steiner et a l . ( 1972 ), using New England
Nuclear RIA kits (Dupont). The standards and samples were not 
acetylated since high concentrations of cyclic AMP are found in 
endothelial cells and enhanced sensitivity is not required. The 
labelled antigen was a succi n y l  t y r o s i n e - [ 125I ]-methyl ester 
derivative of cyclic AMP. Separation of bound from free antigen 
was achieved by the use of a pre-reacted primary and secondary 
antibody complex. The primary antibody was prepared in rabbits 
against a succinyl cyclic AMP albumin conjugate, while the second 
antibody was prepared in sheep against rabbit globulin.
Chemicals for RIA
1. Cyclic AMP antiserum complex 
One vial of lyophilized pre-reacted, first and second antibody 
was supplied, it was reconstituted with 21 ml of distilled water.
Th G
resulting solution, in 0 . 1M sodium p h o s p h a t e  bu f f e r  w i t h  
0-05% thimerosal, pH 6.2, contained sufficient antibody to bind
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TOTAL COUNTS
BLANK
'0’ STANDARD
0.025 pmol/ ml
0.05 pmol/ ml
0.1 pmol/ ml
0.25 pmol/ ml
0 .5 pmol/ ml
1.0 pmol/ ml
2 .5 pmol/ ml
5 .0 pmol/ ml
CPM
6267
5761
98
107
3594
3316
2951
3219
2762
2727
2340
2223
1485
1488
1012
1098
757
741
469
514
325
328
AVERAGE CPM 
6014 
103 
3455 
3085 
2745 
2282 
1487 
1055 
749 
492 
327
Table 5: Typical standard curve for acetylated RIA of cyclic GMP, 
showing d e c r e a s e d  b i n d i n g  of [125I ] - S c G M P  TME t r a c e r  to the 
antibody and therefore decreasing counts as the concentration of 
unlabelled cyclic GMP standard increases. "Total counts" measures 
total activity of [125I]-ScGMP TME tracer, "Blank" measures non­
specific binding, and "0 standard" m e a s u r e s  total b i n d i n g  of 
[ 125I]-ScGMP TME tracer to antibody.
3085 f=^ r
"3k
CPM
327
0.025 pmol cyclic GMP 5.0
Figure 6: Typical computer printout of an acetylated cycli 
RIA standard curve. U n k n o w n  c y c l i c  GMP c o n c e n t r a t i o n  
calculated from this curve by the computer.
approximately 50-60% of the labelled antigen in the absence of 
unlabelled antigen when used as directed later. The reconstituted 
antiserum complex was stable for at least two months when stored 
at 2-8 C.
3.6.7.2. Succinyl cyclic AMP tyrosine methyl ester-[125I] 
(ScAMP-TME-[125I] )
Two vials of concentrated tracer were supplied. Each vial con­
tained approximately 1.5pCi on the calibration date in 1 ml of 
propanol: water solution (1:1). The concentrate was stable for at 
least two months when stored at 2 - 8 °C.
3.6.7.3. Cyclic AMP carrier serum
Two vials of lyophilized carrier serum were supplied. 5 ml of 
distilled water was added to one vial of ScAMP-TME-[ 125I ] concen­
trate, and to one vial of lyophilized cyclic AMP carrier serum. 
The entire contents of the reconstituted cyclic AMP carrier serum 
was added to the d i l u t e d  S c A M P - T M E - [ 125I ] and the r e s u l t i n g  
solution mixed well. The resulting solution (approximately 11 ml) 
contained S c A M P - T M E - [ 125I ] (0.14pCi/ ml), 1% carrier serum, and
0.1% sodium azide in sodium acetate buffer, pH 6.2.
j_:6.7.4. Cyclic AMP standard
This is the unlabelled antigen. One vial of lyophilized standard 
was supplied. It was reconstituted with exactly 2 ml of distilled 
water and contained 5000 pmol/ ml in 0.05M sodium acetate buffer, 
PH 6.2 and 0.1% sodium azide. The cyclic AMP standard had been 
calibrated spectrophotometrically by the manufacturer using the 
m°lar absorption coefficient for AMP, e=14.6 xl03/mol/cm at 259
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nm, pH 6.9. The reconstituted standard was stable for at least 
two months when stored at 2-8°c.
3.6.8. Preparation of standard curve and assay of neutralized 
cell extracts
A series of 3.5 cm p l a s t i c  tubes (Sarstedt) was n u m b e r e d  for 
identification and the standard cyclic AMP stock solution (5000 
pmol/ ml) diluted with sodium acetate buffer, pH 6.2 to obtain 
the following cyclic AMP standards for assay: 0.5, 1.0, 2.5, 5.0, 
10.0, 25.0 and 50.0 pmol/ ml. All standards were run in d u p l i ­
cate .
Tubes 1 end 2 were used to measure "total counts", tubes 3 and 4 
were "blanks" and tubes 5 and 6 were used to measure the" 'O' 
standard". 50pl of e a c h  s t a n d a r d  s o l u t i o n  (in d u p l i c a t e )  or 
sample was added to the appropriately labelled tube. All tubes 
received 50pl of [1251 ] t racer s olution and 50pl of a n t i s e r u m  
complex except for "total counts" and "blanks". All tubes were 
vortex mixed for 5 seconds, c o v e r e d  w i t h  a l u m i n i u m  foil and 
equilibrated overnight (16-18 hours) at 4°C.
Following overnight incubation at 4 °C, 1 ml of ice cold propan-1- 
°1 was added to each tube except for "total c o u n t s " . This aided 
the precipitation of the antigen-antibody complex. The tubes were 
vortex mixed and spun at 2000 g for 30 minutes at 4°C (Damon IEC 
Centrifuge). The supernatants were removed by aspiration (except 
tor the "total counts"). All tubes were counted for 5 minutes in 
a gamma counter (Packard Cobra Auto g a m m a ) .
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3.6.9. Analysis of radioactivity
Analysis of the radioactivity in tubes (counting and background 
r e d u c t i o n )  was performed by an IBM-compatible computer with a 
defined RIA protocol. This allowed the user to define the nature 
of the sample (i.e. total counts, blanks, standards, unknowns and 
the number of replicates) and the count time. The standard curve 
was plotted wit h  the c h a r a c t e r i s t i c s  of a Bound Fraction RIA 
curve with a negative slope (spline fitted). The concentration 
for each unknown was calculated by interpolation from the stand­
ard curve and the value printed. Table 6 and Figure 7 represents 
a typical standard curve obtained for a cyclic AMP RIA.
3.7. MEASUREMENT OF DNA CONTENT OF SAMPLES
3.7.1 Principles of DNA Assay
The DNA content of the samples was measured by the fluorescence
technique as previously described by Kissane and Robins (1958). 
Briefly, the DNA content of the samples can be quantified fluoro- 
metrically by the reaction of 3,5, diaminobenzoic acid (DABA, 
Sigma) with the deoxyribose liberated from DNA.
3.7.2. Preparation of 3,5,diaminobenzoic acid
A 2M solution was prepared by dissolving 12g of DABA in 40 ml of 
4M Hci acid. The resulting dark brown solution was decolourized 
by extraction with activated charcoal. 100 mg of activated char- 
C°1 (Sigma) was added, the solution was vortex mixed then spun at 
2000 9 for 5 minutes at 4°C (IEC Centra 8R Centrifuge). The super­
natant was decanted and re-extracted with a further 100 mg of 
activated charcoal w i t h  v o r t e x  m i x i n g  and c e n t r i f u g a t i o n  as 
before. This procedure was repeated until the resulting solution
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TOTAL COUNTS
BLANK
'0' STANDARD
0 .5 pmol/ ml
1.0 pmol/ ml
2 .5 pmol/ ml
5 .0 pmol/ ml
10.0 pmol/ ml
25.0 pmol/ ml
50.0 pmol/ ml
AVERAGE CPM 
12556 
186 
7154 
6271 
6102 
5236 
4183 
3175 
2042 
1396
CPM
13180
11931
180
191
6809
7489
6247
6295
6118
6085
5290
5182
4197
4168
2928
3422
2061
2022
1425
1367
Table 6: Typical curve for RIA of cyclic AMP, showing decreased 
binding of [125I]-ScGMP TME tracer to the antibody and therefore 
decreasing counts as the concentration of unlabelled cyclic GMP 
standard increases. "Total counts" measures total activity of 
[125I]-ScGMP TME tracer, "Blank" measures non- specific binding, 
and "0 standard" m e a s u r e s  t o t a l  b i n d i n g  of [125I ] - S c G M P  TME 
tracer to antibody.
0.5 pmol cyclic AMP 50.0
Figure 7: Typical computer printout of a cyclic AMP RIA standard 
curve. Unknown cyclic AMP concentrations were calculated from 
this curve by the computer.
was a pale straw colour. The solution was used immediately or 
s t o r e d  at -20 °C in 1 ml aliquots.
3.7 .3 Preparation of DNA standards
A 500 pg/ ml solution of DNA was prepared by dissolving 5 mg DNA 
(Salmon-testes, Sigma) in 10 ml of 1M N H 40 H . An aliquot of the 
solution was d i l u t e d  f urther w i t h  d i s t i l l e d  w a t e r  to p repare 
another stock solution of 50pg DNA/ ml. The DNA standards for 
preparation of a stand a r d  curve were 1.0, 2.5, 5.0, 10.0 and
20.0pg DNA/ ml prepared in duplicate from the stock DNA sol u ­
tions. Duplicate blanks were also prepared by adding 20pl of 1M 
NH40H to two eppendorf t u b e s . The DNA standards and blanks were 
evaporated to dryness in drying oven.
3.7.4. Preparation of cell pellets for analysis
Before the DNA content of the cell pellets could be determined, 
an extraction procedure had to be carried out to remove other 
materials, for example lipids, which yield fluorescent products 
with DABA, and therefore interfere with the accuracy of the DNA 
measurement. This was as follows: 200pl of 0.1M potassium acetate 
was added to the cell p e l l e t s . The samples were vortex mixed and 
then centrifuged at 10000 g for 5 minutes at room tem p e r a ­
ture. The supernatants were removed by aspiration and discarded. 
200pl of ethanol was added to the pellets followed by an incuba­
tion at 60 c for 30 minutes. The samples were left to cool then 
centifuged at 10000 g for 5 minutes and the supernatants
discarded, a further 200pl of ethanol was added to the pellets, 
f°llowed by v o r t e x  mixi n g ,  centrifugation and r e m o v a l  of the 
Supernatants as before. The extracted pellets were evaporated to
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dryness overnight
After allowing the extracted pellets and DNA standards to evapo­
rate to dryness, 120pl of 2M D A B A  was a d d e d  and the s a m p l e s  
incubated at 60°C for 30 minutes. In this step, the purine deoxy- 
nucleotides are hydrolysed by the strongly acidic DABA, and a 
fluoroscent p roduct is f ormed between D AB A  and the liberated 
deoxyribose. After cooling, 720pl of 0. 6M perchloric acid was 
added to each sample followed by centrifugation at 10000 g
for 5 minutes at room temperature.
The Fluorimeter (A m i n c o - B o w m a n ) was c a l i b r a t e d  using the DNA 
standards and blanks. Excitation was at a wavelength of 406 nm 
and fluorescence was measured at 520 nm. The fluorescence of each 
sample was m e a s u r e d  and the D N A  c o n t e n t  d e t e r m i n e d  f r o m  the 
standard curve. The fluorescence obtained was linearly p r o p o r ­
tional to the amount of DNA present in the sample. Figure 8 shows 
a typical standard c u r v e .
3.8. DRUGS AND REAGENTS
3.8.1. Tissue culture
Dulbecco's modified Eagle's me d i u m  (DMEM), benzyl penicillin, 
streptomycin, glutamine, foetal calf serum and newborn calf serum 
were purchased from Gibco Ltd (Paisley, Scotland). Trypsin/ EDTA 
was purchased from Flow Laboratories (Irvine, Scotland).
Tissue culture flasks (25 c m2 and 80 c m 2 ), six-well multidishes 
cm2) were supplied from Nunc (Denmark) and sterile centifuge 
tubes (15 m i an£ 5Q  ^ were supplied by Falcon (UK). Sterile
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Figure 8: Typical standard curve for DNA determination. The D N A
c o n t e n t  of the u n k n o w n  s a m p l e s  w e r e  o b t a i n e d  by 
interpolation from the standard curve by the computer.
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normal saline (0.9% w/v) was purchased from Baxter (UK)
3.8.2. Reagents
Freon (1,1,2,t r i c h l o r o t r i f l u o r e t h a n e ), NaOH pellets, trisodium 
citrate and trichloroacetic acid were supplied from AnalaR (UK). 
Potassium acetate and sodium dithionite were obtained from BDH 
(Glasgow, S c o t l a n d ) . Perchloric acid was obtained from Searle 
Company Ltd (UK). Methyl [3H]-thymidine was supplied from Amer- 
sham (UK). Ecoscint was supplied from National Diagnostics (UK)„
3.8.3. Drugs
Atriopeptin II, Brij- 35 s o l u t i o n  (p o l y o x y e t h y l e n e  23 lauryl 
ether), 8 bromo guanosine 3' :5’-cyclic monophosphate, butylated 
hydroxytoluene, L- canavanine, clonidine, collagenase (Type II) , 
catalase (bovine liver), diaminobenzoic acid, dimethyl sulphox- 
ide, deoxyribonucleic acid (DNA, salmon testes), dipyridamole, 
dibutyryl adenosine 3 ':5'-cyclic monophosphate, drabkins reagent, 
elastase (Type I, porcine pancreas), haemoglobin (bovine erythro­
cytes), haemoglobin (human), histamine diphosphate, (f)isoprena- 
line hydrochloride, , m e t h y l e n e  blue, L - N G- n i t r o  a r g inine, 
phorbol 12- myristate 13-acetate, 4a- phorbol 12,13- didecanoate, 
paraquat (1,1'- d i m e t h y l - 4 ,4'-bipyridinium dichloride), L-phe- 
nylephrine h y d r c h l o r i d e , p o t a s s i u m  f e r r i c y a n i d e , salbutamol, 
sodium nitroprusside, superoxide dismutase (bovine erythrocytes), 
thymidine, t r i - n - o c t y l a m i n e , and v i t a m i n  E (D L - a - t o c o p h e r o l  
dcetate) were p u r c h a s e d  f r o m  the S i g m a  C h e m i c a l  C o m p a n y  L t d  
(Poole,U K ) .
Dideoxyforskolin, forskolin and staurosporine were purchased from
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C a lb io c h e m  (Nottingham, UK) . Dobutamine was obtained from Eli 
Lilly Company Ltd (UK), glyceryl trinitrate (10% w/w lactose) was 
o b t a i n e d  from Napp Laboratories (UK) and cimetidine was obtained 
from SmithKline Beecham (UK).
NG-monomethyl L- arginine and N G-monomethyl D- arginine were a 
generous gift from D r .R .M .J .Palmer of Wellcome Laboratories (UK).
M & B 22948 (2-0-propoxyphenyl-8-azapurin-6-one), rolipram (4-[3- 
cyclopentyloxy-4-methoxyphenyl]- 2- p y r r o l i d o n e ) and trequinsin 
(9,10-dimethoxy-2-mesitylimino-3-methyl-3,4,6,7,-tetrahydro-2H- 
pyrimido[6 ,1 - a ] i s o q u i n o l i n - 4 - o n e )  w e r e  a g e n e r o u s  gift f r o m 
Dr.J.E . Scuncess of Rhone-Poulenc Ltd (UK).
All drugs in an aqueous solution were sterilised by filtration 
through a Millipore filter (0.2pM pore size). Some drugs did not 
require sterilisation i.e. butylated hydroxytoluene, phorbol 12- 
nyristate 13~acetate, 4a-phorbol 12,12- d i d e c a n o a t e , trequinsin 
and vitamin E s i n c e  t h e y  w e r e  d i s s o l v e d  in 100% e t h a n o l  and 
dideoxyforskolin, forskolin and rolipram since they were d i s ­
solved in D M S O . At the dilutions used, the maximum concentrations 
°f ethanol (0.1% v/v) and DMSO (0.1% v/v) had no effect on pr o ­
liferation of e n d o t h e l i a l  or s m o o t h  m u s c l e  cells (data not 
shown).
The Kreb's solution was made from a lOx concentrate which co n ­
tained the following (mM) : NaCl 1180, KCl 48, MgS 04 12, KH2P04 12 
and CaCl2 25. The solution was diluted 1:10 with distilled water
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when required and glucose and N a H C 03 added to achieve final 
concentrations 11 mM and 24 mM, respectively. The working Kreb's 
solution was incubated at 3 7 °C and gassed with 5% C02 in air for 
an hour before use.
3.8.5. Preparation of oxyhaemoglobin
Bovine haemoglobin type 1 (Sigma) contains a mixture of oxyhaemo­
globin and its oxidized form, methaemoglobin. Pure reduced haemo­
globin (oxyhaemoglobin) was prepared by adding to a 1 mM solution 
of Sigma haemoglobin in distilled water, a 20- fold molar excess 
of the reducing agent, sodium dithionite. The sodium dithionite 
was then removed by dialysis against 100 volumes of distilled 
water for 2-3 hours at 4°C. The resulting solution of oxyhaemo­
globin was used immediately or stored frozen in aliquots at -20°C 
for up to 14 d a y s .
3.8.6. Preparation of methaemoglobin
50 ml of whole blood was removed from a volunteer and placed in 
two sterile centifuge tubes (50 ml, Falcon). Tri sodium citrate 
(3.8%) was added to prevent the blood from clotting. The blood 
was then centrifuged at 200 g for 5 minutes at room tempera­
ture (IEC Centra 8R Centrifuge). The clear supernatant was d i s ­
carded and the red blood cells were resuspended with 10 ml of 
sterile saline (0.9% w/v, Baxter, UK), centrifugeas before, and 
^en, discard clear supernatant and the cells were resuspended 
with 10 ml of s t e r i l e  saline. This p r o c e d u r e  was r e p e a t e d  3 
times. 5 mi Qf sterile distilled water was added to lyse the red 
blood cells. This solution was then centrifuged at 1100 g. for
15 minutes to remove cellular d e b r i s . Pure oxidised haemogloblin
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(methaemoglobin) was p r e p a r e d  by adding 2 ml of the oxidant, 
potassium ferricyanide (0.06M). The potassium ferricyanide was 
then removed by dialysis against 100 volumes of sterile distilled 
water for 2 to 3 hours at room temperature.
3.8.6.1. Quantification of methaemoglobin
3.8.6.2. Principles of assay
Determination of the concentration of methaemoglobin is based on 
the principle first proposed by Stadie (1920) with several mod i ­
fications (Drabkin & Austin, 1935). Briefly, the methaemoglobin 
content in a sample can be q u a n t i f i e d  s p e c t r o p h o t o m e t r i c a l l y  
following the r e a c t i o n  b e t w e e n  m e t h a e m o g l o b i n  and p o t a s s i u m  
cyanide. The product cyanmethaemoglobin has an absorption maximum 
at 540 nm. The colour intensity at this wavelength is proportion­
al to total methaemoglobin concentration.
3.8.6.3. Chemicals for assay
3.8.6.3.1. Drabkin's Solution
One vial of d r y  m i x t u r e  c o n s i s t i n g  of s o d i u m  b i c a r b o n a t e ,  
potassium ferricyanide and potassium cyanide (100: 20: 5 ) was
supplied. This was reconstituted with 1000 ml of distilled water. 
The resulting solut i o n  was m i x e d  w i t h  0.5 ml of 30% Brij- 35 
solution (polyoxyethylene 23 lauryl ether). When protected from 
llSfht, this solution was stable for at least 6 months.
Ijjj .3 . 2 . Cyanmethaemoglobin Standard
The cyanmethaemoglobin standard was prepared as follows: one vial 
of lyophilized haemoglobulin (human) was added to 50 ml of Drab- 
s solution. The resulting solution is mixed well and allowed
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to stand for at least 30 minutes before use. The cyanmethaemoglo­
bin standard had been calibrated spectrophotometrically by the 
manufacturer at 540 nm and the molecular weight of haemoglobin 
was taken as 64458 d a l t o n s . The c y a n m e t h a e m o g l o b i n  s o l u t i o n  
gives an absorbance equivalent to that of a whole blood sample 
containing 18 grams haemoglobin per 100 ml. This solution was 
stable for at least 6 months when stored at 0-5 °C.
3.8.6.3.3. Preparation of standard curve and assay of samples 
A series of tubes was numbered for identification. The cyanme­
thaemoglobin standard solution was diluted with Drabkin's solu­
tion to p r e p a r e  the f o l l o w i n g  s t a n d a r d s :  0 , 6 , 12 , 18 g r ams
haemoglobin per 100 ml. All standards were run in duplicate. The 
tubes containing the "0 standard" are referred to as the "refer­
ence". For measurement of unknowns, 20pl of sample was added to 5 
ml of Drabkin's solution. Allow to stand for 15 minutes at room 
temperature. The a b s o r b a n c e  of the standards and samples was 
determined against the "reference" at a wavelength at 540 nm in 
an UV- visible recording spectrophotometer (UV- 240, Shimadzu). 
The same cuvette was used for each recording.
j-8.6.3.4. Analysis of methaemoglobin content
Analysis of methaemoglobin content was determined by plotting a 
standard curve, this was found to be linear and passed through 
the origin. The concentration for each sample (grams of methaemo- 
9lobin per 100 ml) was c a l c u l a t e d  by i n t e r p o l a t i o n  f r o m  the 
standard curve. Figure 9 repr e s e n t s  a typical st a n d a r d  curve 
Stained for a methaemoglobin assay.
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Figure 9: Typical standard curve for methaemoglobin determina­
tion.
The methaemglobin concentration of the samples were obtained by 
interpolation from the standard curve by the spectrophotometer 
(UV- 240, Shimadzu) .
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3.8.7 Statistical analysis
R e s u l t s  are expressed as the mean ± s.e. mean and comparisons 
were made by the use of Student's t-test or by the non-parametric 
Mann Whitney test when there was unequal variance between s a m ­
ples. A probability of 0.05 or less was considered to be signifi­
cant. In the Results, n represents the number of observations.
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RESULTS
4.1. PIG AORTIC ENDOTHELIAL PHOSPHODIESTERASES
Little is k n o w n  a b o u t  the p r o c e s s e s  in e n d o t h e l i a l  c e l l s  
responsible for the catabolism of cyclic AMP and cyclic GMP. In 
this study, we a t t e m p t e d  to e v a l u a t e  the role of the 
phosphodiesterase (PDE) enzymes present in endothelial cells by 
isolating the v a r i o u s  s u b t y p e s  and s t u d y i n g  the e f f e c t s  of 
selective inhibitors on cyclic AMP and cyclic GMP accumulation.
4.1.1. Isolation of PDE isozymes from PAEC
This part of the project was carried out in collaboration with 
Dr. J. E. S o u n e s s ,  R h o n e -  P o u l e n c  Ltd., in his D a g e n h a m  
laboratory.
Two peaks of c y t o s o l i c  PDE a c t i v i t y  w e r e  r e s o l v e d  by D E A E -  
Trisacryl chromatography (Figure 10). The first peak, eluted at 
0.12M NaCl, exhibited activity against both cyclic AMP and cyclic 
GMP, and the addition of lpM cyclic GMP stimulated cyclic AMP 
hydrolysis 2- fold. The ability of this first enzyme to hydrolyse 
cyclic GMP was not augmented in the presence of calcium (2 mM) 
and calmodulin (0.5 unit/ml). The second peak of activity was 
eluted with 0.19M NaCl and selectively hydrolysed cyclic AMP, 
displaying little or no activity against cyclic GMP (Figure 10, 
Souness et a l . , 1990 ).
The method for purification of the PDE isozymes is described m  
Appendix I .
These results indicate the presence of two PDE isozymes in pig 
aortic endothelial cells, a cyclic GMP- stimulated PDE (Type II) 
and a cyclic A M P  PDE (Type IV). It was f o u n d  t h a t  e q u a l  
hydrolytic a c t i v i t y  w a s  a s s o c i a t e d  w i t h  the c y t o s o l i c  an d 
Particulate fraction of pig aortic endothelial cell homogenates.
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Figure 10: DEAE- Trisacryl chromatography of PDE activity of the 
lOOOOOg supernatant fraction from the pig aortic endothelial 
cells. Preparation of a cytosolic fraction from the pig aortic 
endothelial cells and its chromatography on DEAE- Trisacryl is 
described in Souness et a l . (1990). Fractions were assayed for 
cyclic AMP PDE activity (2pM substrate) in the absence (♦) and 
presence (y) of lpM- cyclic GMP, and for cyclic GMP PDE activity 
(lpM substrate) in the absence (■) and presence (•) of 2mM- CaCl2 
pdus 0.5 unit of calmodulin. All assays were performed in the 
presence of 200pM- EGTA.
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4,1.2. Selective inhibitors
The activity of s e l e c t i v e  c y c l i c  n u c l e o t i d e  PDE i n h i b i t o r s  
against endothelial cell cyclic GMP- stimulated and cyclic AM? 
PDEs are shown in Table 7 (Souness et al. , 1990 ).
The method for this is described in Appendix II.
M & B 22948, a selective inhibitor of cyclic GMP PDEs (Type I) in 
smooth muscle was only weakly effective in inhibiting the two 
PDE- isozymes p r e s e n t  in P A E C  . SK & F 94120, a s e l e c t i v e  
inhibitor of cyclic GMP- inhibited PDE (Type III) also exhibited 
weak a c t i v i t y  a g a i n s t  the two PDE i s o z y m e s .  In c o n t r a s t ,  
dipyridamole and trequinsin, two non- selective PDE inhibitors, 
potently inhibit both isozymes, whereas rolipram, a selective 
cyclic AMP PDE (Type IV) inhibitor, selectively inhibited the 
cyclic AMP PDE present in PAEC.
We next examined the effects of dipyridamole, t r e q u i n s i n  and 
rolipram to det e r m i n e  w h e t h e r  the PDE isozymes found in cell 
homogenates had any role in regulating cyclic AMP and cyclic GMP 
levels in intact pig aortic e n d o t h e l i a l  cells. All these and 
subsequent experiments were carried out in Glasgow.
jj2. CYCLIC GMP CONTENT IN ENDOTHELIAL CELLS
2 .1. E f f e ct of s p o n t a n e o u s l y -  r e l e a s e d  E D R F  on c y c l i c  GMP 
gontent in pig aortic endothelial cells
^  has been s u g g e s t e d  that s p o n t a n e o u s l y -  r e l e a s e d  E D R F  is 
responsible for the resting level of cyclic GMP in endothelial 
cells through the activation of soluble guanylate cyclase (Martin 
/ 1988b).
74
Cyclic GMP-stimulated PDE Cyclic AMP PDE
Inhibitor Cyclic AMP Cyclic AMP 
(+ cyclic GMP)
Cyclic GMP
M & B 22948 708 45 50 93
Trequinsin 4 0.6 0.6 0.2
Dipyridamole 17 5 3 6
SK&F 94120 643 485 558 >1000
Rolipram 435 448 417 3
Table 7: Inhibition of seperate PDE activities by various com­
pounds. IC50 values (expressed as pM) were determined on cyclic 
GMP- stimulated PDE with 2pM- cyclic AMP as substrate in the 
presence or absence of lpM- cyclic GMP, or with lpM- cyclic GMP 
as substrate. Cyclic AMP PDE was assayed with lpM- cyclic AMP as 
substrate. The results represent the means of duplicate 
determinations performed on two different batches of the e n z y m e s .
When primary cultures of P A E C  were pretreated with haemoglobin 
(lOpM) which binds to and inactivates E D R F , the resting level of 
c y c l i c  GMP was reduced from 6 7  ± 6 to 9 . 9  ± 2 . 8  fmol pg' D N A -1 
(n=6). Bradykinin (O.lpM) induced an increase in intracellular 
c y c l i c  GMP content after a 1.5 minute exposure, from 67 ± 6 to
650.8 ± 92.2 fmol pg D N A “ 1 ( n = 6 ) ,  a 9 . 7 -  fold increase. This 
increase was b l o c k e d  by p r e t r e a t m e n t  with h a e m o g l o b i n  (lOpM, 
Figure 11) .
4.2.2. Effects of L- NMMA and L- canavanine
EDRF has been identified as nitric oxide and endothelial cells 
are known to synthesize nitric oxide from L- arginine. There is 
general agreement that the converting enzyme, N O -  synthase can be 
inhibited by N G- monomethyl L- arginine (L- NMMA) and some but. 
not all reports suggest that L- canavanine can also inhibit this 
enzyme in endothelial cells (Palmer et al., 1988b; Schmidt et
al., 1988; Rees et a l ., 1988; 1990).
Untreated cells had a resting intracellular cyclic GMP content of 
77 - 17 fmol pg D N A -1 ( n = 6 ) . F o l l o w i n g  p r e t r e a t m e n t  fo r  20 
Minutes, L- NMMA ( 300pM) reduced the intracellular cyclic GMP 
content to 17 ± 2 . 5  fmol pg D N A"1 (n=6 ), a 4.5- fold decrease, 
whereas L- c a n a v a n i n e  ( 3 0 0 p M )  had no e f f e c t  ( F i g u r e  12). 
Bradykinin (O.lpM), a stimulant of endothelial EDRF production, 
induced an increase in intracellular cyclic GMP content after a
■^5 minute exposure to 342.9 ± 74.6 fmol pg DNA~X (n=6), a 4.5-
fold increase. This increase was blocked following 20 minutes 
P r e t r e a tm e n t  of P A E C  w i t h  L- N M M A  ( 3 00pM) but not w i t h  L- 
Canavanine (300pM, Figure 12).
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Figure 11: Effects of haemoglobin on the cyclic GMP content of 
PAEC in the presence and absence of bradykinin. Cells were ex 
posed either to no drugs (C) or haemoglobin (10pM, Hb) for 18.5 
minutes before being incubated with or without bradykinin (O.lpM, 
BK) for a further 1.5 minutes. The incubation was terminated by 
removal of Krebs and addition of 6% trichloroacetic acid (TCA) 
and cyclic GMP quantified by radioimmunoassay. Bars represent 
mean t s.e. mean content of cyclic GMP (fmol pg DNA , n -6). * P< 
0.05; ** p< 0.005; denotes a difference from untreated cells, or 
Between two groups joined with a bracket.
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Figure 12: Effects of N G- monomethyl L- arginine (L- NMMA) and L- 
canavanine on cyclic GMP content of PAEC in the presence and 
absence of bradykinin. Cells were exposed to either no drugs (C) , 
L-NMMA (300pM) or L- canavanine (300pM) for 18.5 minutes before 
being incubated with or without bradykinin (O.lpM, BK) for a 
further 1.5 minutes. The incubation was terminated by removal of 
fcebs and addition of 6% TCA and cyclic GMP quantified by ra­
dioimmunoassay. Bars represent mean ± s.e. mean content of cyclic 
(fmol pg DNA-1, n =6 ). * P< 0.05; ** P< 0.005; denotes a 
difference from untreated cells, or, between two groups joined 
with a bracket.
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4.2.3. Effects of dipyridamole
Although dipyridamole is a potent inhibitor of both the cyclic 
GMP- stimulated PDE and the cyclic AMP PDE present in homogenates 
of PAEC, only the former hydrolyses cyclic GMP (Table 7, Figure 
10). The effects of dipyridamole were investigated on the cyclic 
GMP content to d e t e r m i n e  if thi s  e n z y m e  p l a y e d  a r o l e  in 
regulating the cellular content of this cyclic nucleotide.
The intracellular cyclic GMP content in untreated cells remained
constant over a period of 60 minutes (Figure 13A) . Dipyridamole
(25pM) induced an increase in intracellular cyclic GMP content
which peaked at 5 minutes: it rose from 40.1 ± 4.2 to 379.5 ±
80.1 fmol pg DNA-1 (n=6-18), a 9.5- fold increase, then declined
rapidly to a level 2- 3 fold above the original resting level and
subsequently r e m a i n e d  c o n s t a n t  for up to 60 m i n u t e s .  T h i s
increase was b l o c k e d  c o m p l e t e l y  f o l l o w i n g  p r e t r e a t m e n t  w i t h
haemoglobin (lOpM, Figure 1 3 A ) . At this point it was not certain
that the elevation of cyclic GMP induced by dipyridamole resulted
from inhibition of the cyclic GMP- stimulated PDE isozyme. It is
known that dipyridamole blocks the nucleoside transporter protein
in several cell types (Pearson et al., 1978; Cabral et a l ., 1984;
Plagermann & Woffendin, 1988). The nucleoside transporter is a
simple carrier with a broad substrate specificity which includes
cyclic nucleotides. Therefore, dipyridamole may have elevated
cyclic GMP content by inhibiting the efflux of this molecule
from the cell. This possibility was investigated by measuring the
leakage of cyclic GMP into the Kreb's bat h i n g  m e d i u m  (Figure 
13B).
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Figure 13A: Time course of the effects of dipyridamole on the 
intracellular cyclic GMP content of PAEC. Cells were exposed 
either to no drugs (o), dipyridamole (25pM, •), or a combination 
of dipyridamole (25pM) and haemoglobin ( 1 0 p M , A ). The cells were 
then incubated for 60 minutes at 3 7 °C. At the time points indi­
cated the incubation was terminated by removal of the krebs and 
addition of 6% TCA and the intracellular cyclic GMP content 
quantified by radioimmunoassay. Points represent mean ± s.e. mean 
content of cyclic GMP (fmol pg DNA-1, n =6) . When error bars are 
n°t seen they are contained within the symbols. * P<0.05; **
P<0.005 ; denotes a significant difference from untreated cells.
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Figure 13B: Time course of the effects of dipyridamole on the 
extracellular accumulation of cyclic GMP. These data were obtained 
from the same experiment shown in Figure 13A. Cells were exposed 
either to no drugs (o), dipyridamole (25pm, •) or a combination 
of dipyridamole (25pM) and haemoglobin (lOpM, A). The cells were 
then incubated for 50 minutes at 3 7 “ c. At the time points indi­
cated the Krebs was removed and the extracellular content of 
cyclic GMP quantified by radioimmunoassay. Points represent mean 
- s-e. mean content of cyclic GMP (fmol pg DNA-1, n =6). When 
' error bars are not seen, they are contained within the symbols, 
i 0.05; ** p< 0.005;  denotes a significant difference from
' ^treated cells.
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The c y c l i c  GMP content of the K r e b 's bath i n g  u n t r e a t e d  cells 
1 i n c r e a s e d  during the 60 minutes incubation, indicating leakage 
does occur: it rose from 2.8 ± 0.3 to 67.4 ± 11.0 fmol pg DNA-1
I
i (n=18) at 60 minutes (Figure 13B). Dipyridamole (25 pM) increased 
! the leakage of cyclic GMP into the Kreb's bath i n g  medium: it
| reached a plateau after 15 minutes of 241.7 ± 38.0 fmol pg DNA-1 
I (n=6), a 9.5- f o l d  i n c r e a s e ,  an d  t h e n  r e m a i n e d  r e l a t i v e l y  
| constant for the remainder of the 60 minutes incubation period.
1 This i n c reased a c c u m u l a t i o n  of c y c l i c  GMP s t i m u l a t e d  by 
i dipyridamole was blocked following pretreatment with haemoglobin 
j (10pM, Figure 13B) .
[ From these results it is likely that dipyridamole (25pM) elevates 
intracellular cyclic GMP content, not by blocking the efflux of 
this molecule from the cell, but by inhibiting the cyclic GMP-
I stimulated PDE isozyme.
!
i
j 4-2.4. Effects of trequinsin
- Trequinsin is a p o t e n t  i n h i b i t o r  of b o t h  the c y c l i c  GMP -  
stimulated PDE and the cyclic AMP PDE (Table 7). The effects of
I trequinsin on the c y c l i c  GMP c o n t e n t  of PAE C  w e r e  t h e r e f o r e
I
examined.
intracellular cyclic GMP content of untreated cells remained
telatively constant during 60 minute incubation period (Figure 
[ .
| i4)- Trequinsin (lOpM) i n d u c e d  an i n c r e a s e  in i n t r a c e l l u l a r  
I cyclic GMP content which peaked at 30 minutes exposure: it rose 
, from 98.0 ± 14.9 to 454.4 ± 69.7 fmol pg D N A"1 (n=6-7), a 4.5- 
( c^ctease, and then remained relatively constant during the
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I Figure 14: Time course of the effect of trequinsin on intracel- 
j iular cyclic GMP content in PAEC. Cells were preincubated for 15 
1 minutes in the absence or presence of haemoglobin (lOpM, o) . Then 
j received no drugs (o), or trequinsin (lOpM) in the presence (•)
! °r absence (a) of haemoglobin and were incubated at 37 C for a 
i further 60 minutes. At the time points indicated, the incubation 
Was terminated by the removal of the Krebs and addition of 6% TCA 
and cyclic GMP content quantified by radioimmunoassay. Points 
represent mean ± s.e. mean content of cyclic GMP (fmol pg DNA , 
when error bars are not seen they are contained within 
I s y m b o l s. * p< 0.05; ** P< 0.005; denotes a significant difference 
| froitl untreated cells .
I
I
!
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60 minute incubation. The increased accumulation of cyclic GMP 
was blocked following pretreatment with haemoglobin (lOpM, Figure 
14).
4.2.5. Effects of sodium nitroprusside
Having established that inhibitors of the cyclic GMP- stimulated 
PDE could elevate the cyclic GMP content of PAEC by inhibiting 
the hydrolysis of cyclic GMP formed f o l lowing st i m u l a t i o n  of 
soluble guanylate cyclase by spontaneously produced EDRF, the 
ability of d i p y r i d a m o l e  to p o t e n t i a t e  the actions of a nother  
stimulant of soluble guanylate cyclase, sodium nitroprusside was 
examined.
Untreated cells had a resting intracellular cyclic GMP content of
48.7 + 11.7 fmol pg DNA-1 (n=6 , Figure 1 5 A ) . Dipyridamole (25uM) 
induced a rapid rise in intracellular cyclic GMP content after 5 
minutes exposure: the maximum increase was 6.4- fold and then
diminished to 2.3- fold above control after 35 minutes (Figure 
ISA). Sodium n i t r o p r u s s i d e  (lpM) was a d d e d  for 2 m i n u t e s  to 
untreated cells or to cells pretreated with dipyridamole (25uM) 
for 33 minutes. In untreated cells, sodium nitroprusside (luM) 
increased the intracellular cyclic GMP content from 48.7 ± 11.7 
to 504.5 ± 172.7 fmol pg D N A -1 (n=5-6), a 10.9- fold increase 
(Figure 15A). In d i p y r i d a m o l e  p r e t r e a t e d  cells, the s o d i u m  
nitroprusside- s t i m u l a t e d  increase in cyclic GMP content was 
enhanced 3.25- fold (Figure 15A) .
leakage of cyclic GMP into the Kreb's bathing medium was also 
examined. The cyclic GMP content of the Kreb's bathing untreated
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Figure 15: E f f e c t s  of dipyridamole and sodium nitroprusside on 
i n t r a c e l l u l a r  and extracellular accumulation of cyclic GMP. PAEC 
were incubated for 35 minutes with or without dipyridamole (25pM, 
DiP) during which time the rapid rise in intracellular cyclic GMP 
content had diminished from the peak value obtained at 5 minutes 
to th e  value indicated after 35 minutes. Untreated cells or cells 
p re tre a te d  with dipyridamole (25pM, DiP) for 33 minutes were then 
exposed to sodium nitroprusside (lpM, SNP) for a further 2 
minutes. The incubation was terminated by removal of the Krebs 
bathing solution and addition of 6% TCA. The cyclic GMP content 
of th e  cells and the Krebs bathing solution was then measured by 
r a d io im m u n o a s s a y. The cyclic GMP content of the cells is shown on 
the top panel (A) and that of the Krebs bathing solution is shown 
rn th e  bottom panel (B). Bars represent mean ± s.e. mean content 
°£ cyclic GMP (fmol pg DNA"1, n=5-6). * P< 0.05; ** P< 0.005; de- 
n°tes a significant difference from untreated cells, or, between 
tw° groups joined by a bracket.
cells after 35 minutes incubation was 89.9 ± 11.1 fmol pg DNA-1 
(n=6). D i p y r i d a m o l e  (25pM) i n d u c e d  a rise in the c y c l i c  GMP 
content of the Kreb's: after 5 minutes it rose to 277.4 ± 64.6 
fmol pg DNA-1 (n=6), a 3- fold increase and remained constant for 
the re m a i n d e r  of the 35 m i n u t e  i n c u b a t i o n .  W h e n  a d d e d  to 
untreated cells, s odium n i t r o p r u s s i d e  (lpM) induced a m a r k e d  
increase in the cyclic GMP content of the Kreb's after 2 minutes 
exposure to 594.3 ± 189.0 fmol pg D N A -1 ( n =6 ), a 6 .6- fold
increase. In cells pretreated with dipyridamole (25pM) for 35 
minutes, the sodium nitroprusside (lpM)- induced accumulation of 
cyclic GMP in the kreb's was enhanced by 1.7- fold (Figure 1 5 B ) .
4.2.6. Effects of atriopeptin II
Having established that inhibition of the cyclic GMP- stimulated 
PDE could potentiate the increase in cyclic GMP content induced 
by two stimulants of soluble guanylate cyclase, namely EDRF and 
sodium nitroprusside, the ability of PDE inhibitors to potentiate 
the actions of a t r i o p e p t i n  II, a s t i m u l a n t  of p a r t i c u l a t e  
guanylate cyclase, was investigated. In these experiments, the 
cells were pretreated for 20 minutes with haemoglobin (lOpM). 
This abolished any activation of soluble guanylate cyclase by 
spontaneously- released EDRF, thereby allowing a clearer investi­
gation of the e f f e c t s  of a c t i v a t i n g  p a r t i c u l a t e  g u a n y l a t e
cyclase.
When cells were exposed to haemoglobin (lOpM) the resting content 
of cyclic GMP was 10.5 ± 1.6 fmol pg D N A -1 (n = 12). In t h e s e  
ceUs, atriopeptin II (lOnM) induced an increase in intracellular 
cYclic GMP content which peaked after 5 minutes exposure, rising
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to 53.8 ± 8.5 fmol pg D N A -1 ( n =6 ), a 5.1- fold increase. It 
subsequently stayed relatively constant for the remainder of the 
30 minute incubation (Figure 16). The ability of atriopeptin II 
to induce increases in intracellular cyclic GMP content in haeno- 
globulin (lOpM) pretreated cells was observed over the concentra­
tion range of 0.1 to 100 nM and the maximum obtained was 485.9 ± 
44.0 fmol pg DNA-1 (n=8 , Figure 17).
4.2.7. Effect of d i p y r i d a m o l e , t r e q u i n s in and rolipram on the 
atriopeptin II- induced elevation of cyclic GMP
In these experiments all cells were pretreated with haemoglobin 
(lOpM) to inhibit stimulation of soluble guanylate cyclase, and 
under these conditions the resting level of cyclic GMP was 14.8 ± 
1.8 fmol pg DNA-1 (n=29). Subsequent treatment with atriopeptin 
II (lOnM) for 15 minutes induced an increase in intracellular 
cyclic GMP content to 92.8 ± 8.2 fmol pg D N A '1 (n = 12), a 6.3- 
fold increase ( F i g u r e  18) . T r e a t m e n t  for 35 m i n u t e s  w i t h  
dipyridamole (25pM) had no effect on the resting level of cyclic 
GMP but trequinsin (25pM), induced a 5.3- fold increase (Figure 
18). The s e l e c t i v e  i n h i b i t o r  of the c y c l i c  A M P  PDE isozyme, 
rolipram (25pM) had no effect on the resting level of cyclic GMP 
following a 35 minute incubation. Furthermore, pretreatment with 
dipyridamole (25pM) and t r e q u i n s i n  (25pM) eac h  e n h a n c e d  the 
elevation of cyclic GMP content induced by atriopeptin II (IQnM, 
Figure 18). in contrast, rolipram (25pM) had no effect on the 
atriopeptin II (10nM)- induced increase in cyclic GMP content 
(Figure 18) .
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I Figure 16: Effects of atriopeptin II on the cyclic GMP content of 
|PAEC in the presence of haemoglobin. All cells were pretreated 
-or 20 minutes with haemoglobin (lOpM) to inhibit stimulation of 
j soluble guanylate cyclase before being incubated with (•) or 
I without (o) atriopeptin II (lOnM). At the time points indicated 
, "he incubation was terminated by removal of Krebs and addition of 
^TCA and the cyclic GMP content measured by radioimmunoassay.
Points represent mean ± s.e. mean content of cyclic GMP (fmol pg 
1, n=6-12). When error bars are not seen they are contained 
I vithin symbols. * P< 0.05; ** P< 0.005; denotes a significant 
Inference from cells not receiving atriopeptin II.
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| Figure 17: Concentration- effect relationship showing the ability 
| of atriopeptin II to elevate the cyclic GMP content of PAEC in 
the presence of haemoglobin. All cells were pretreated for 20 
j minutes with haemoglobin (lOpM) to block any stimulation of 
| soluble guanylate cyclase. Cells then received either no drugs 
| (C) or were treated for a further 15 minutes with atriopeptin II 
I (0-1- lOOnM) . The incubation was then terminated by removal of 
Sebs and addition of 6% TCA and the cyclic GMP content quanti­
sed by radioimmunoassay. Bars represent mean ± s.e. mean content 
of cyclic GMP (fmol pg DNA'1, n=6-29). ** P< 0.0005 denotes a
significant difference from cells which did not receive atriopep- 
Sn II.
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Figure 18: Effect of dipyridamole, rolipram and trequinsin on the 
atriopeptin II- induced increase in cyclic GMP content in PAEC.
All cells were pretreated for 20 minutes with haemoglobin (lOpM). 
Khere indicated cells received either no drugs (C), or received 
dipyridamole (25pM, DiP), rolipram (25pM, ROL). or trequinsin 
(lOpM, TREQ) during the 20 minute pre- incubated period. The 
cells were then incubated with or without atriopeptin II (lOnM,
for a further 15 minutes. The incubation was terminated by 
removal of Krebs and addition of 6% TCA and cyclic GMP content 
was quantified by radioimmunoassay. Bars represent mean ± s.e.
“ean cyclic GMP content (fmol pg DNA 1, n=6-29).
** p< 0.0005; denotes a significant difference from untreated 
e^lls/ or, between groups joined by a bracket.
4.3. CYCLIC AMP CONTENT IN ENDOTHELIAL CELLS
It was clear from the preceding section (4.2) that drugs which 
had been s hown to i n h i b i t  the c y c l i c  GMP- s t i m u l a t e d  PDE in 
endothelial cell homogenates had the ability to elevate cyclic 
GMP levels in in t a c t  cells. It is l i k e l y  t h e r e f o r e  that the 
cyclic GMP- stimulated PDE has an important role in regulating
I
the cyclic GMP content of endothelial cells. In this section an 
I attempt was made to d e t e r m i n e  if the cyclic AMP PDE found in 
endothelial cel l  h o m o g e n a t e s  had a rol e  in r e g u l a t i n g  the 
intracellular content of cyclic AMP in intact cells by examining 
| the effects of inhibitors of this e n z y m e .
4.3.1. Effects of dipyridamole and isoprenaline
The resting level of cyclic AMP in primary cultures of PAEC was
256.7 ± 39.5 f m o l  pg D N A -1 (n = 4, F i g u r e  19). A d d i t i o n  of
!
isoprenaline (lOpM), a p- adrenoceptor agonist, for 5 minutes had 
no effect on the resting content of cyclic AMP (Figure 19). The 
non- selective inhibitor, dipyridamole (25pM), had no effect on 
the resting level of cyclic AMP after a 35 m i n u t e  incubation 
period, but e n h a n c e d  the a b i l i t y  of i s o p r e n a l i n e  (lOpM) to 
increase c y c l i c  A M P  c o n t e n t :  in the c o m b i n e d  p r e s e n c e  of
isoprenaline and dipyridamole the cyclic AMP content rose 1.7- 
fold (Figure 19).
iij-2. Effects of dipyridamole and forskolin
Untreated cells had a rest i n g  cyclic AMP content of 1080.0 ± 
130-0 fmol pg DNA-1 (n = 1 0 ) . Forskolin (lOpM), a direct activator 
the catalytic subunit of adenylate cyclase (Seamon & Daly, 
had no e f f e c t  u p o n  the r e s t i n g  l e v e l  of c y c l i c  A.MP
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Figure 19: Effects of dipyridamole and isoprenaline on the cyclic 
MP content of PAEC. Cells were treated with either no drugs (C), 
or with dipyridamole (25pM, DiP) for 30 minutes before being 
incubated with or without isoprenaline (lOpM. IPR) for a further
5 minutes. The incubation was then terminated by the removal of 
Krebs and addition of 6% TCA and cyclic AMP content quantified by 
ra^ ioimmunoassay. Bars represent mean ± s.e. mean content of
cyclic AMP (fmol pg DNA-1, n =6). * P< 0.05; ** P< 0.005; denotes
6 significant difference from untreated cells, or, between two 
5rouPs joined by a b r a c k e t .
following a 2 minute exposure (Figure 20). Pretreatment for 10 
minutes with dipyridamole (lOOpM) induced an increase in cyclic 
AMP content from 1080.0 ± 130.0 to 1640.0 ± 200.0 fmol ug DNA'1 
(n=10). When forskolin (lOpM) was added subsequently, the cyclic 
AMP content rose to 3880.0 ± 850.0 fmol ug DNA ' L (n = 5 ) # a 2.8- 
fold rise (Figure 20).
4.3.3 Effects of rolipram and forskolin
Untreated cells had a resting cyclic AMP content of 230.5 ± 10.3 
fmol pg D N A -1 (n=7). T r e a t m e n t  w i t h  f o r s k o l i n  (30uM) for 5 
minutes induced an increase in the cyclic AMP content: it rose to
811.9 ± 84.6 fmol pg D N A'1 (n=7), a 3.5- fold increase (Figure 
21). Pretreatment for 30 minutes with the selective inhibitor of 
the cyclic AMP PDE, r o l i p r a m  (25pM), i n d u c e d  an i n c r e a s e  in 
cyclic AMP content: it rose to 296.4 ± 10.7 fmol pg DNA-1 (n=6 )/ 
a 1.3- fold increase, and enhanced the forskolin (30pM)- induced 
increase in cyclic AMP content to 2232.0 ± 386.0 fmol pg D N A'1 
(n=7), a 2.7- fold enhancement (Figure 21).
From this section it is clear that the cyclic AMP PDE found in 
endothelial homogenates has a role in regulating the cyclic AMP 
content in intact c e l l s .
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| Figure 20: Effects of dipyridamole and forskolin on the cyclic 
jMPcontent of PAEC. Cells were treated with either no drugs (C), 
| or with dipyridamole (lOOpM, DiP) for 10 minutes before being
i
| incubated with or without forskolin (lOpM, FOR) for a further 2
I
minutes. The incubation was terminated by removal of Krebs and 
addition of 6% TCA and cyclic AMP content quantified by radioim­
munoassay. Bars represent mean ± s.e. mean content of cyclic AMP 
1 (fmol pg DNA-1, n =6 ) . * P< 0.05; denotes a significant difference 
| from untreated cells, or, between two groups joined by a bracket.
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Figure 21: Effects of rolipram and forskolin on the cyclic AMP 
content of PAEC. Cells were treated with either no drugs (C), or 
with rolipram (25pM, ROL) for 30 minutes before being incubated 
with or without forskolin (30pM, FOR) for a further 5 minutes.
The incubation was terminated by removal of Krebs and addition of 
^ TCA and cyclic AMP content quantified by radioimmunoassay.
Sars represent mean ± s.e. mean content of cyclic AMP (fmol pg 
^'l, n=6-7). ** p< 0.005 denotes a significant difference from 
^treated cells, or, between two groups joined by a bracket.
5.1. PROLIFERATION OF P I G AORTIC ENDOTHELIAL CELLS
5.1.1. Effects of phorbol 12-myristate 13-acetate on prolifera­
tion of PAEC
To determine whether stimulation of protein kinase C (PKC) mod u ­
lates the a b i l i t y  of pi g  a o r t i c  e n d o t h e l i a l  cells (PAEC) to 
proliferate in normal serum-supplemented DMEM, the effects of an 
activator of PKC, phorbol 12-myristate 13-acetate (PMA)(Ashendel, 
1985 ), were examined.
PAEC seeded at a d e n s i t y  of 1 0 4 c e l l s /  c m 2 in n o r m a l  s erum-  
supplemented DMEM ( 10% foetal calf and 10% newborn calf serum)
grew to confluence within 6-8 days (Figure 22). PMA (0.3pM), when 
added twice daily, produced a marked reduction in cell numbers 
compared with untreated cells: 86 ± 2% (n = 6 ) reduction was o b ­
served at day 8 (Figure 22). The ability of PMA to reduce cell 
numbers was observed over the concentration range of 0. InM to 
lpM: the maximum reduction obtained after 4 days growth was 63 ± 
2% (n=6, Figure 23). The ability of PMA (0.3pM) to reduce cell 
numbers was not associated with the accumulation of the vital 
stain, trypan blue, but a small increase in cell detachment was 
observed (Figure 24).
The inactive p h o r b o l  ester, 4a- p h o r b o l  12,13- d i d e c a n o a t e  
(0.3pM), lacked the ability of PMA (0.3pM) to reduce cell numbers 
when assessed t h r o u g h o u t  an 8 d a y  p e r i o d  (Figure 22). It is 
likely therefore that the ability of PMA to reduce cell numbers 
results from the activation of PKC.
IlL A- Effects of staurosporine
Gffects of s t a u r o s p o r i n e ,  a m i c r o b i a l  a l k a l o i d  k n o w n  to
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Figure 22: Effects of the active phorbol ester, phorbol 12- 
myristate 13- acetate (PMA) and the inactive phorbol ester, 4a- 
phorbol didecanoate (4a- PDD) , on the proliferation of PAEC. PAEC 
were seeded at a density of 104 cells/ c m2 in normal serum- 
supplemented DMEM and received either no drug (o), PMA (0.3pM,A) 
or 4a- PDD (0.3pM, •) twice daily. At the points indicated, cells 
were counted by haemocytometry. Points show mean cell numbers 
(n=6); all s.e. means are contained within the symbols.
* P< 0.05; ** p< 0.0005; denotes a significant difference from 
^treated cells on that day.
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Figure 23: Concentration- effect curve showing the ability of PMA 
to inhibit proliferation of PAEC. PAEC were seeded at a density 
of 104 cells/ c m2 in normal serum- supplemented DMEM. PMA (0. lnM- 
ipM) was added twice daily. The cells were allowed to grow for 4 
foys and then counted by haemocytometry . The results are ex­
pressed as the mean ± s.e. mean reduction (%) of cell number when 
compared with untreated cells (n=6 ); when error bars are not seen 
they are contained within symbols. * P< 0.005; ** P< 0.0005; 
denotes a significant difference from untreated cells.
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IFigure 24: Effects of PMA and paraquat on proliferation, attach­
ment a n d  on trypan blue uptake by PAEC. PAEC were seeded at a 
density (SD) of 1.25 x 104 cells / c m 2 in normal serum- supple­
mented DMEM and received either no drug (CONTROL), PMA (0.3pM) or 
paraquat (ImM, PAR), added twice daily. The cells were allowed to 
grow for 4 days. (A) The cells attached ( □  ) and cells floating 
in m e d i u m  ( |  ) were counted by haemocytometry • Bars show the 
mean cell number ± s.e. mean (n=6). (B) Cells were treated with
trypan blue (0.1% v/v in 0.9% NaCl) for 30 minutes. Bars show 
mean + s.e. mean percentage of cells taking up trypan blue (n=6). 
* P< 0.05; ** p< 0.005; denotes a significant difference from 
untreated cells.
inhibit the activation of PKC (Tamaoki et a l . , 1986), was there­
fore examined on PAEC grown in normal serum- supplemented DMEM in 
the absence and presence of PMA.
Staurosporine (lOnM), when added twice daily, produced a slight 
inhibition of cell numbers by itself (15 ± 1% at day 8) but had 
no effect on the ability of PMA (0.3pM) to reduce cell numbers 
(Figure 25) .
5.1.3. Effects of PMA assessed by [3H]-thymidine incorporation 
Phorbol esters have been reported to initially stimulate then 
inhibit proliferation of pig aortic endothelial cells through 
activation then down- regulation of PKC (Uratsuji & DiCorleto,
1988 ).
My studies count i n g  cells by h a e m o c y t o m e t e r y  showed that PMA 
(0.3pM) induced only a reduction in cell numbers with no early 
stimulatory phase. By employing a more sensitive index of prolif­
eration, i . e .[3H]-thymidine incorporation, it was expected that 
any early stimulation of proliferation would be measured with 
ease.
?AEC were seeded at a density of 1.5 x 104 cells/ c m 2 in 6 well 
Wishes and allowed to grow for 24 hours in normal serum- supple­
mented DMEM. The cells were incubated for a further 24 hours in 
serum- free DMEM in order to slow growth. The cells were then 
^allenged with PMA (0.3pM) in DMEM containing a range of serum 
-oncentrations and pulsed with a mixture of [3H]-thymidine (2pCi/ 
and thymidine (lpM).
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Figure 25: Effects of staurosporine on the antiproliferative a c ­
tion o f PMA on PAEC. PAEC were seeded at a density of 1.3 x 104
tells / cm2 in normal serum- supplemented DMEM and received
either no drug (o), PMA (0.3pM, A ) ,  staurosporine (10nM, • ), or a
tombination of PMA and STAUR (A), added twice daily. At the time
points indicated, cells were counted by haemocytometry • Points 
show mean cell number ± s.e. mean (n=6); all s.e. means are 
contained within the symbols. * P< 0.01; ** P< 0.005; denotes a 
% i f leant difference from untreated cells on that day.
The concentration d e p e n d e n c e  of s e r u m  in s t i m u l a t i n g  [ 3H ] — 
thymidine incorporation by PAEC in an 18 hour period was observed 
over the range 0 to 20%: the i n c o r p o r a t i o n  of [ 3H ] - t h y m i d i n e
observed with normal serum- supplemented DMEM (10% foetal calf 
and 10% n e w b o r n  calf serum) was 3.1- fold g r e a t e r  that that 
obtained in serum- free DME M  (Figure 26). Tre a t m e n t  wit h  PMA 
(0.3pM) was found to inhibit incorporation of [3H]-thymidine by 
PAEC grown in 0% serum-, 4% serum-, and normal serum- s u pple­
mented DMEM during the 18 hour incubation (Figure 26): the inhi­
bitions were 43.5 ± 3.5% (n=12) for 0% serum-, 42.1 ± 4% (n=12) 
for 4% s e r u m -  a n d  43.7 ± 4.0 %  (n = 12) for n o r m a l  s e r u m -
supplemented D M E M .
5.1.4. Time Course of action of PMA on [3H]~ thymidine incorpora­
tion
PAEC were seeded at a density of 1.5 x 104 cells/ c m 2 in 6 well 
dishes and allowed to grow for 24 hours in normal serum- supple­
mented DMEM and then for a further 24 hours in serum- free DMEM 
in order to slow growth. The cells were then c h a l l e n g e d  w i t h  
either serum- free DMEM, 4% serum- supplemented DMEM, or, PMA 
(0-3pM) in 4% serum- supplemented DMEM. [3H]- thymidine was added 
at time zero and incorporation measured after 4, 8, 12, and 24 
hours.
Even PAEC incubated in serum- free DMEM continued to incorporate 
[ ii]“thymidine over the 24 hour pulse period (Figure 27). The 
ability of 4% serum to stimulate incorporation of [3H]-thymidine 
Was observed at 4, 8, 12, and 24 hours (Figure 27). As observed
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Figure 26: Effects of PMA and staurosporine on [3H]-thymidine 
incorporation by PAEC grown in a range of serum concentrations.
PAEC were seeded at a density of 1.5 x 104 cells/ c m 2 and
flowed to grow for 24 hours in normal serum- supplemented DMEM. 
After a further 24 hours incubation in serum- free DMEM, the 
cells were challenged with either no drugs ( Q ) ,  PMA ( 0 . 3pM,H),  
staurosporine (lOnM, S3 ), or a combination of PMA and staurospo- 
rine ( 0  ) in serum- free, 1%, 4% and 20% serum- supplemented
and pulsed with a mixture of [3H]-thymidine (2pCi/ well) and 
%iidine (lpM) for 18 hours. Bars show the mean ± s.e. mean 
“thymidine incorporation (n=6-12). * P< 0.05; ** P< 0.005, 
n^otes a significant difference from untreated cells at that 
articular serum concentration.
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Figure 27: Effects of PMA on [3H]-thymidine incorporation by 
PAEC. PAEC were seeded at a density of 1.5 x 104 cells/ c m 2 and 
allowed to grow for 24 hours in normal serum- supplemented DMEM. 
After a further 24 hour incubation in serum- free DMEM* the cells 
were challenged with no drugs in either 4% serum- supplemented 
DMEM (o), or serum- free DMEM (•), or PMA (0.3pM) in 4% serum- 
supplemented DMEM (A) and [3H]-thymidine incorporation measured 
4, 8, 12 and 24 hours. Points show the mean ± s.e. mean [ H]- 
thymidine incorporation (n=6); when error bars are not seen they 
are contained within s y m b o l s „ * P ; 0.05; ** P< 0.005; denotes a 
significant difference from untreated cells grown in 4% serum- 
SuPplemented DMEM.
in e x p e r i m e n t s  w h e r e  p r o l i f e r a t i o n  was a s s e s s e d  by 
haemocytometery, PMA (0.3pM) inhibited proliferation as assessed 
by [3H ] - t h y m i d i n e  i n c o r p o r a t i o n  by cells g r o w n  in 4% serum- 
supplemented DMEM. Inhibition was observed at 4, 8, 12, and 24
hours with no stimulation at any time point (Figure 27).
The inhibitor of protein kinase C, staurosporine (lOnM) had no 
effect upon the a b i l i t y  of s e r u m  (1-20%) to s t i m u l a t e  [3H]- 
thymidine incorporation by PAEC (Figure 26). At a higher concen­
tration of lOOnM, however, staurosporine decreased [3H]-thymidine 
incorporation by PAEC grown in 4% serum- supplemented DMEM by 
34.1 ± 5.5% (n=6, Figure 28). At neither concentration (10 or
lOOnM) did staurosporine have any effect upon the ability of PMA 
(0.3pM) to decrease [3H]-thymidine incorporation in response to 
serum (1-20%, Figures 26 and 28).
5.1.5. Role of Oxygen- Derived Free Radicals
It is known that p h o r b o l  e s t e r s  s t i m u l a t e  the p r o d u c t i o n  of 
oxygen- derived free radicals in endothelial cells (Matsubara & 
Ziff, 1986). To determine whether the inhibitory actions of PMA 
were due to the e x t r a c e l l u l a r  actions of d e s t r u c t i v e  oxygen- 
derived free radicals , the effects of the superoxide scavanger, 
superoxide dismutase (SOD) were examined. SOD (30U/ ml), when 
added twice daily, produced a slight inhibition of cell numbers 
bY itself (29 ± 2%, n=6, at day 5, but no significant inhibition 
was observed at day 8), and had no effect on the ability of PMA 
(0• 3pM) to inhibit cell numbers (Figure 29).
If PMA reduces cell numbers by generating free radicals intracel-
86
E
Q.
V
z
0
HI
0 S'
11 n O' °
0
0 x
z w
kJ
Z
Q
2
>■
X
h
10
20
15
10
5
0
C PMA STAUR PMA
•f
STAUR
Figure 28: Effects of PMA and staurosporine on [3H]-thymidine 
incorporation by PAEC. PAEC were seeded at a density of 1.5 x 104 
cells/ cm2 and allowed to grow for 24 hours in normal serum- 
supplemented DMEM. After a further incubation in serum- free 
DMEM, the cells were grown in 4% serum- supplemented DMEM, chal­
lenged with either no drugs (C), PMA (0.3pM), staurosporine 
(O.lpM, STAUR) , or a combination of PMA and STAUR and pulsed with 
a mixture of [3H]- thymidine (2pCi/ well) and thymidine (lpM) for 
18 hours. Bars show the mean ± s.e. mean [3H]-thymidine incorpo- 
ration (n=6). ** P< 0.005; denotes a significant difference from
untreated c e l l s .
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Figure 29: Effects of superoxide dismutase on the antiprolifera
hve action of PMA on PAEC. PAEC were seeded at a density of 1.4
x 104 cells / c m 2 in normal serum- supplemented DMEM and received
either no drug (o), PMA (0.3pM, A ) ,  superoxide dismutase (30U/
:1, SOD, •)/ or a combination of PMA and SOD (A), added twice
uaily. At the time points indicated cells were counted by haemo-
'-y tom etry  . Points show mean cell number ± s.e. mean (n=6); all
means are contained within the symbols. * P< 0.005; ** P<
“ 0005 ; denotes a significant difference from untreated cells on 
“hat day.
f
I
lularly it might be expected that paraquat, an agent known to 
generate oxygen derived free radicals intracellularly (Minakami 
et al., 1990) would share this property. Paraquat (IpM-lmM), when 
added twice daily, produced a concentration- dependent reduction 
in cell numbers (Figure 30): the maximum reduction obtained after 
4 days growth was 91 ± 2% (n=6). This reduction in cell number, 
unlike that induced by PMA, was associated with accumulation of 
trypan blue and a significant increase in the detachment of cells 
(Figure 24) .
Superoxide dismutase converts superoxide dismutase to hydrogen 
peroxide and this can be removed subsequently by catalase. The 
effects of combined treatment with SOD and catalase (CAT) on the 
ability of PMA and paraquat to reduce cell numbers were examined. 
When a combination of SOD (30U /ml) and CAT (30U /ml) was added 
twice daily, no r e d u c t i o n  in c e l l  n u m b e r s  w a s  o b s e r v e d  in 
contrast to the i n h i b i t o r y  effects of SOD alone (Figure 31). 
Furthermore, this combination of SOD and CAT had no effect on the 
ability of PMA (0.3pM) or paraquat (lOpM) to reduce cell numbers 
(Figure 31) .
Vitamin E and butylated hydroxytoluene (BHT), two lipid soluble 
agents known to act as intracellular radical scavangers (Ruch & 
Klaunig, 1988; Hennig et a l . , 1990) were examined on the ability 
PMA and paraquat to reduce cell numbers. Vitamin E (30uM) and 
BHT (30pM) when added twice daily, each had no effect on cell 
numbers by t h e m s e l v e s ,  had no e f f e c t  on the a b i l i t y  of P M A  
(0.3pM) to r e d u c e  cell n u m b e r s ,  but r e v e r s e d  the a b i l i t y  of 
Paraquat (lOpM) to reduce cell numbers (Figure 32). It is likely
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Figure 30: Concentration- effect curve showing the ability of 
paraquat to inhibit proliferation of PAEC. PAEC were seeded at a 
density of 1.5 x 104 cells / c m 2 in normal serum- supplemented 
DMEM. Paraquat (lpM- ImM) was added twice daily. The cells were 
allowed to grow for 4 days and then counted by haemocytometry •
Ihe results are expressed as the mean ± s.e. mean reduction (%)
°f cell number when compared with untreated cells (n=6); when 
shor bars are not seen they are contained within the sym b o l s .
* p< 0.05; ** p< 0.005; denotes a significant difference from
'^ treated cells.
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| Figure 31: Effects of combined treatment with superoxide 
J  dismutase and catalase on the antiproliferative actions of PMA 
| and paraquat on PAEC. PAEC were seeded at a density (SD) of 1.25- 
J  1.5 x 104 cells/ c m 2 in normal serum- suppplemented DMEM.
J  (A) Cells received either no drug (C) , PMA (0.3pM), a combination 
'of superoxide dismutase (30U / ml, SOD) and catalase (30U / ml, 
CAT), or a combination of PMA, SOD and CAT.
(B) Cells received either no drug (C) , paraquat (lOpM, PAR), a 
combination of SOD (30U / ml) and CAT (30U / ml), or a combina­
tion of PAR, SOD and CAT.
| Drugs were added twice daily. The cells were allowed to grow for 
J  4 days and then counted by haemocytometry • Bars show the mean 
J  cell number ± s.e. mean (n=6). * P< 0.05; ** P< 0.005; *** P<
J 0.0005 ; denotes a significant difference from untreated cells.
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Figure 32: Effects of vitamin E and butylated hydroxytoluene on 
the antiproliferative actions of PMA and paraquat on PAEC. PAEC 
were seeded at a density of 1.3- 1.5 x 104 cells/ c m 2 in normal 
serum- supplemented DMEM.
(A) Cells received either no drug (C), paraquat (lOpM, PAR), 
vitamin E (30pM, VitE), butylated hydroxytoluene (30pM, BHT), a 
combination of PAR and vitamin E, or a combination of PAR and
BHT.
(B) Cells received either no drug (C), PMA (0.3pM), vitamin E 
(30pM, VitE), BHT (30pM), a combination of PMA and vitamin E, or 
a combination of PMA and BHT.
-rugs were added twice daily. The cells were allowed to grow for 
4 days and then counted by haemocytometry . Bars show the mean 
"ell number ± s.e. mean (n=6). * PC0.005; ** P< 0.0005; denotes a 
significant difference from untreated cells.
therefore that the reduction in cell numbers produced by superox-
!
I ide dismutase, paraquat and PMA result from increased generation 
I of hydrogen peroxide extracellularly, intracellular generation of 
| radicals, and a mechanism unrelated to radical generation, re- 
I spectively.
, 5.2. EFFECTS OF CYCLIC NUCLEOTIDES ON PROLIFERATION OF PAEC 
, Cyclic nucleotides have been shown to modulate the proliferation 
| of many diverse cell types (Friedman, 1981). Furthermore, it has 
■ been r e p o r t e d  t h a t  c y c l i c  A M P  has d i f f e r i n g  a c t i o n s  on 
| proliferation of e n d o t h e l i a l  cells from d i f f e r e n t  sources in 
I culture: stimulation of proliferation in foetal bovine aortic, 
bovine a o r t i c  c o r o n a r y ,  a n d  h u m a n  d e r m a l  m i c r o v a s c u l a r  
i endothelial cells (Davison & Karasek, 1981; Presta et a l . , 1989a;
I Meininger et al . , 1988; M e i n i n g e r  & G r a n g e r ,  1990 ) a n d
| inhibition of p r o l i f e r a t i o n  in b o v i n e  a o r t i c  a n d  rat 
I cerebrovascular endothelial cells (Leitman et a l . , 1986; Kempski 
I et al., 1987) .
i In contrast to cyclic AMP, the effects of cyclic GMP on endothe- 
I lial cell proliferation has not been extensively investigated.
I One report on b o v i n e  a o r t i c  e n d o t h e l i a l  c e l l s  s h o w e d  t h a t  
j elevation of c y c l i c  G M P  c o n t e n t  i n h i b i t e d  g r o w t h  s l i g h t l y  
I (hitman et a l . , 1986).
I The objects of this p a r t  of the s t u d y  w e r e  to d e t e r m i n e  the 
j effects of cyclic AMP and cyclic GMP on proliferation of PAEC in 
I culture and to investigate any possible interactions between PMA 
| an^  the cyclic nucleotides on proliferation.
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5,2.1. Effects of dibutyryl cyclic AMP
The membrane permeant analogue of cyclic AMP, dibutyryl cyclic 
AMP (30pM), w h e n  a d d e d  t w i c e  d a i l y  to cells g r o w n  in n o r m a l  
serum- s u p p l e m e n t e d  DMEM induced a reduction in cell numbers 
throughout an 8 day period: 35 ± 2% (n=6) reduction was observed
at day 8. In addition dibutyryl cyclic AMP (30pM) had no effect 
on the ability of PMA (0.3pM) to reduce cell numbers at any time 
during the 8 day period (Figure 33).
The effects of dibutyryl cyclic AMP (30pM) were further studied 
on proliferation using an alternative index i.e. [3H]-thymidine 
incorporation. PAEC were seeded at a density of 1.5 x 104 cells/ 
cm2 in 6 well dishes and allowed to grow for 24 hours in normal 
serum- s u p p l e m e n t e d  D M E M  and then for a f u r t h e r  24 h o urs in 
serum- free DMEM in order to slow growth. The cells were then 
challenged with dibutyryl cyclic AMP (30pM) in DMEM containing a 
range of serum concentrations and pulsed with a mixture of [3H]- 
thymidine (2pCi/well) and thymidine (IpM). Treatment with dibuty­
ryl cyclic AMP (30pM) was found to have no effect on PAEC grown 
in 1% serum-, 4% serum- and 20% serum- supplemented DMEM during 
the 18 hour incubation (Figure 34). Dibutyryl cyclic A*MP (30pM) 
was found to have no effect upon the ability of PMA (0.3pM) to 
decrease [3H]-thymidine incorporation in response to serum (1- 
20%, Figure 34).
^possible explanation for the difference observed between [3H]- 
thymidine incorporation and haemocytometery studies (no effect 
and inhibiton, respectively) might be attributed to the different
89
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Figure 33: Effects of dibutyryl cyclic AMP on the antiprolifera­
tive action of PMA on PAEC. PAEC were seeded at a density of 1.3 
x 104 cells/ c m 2 and grown in normal serum- supplemented DMEM and 
received either no drug (o), dibutyryl cyclic AMP (30pM, •), PMA 
(0.3 pM, A  ), or a combination of PMA and dibutyryl cyclic AMP (A), 
sdded twice daily. At the points indicated the cells were counted 
DY haemo cytometry ■ Points show mean ± s.e. mean cell numbers 
'n=6); all s.e. means are contained within the symbols.
‘ p< 0.005; ** P< 0.0005; denotes a significant difference from 
^treated cells on t h a t  day.
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Figure 34: Effects of PMA and dibutyryl cyclic AMP on [3H] 
thymidine incorporation by PAEC grown in a range of serum 
concentrations. PAEC were seeded at a density of 1.5 x 104 cells/ 
cit2 and allowed to grow for 24 hours in normal serum- supplement­
ed DMEM. After a further 24 hour incubation in serum- free DMEM 
the cells were challenged with either no drugs ( □  ), PMA (0.3pM, 
I), dibutyryl cyclic AMP ( 3 0 p M , ^  )/ or a combination of PMA 
end dibutyryl cyclic AMP ( EH) in serum- free, 1%, 4% and 20% 
Senim- supplemented DMEM and pulsed with a mixture of [ H]- 
thymidine (2pCi/ well) and thymidine (lpM) for 18 hours. Bars 
show the mean ± s.e. mean [3H]-thymidine incorporation (n=6-12).
* 0 . 0 5 ;  ** p< 0.005; denotes a significant difference from the 
^treated cells at that particular serum concentration.
time course employed in the two m e t h o d s : 18 hours in thymidine
j incorporation but 48 hours in the haemocytometeric experiments.
j 5.2.2. Effects of 8 bromo cyclic GMP
■ The membrane permeant analogue of cyclic GMP, 8 bromo cyclic GMP 
| (30pM) , when added twice daily to cells grown in normal serum-
| supplemented DMEM had no effect upon cell numbers throughout an 8 
J  day period and had no effect on the ability of PMA (0.3pM) to 
reduce cell numbers at any time during the 8 day period (Figure
i
I 35).
j 5.2.3. Effects of glyceryl trinitrate and bradykinin
The effects of cyclic GMP on p r o l i f e r a t i o n  were inve s t i g a t e d  
further by examining the effects of drugs which alter cyclic GMP 
content of PAEC.
!
I
, Glyceryl t r i n i t r a t e  (lpM), w h i c h  activates soluble g u a n ylate 
' cyclase through the formation of nitric oxide , and the stimula- 
tor of EDRF production, b r a d y k i n i n  (O.lpM), when added twice 
i daily to cells grown in normal serum- supplemented DMEM had no 
, effect on cell numbers when examined throughout a 6 day period 
I (Figure 36). T h e s e  r e s u l t s  s u g g e s t e d  that c y c l i c  GMP had no 
I effect on proliferation of PAEC in culture.
I
j
| Effects of haemoglobin and methylene blue
I effects of two agents which lower intracellular cyclic GMP 
j content by inhibiting the ability of spontanoeously- released 
I EDRf to s t i m u l a t e  s o l u b l e  g a u n y l a t e  c y c l a s e  (Martin et a l .,
| T988b) , m e t h y l e n e  b l u e  and h a e m o g l o b i n  w e r e  e x a m i n e d  on the
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Figure 35: Effects of 8 bromo cyclic GMP on the antiproliferative
action of PMA on PAEC. PAEC were seeded at a density of 1.3 x 104
cells/ cm2 in normal serum- supplemented DMEM and received either
no drugs (o), 8 bromo cyclic GMP (30pM,«), PMA (0.3pM,A), or a
combination of PMA and 8 bromo cyclic GMP (A), added twice daily.
Atthe time points indicated the cells were counted by haemocy-
tometry • Points show mean ± s.e. mean cell numbers (n=6); all
s'e- means are contained within the symbols. * P< 0.005; ** P<
0-0005 ; denotes a significant difference from untreated cells on 
that day.
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Figure 36: Effects of glyceryl trinitrate and bradykinin on the 
proliferation of PAEC. PAEC were seeded at a density (SD) equiva­
lent to 0.04 pg DNA/ c m 2 in normal serum- supplemented DMEM and 
received either no drugs (C), bradykinin (O.lpM, BK) , or glyceryl 
trinitrate (lpM, GTN). Drugs were added twice daily. The cells 
were allowed to grow for 6 days and the DNA content assessed 
Huorimetrically. Bars show the mean ± s.e. mean content of DNA 
(P9) (n=6) .
proliferation of PAEC. Methylene blue (lOpM), when added once 
daily, and haemoglobin (lOpM), when added twice daily, to cells 
grown in n o r m a l  s e r u m -  s u p p l e m e n t e d  D M E M  e a c h  i n d u c e d  a 
reduction in cell numbers throughout a 10 day period: methylene 
blue caused a c o m p l e t e  i n h i b i t i o n  of p r o l i f e r a t i o n  w h e r e a s  
haemoglobin r e d u c e d  cell n u m b e r s  by 44 ± 4% (n=6) at d a y  10
(Figure 37) .
The p o s s i b i l i t y  that t h e s e  r e d u c t i o n s  in cell n u m b e r s  w e r e  
mediated via a d e c r e a s e  in c e l l u l a r  c y c l i c  GMP c o n t e n t  was
investigated by examining the effects of agents which elevate
endothelial cyclic GMP content.
8 bromo cyclic GMP (30pM), when added twice daily to cells grown 
in normal serum- supplemented DMEM had no effect on cell numbers,
or on the ability of methylene 
blue (lOpM) to reduce cell numbers, but blocked the ability of 
haemoglobin (lOpM) to reduce cell numbers throughout a 10 day 
period (Figure 37).
The atrial natriuretic factor, atriopeptin II (lOnM), when added 
twice daily to cells grown in normal serum- supplemented DMEM had 
no effect on cell n u m b e r s ,  h a d  no e f f e c t  on the a b i l i t y  of 
ethylene blue (lOpM) to reduce cell numbers, but blocked the 
ability of haemoglobin (lOpM) to reduce cell numbers after a 4 
a^Y period (Figure 38).
n i t r o v a s o d i l a t o r , so d i u m  n i t r o p r u s s i d e  (lpM), when added 
twice daily to cells grown in normal serum- supplemented DMEM had
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| Figure 37: 8 bromo cyclic GMP reverses the inhibitory effect of 
j haemoglobin but not of methylene blue on proliferation of PAEC.
I PAEC were seeded at a density of 104 cells/ c m 2 in normal serum- 
| supplemented DMEM.
|(A) Cells received either no drug (o), methylene blue (lOpM, A ) ,
! 8 bromo cyclic GMP (30pM, • ), or a combination of methylene blue 
and 8 bromo cyclic GMP (a ) . 
j (B) Cells received either no drug (o), haemoglobin (lOpM, A), 8 
I bromo cyclic GMP (30pM, • ), or a combination of haemoglobin and 8 
| bromo cyclic GMP ( A  ) . Drugs were added twice daily with the 
j exception of methylene blue which was added once daily. At the 
| time points indicated, the cells were counted by haemocytometry •
| Points show the mean ± s.e. mean cell numbers (n=6); all s.e.
I
| ®eans are contained within the symbols. * P< 0.05; ** P< 0.005;
,*** P< 0.0005; denotes a significant difference from untreated
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Figure 38: The ability of atriopeptin II to reverse the inhibito­
ry action of haemoglobin but not of methylene blue on prolifera­
tion of PAEC. PAEC were seeded at a density of 1.7 x 104 cells/ 
and grown in normal serum- supplemented DMEM and received 
either no drug (C), atriopeptin II (lOnM, AP II) , haemoglobin 
(10pM; Hb), methylene blue (lOpM, MB), a combination of AP II and 
Hkf or a combination of AP II and MB. Drugs were added twice 
daily with the exception of methylene blue which was added once 
daily. The cells were allowed to grow for 4 days and then counted 
haemocytometry • Bars show mean cell number ± s.e. mean (n-6). 
* P< 0.05; ** p< 0.005; denotes a significant difference from 
^treated cells, or, between groups joined with a bracket.
no effect on cell numbe r s ,  had no e f f e c t  on the a b i l i t y  of 
methylene blue (lOpM) to reduce cell numbers but bloc k e d  the 
ability of haemoglobin (lOpM) to reduce cell numbers after a 4
i
I d a y  period (Figure 39).
i
1 5,2.5. Effects of L-NMMA 
EDRF has been identified as nitric oxide and vascular endothelial 
| cells are known to s y n t h e s i z e  n itric oxide from the terminal 
guanidino nitrogen atom(s) of L-arginine( Palmer et a l . , 1988b;
Schmidt et a l . , 1988). The L-arginine analogue, N G-monomethyl L-
I arginine (L-NMMA), but not its D- e n a n t i o m e r ,  i n h i b i t s  the
J
j synthesis of nitric oxide by inhibiting the converting enzyme, 
nitric oxide synthase (Rees et al., 1989; 1990). The effects of 
L-NMMA and D-NMMA were examined on the proliferation of PAEC.
I
I L-NMMA (300pM) and D-NMMA (300pM) when added twice daily to cells 
j  grown in normal serum- s u p p l e m e n t e d  DMEM each induced slight 
! eductions in cell numbers in a 4 day period: 6 ± 1% (n=6) and 9 
| - 1% (n=6), respectively (Figure 40). Since both enantiomers had 
1 equal activity, it is unlikely that the reduction in cell numbers
i
resulted from loss of EDRF activity. 
jj.6. Effects of dipyridamole
lo evaluate the effects of phosphodiesterase inhibition on pr o ­
liferation of PAEC in culture the effects of dipyridamole were
examined.
As shown in Section 4.1.1. (Figure 10), PAEC contain two phospho­
diesterase isozymes (Souness et a l ., 1990), and dipyridamole is a
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I Figure 39: The ability of sodium nitroprusside to reverse the
l!
I inhibitory action of haemoglobin but not of methylene blue on 
'proliferation of PAEC. PAEC were seeded at a density of 1.7 x 104 
cells/ cm2 and grown in normal serum- supplemented DMEM. Cells 
! received either no drug (C), sodium nitroprusside (lpM, SNP), 
haemoglobin (lOpM, H b ) , methylene blue (lOpM, MB), a combination 
of SNP and Hb, or a combination of SNP and MB. Drugs were added 
twice daily with the exception of methylene blue which was added 
°hce daily. The cells were allowed to grow for 4 days and thenI
bunted by haemocytometry . Bars show the mean cell number — s.e. 
^an (n=6). * p< 0.05; ** P< 0.005; denotes a significant differ- 
i ^ Ce from untreated cells, or, between groups joined with a
1 Jacket.
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Figure 40: Effects of N G- monomethyl L- arginine (L-NMMA) and N G- 
monomethyl D- arginine (D-NMMA) on the proliferation of PAEC.
PAEC were seeded at a density (SD) of 1.5 x 104 cells/ c m 2 in 
normal serum- supplemented DMEM and received either no drug (C), 
1-NMMA (300pM), or D-NMMA (300pM). Drugs were added twice daily. 
Cells were allowed to grow for 6 days and then counted by haemo- 
cytome,try . Bars show mean cell number ± s.e. mean (n=6).
* 0.05 denotes a significant difference from untreated cells.
potent inhibitor of both. Dipyridamole (25pM) when added twice 
daily to cells grown in serum- supplemented DMEM produced a 53 1 
1% (n=6) reduction in cell numbers in a 6 day period. Haemoglobin 
(lOpM) , w h i c h  i n h i b i t s  the s t i m u l a t i o n  of s o l u b l e  g u a n y l a t e  
cyclase, when added twice daily, produced a slight inhibiton of 
proliferation by itself of 10 ± 2% (n=6) but had no effect upon 
the ability of d i p y r i d a m o l e  (25pM) to i n h i b i t  p r o l i f e r a t i o n  
(Figure 41). It is likely therefore that the reduction in ceil 
numbers i n d u c e d  by d i p y r i d a m o l e  r e s u l t e d  f r o m  the r e d u c e d  
hydrolysis of cyclic AMP.
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Figure 41: Effects of haemoglobin on the antiproliferative action 
of dipyridamole on PAEC. PAEC were seeded at a density (SD) of 
1.5 x 104 cells/ c m 2 in normal serum- supplemented DMEM and 
received either no drug (C), dipyridamole (25pM, DiP) f • haemoglo­
bin (lOpM, H b ) , or, a combination of DiP and Hb. Drugs were added 
twice daily. The cells were allowed to grow for 6 days and then 
counted by haemocytometry . Bars show mean cell number ± s.e. 
aean (n=6). * P< 0.005; *** P< 0.0005; denotes a significant 
difference from untreated c e l l s .
6.1. PROLIFERATION OF RAT AORTIC SMOOTH MUSCLE CELLS
6.1.1. Effects of serum on the proliferation of rat ASMC 
Since vascular smooth muscle cell proliferation plays a key role 
in the p a t h o g e n e s i s  of a t h e r o s c l e r o s i s ,  i d e n t i f i c a t i o n  of 
intracellular messenger pathways utilised in controlling prolif­
eration is important. Smooth muscle cells are known to exhibit 
growth dependence upon platelet- derived mitogens (Fager et al., 
1988 ). The e f f e c t s  of g r o w i n g  rat A S M C  in a range of serum, 
concentrations was therefore examined.
Rat ASMC were seeded at a density of 1.4 x 104 cells/ c m 2 and the 
concentration d e p e n d e n c e  of s e r u m  (2 to 20%) in s t i m u l a t i n g  
growth was observed throughout an 11 day period: growth in serum- 
supplemented DMEM was clearly concentration- dependent (Figure
! 42). Cell numbers remained constant in 2% serum- supplemented
DMEM but increased in higher concentrations. Unlike pig aortic 
endothelial c e lls, w h i c h  w h e n  c o n f l u e n t  b e c o m e  d e n s i t y -
I
, inhibited, rat ASMC even in the highest concentrations of serum
I continued to proliferate when confluent. Serum therefore contains 
foitogens that stimulate growth of rat ASMC.
I
1-1-2. Effects of phorbol 12-myristate 13- acetate on prolifera­
tion of rat ASMC
There are conflicting reports on the actions of protein kinase C 
(PKC) on the proliferation of smooth muscle cell obtained from 
identical or different s o u r c e s . A stimulation of proliferation 
has been reported for smooth muscle cells obtained from bovine 
Pulmonary a r t e r y  and a o r t a  ( D e m p s e y  et al . , 1990; D o c t r o w  & 
F°lkman, 1987); rat aorta (Owen, 1985 ) and rabbit aorta (Kariya
94
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| Figure 42: The serum- dependent growth of rat ASMC in vitro. Rat 
j ASMC were seeded at a density of 1.4 x 104 cells/ c m 2 and grown 
| in either normal serum- supplemented (20% CS, o), 10% serum- 
I supplemented (10% CS, •), 4% serum- supplemented (4% CS, A ) # or
i
| 2S serum- supplemented (2% CS, ■  ) DMEM. At the time points indi-
!
I cated, the cells were counted by haemocytometry • Points show 
I flean cell number (n=6); all s.e. mean are contained within the 
j symbols . ** P< 0.005 denotes a significant difference from 20% CS 
1 treated cells on that day.
et al - # 1987a). In contrast, inhibition of proliferation has been 
observed for smooth muscle cells obtained from rat aorta (Kihara 
etal., 1989) and rabbit aorta (Kariya et a l . , 1987b; Fukumoto et 
al., 1988 ). O n e  s t u d y  d e m o n s t r a t e d  the a b i l i t y  of P M A  to 
stimulate or inhibit the proliferation of rabbit aortic smooth 
muscle cells when the cells were either grown in plasma- derived 
serum or w h o l e  b l o o d  serum, r e s p e c t i v e l y .  In v i e w  of t h e s e 
conflicting r e p o r t s ,  an a t t e m p t  w a s  m a d e  to d e t e r m i n e  if 
stimulation of P K C  m o d u l a t e s  the a b i l i t y  of rat A S M C  to 
proliferate in serum- supplemented DMEM by examining the effects 
of phorbol 12-myristate 13- acetate (PMA).
i
| Rat ASMC were seeded at a d e n s i t y  of 1.5 x l O 4 cells/ c m 2 and
I grown in DMEM in a range of serum concentrations (4, 10 and 20%).
I PMA (0.3pM), added twice daily after an initial 24 hour plating
| down per i o d  h a d  no e f f e c t  u p o n  c e l l s  g r o w n  at a n y  s e r u m
| concentration throughout a 12 day period (Figure 43).
i
6.1.3. Effects of adrenoceptor stimulation on proliferation of
I
, rat ASMC
I Recent reports i n d i c a t e  tha t  an i n c r e a s e  in p l a s m a  level of 
catecholamines is a m a j o r  risk factor in the development of 
atherosclerosis (Helin et a l . , 1970; Kones, 1979; Kukreja et a l . , 
9^81) and that this a c o n s e q u e n c e  of a d r e n o c e p t o r  - m e d i a t e d  
stimulation of vascular smooth muscle cell growth (Nakaki et a l . , 
1989). The e f f e c t s  of a d r e n o c e p t o r  a g o n i s t s  u p o n  rat A S M C  
Proliferation was therefore examined. To study the effects of the 
various d r u g  t r e a t m e n t s  on g r o w t h  of rat A S M C ,  the s e r u m  
c°ncentration was reduced to a sub- maximal level of 10%. This
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Figure 43: Effects of phorbol myristate acetate (PMA) on the pr o ­
liferation of rat ASMC grown in serum- containing DMEM. Rat ASMC 
were seeded at a density of 1.5 x 104 cells/ c m 2 and grown in 
either normal serum- supplemented (20% CS), 10% serum- supple­
mented (10% CS) or 4% serum- supplemented (4% CS) DMEM. Cells 
received either no drug (o) or PMA (0.3pM, •) which was added 
twice daily after an initial 24 hour plating down period. At the 
time points indicated the cells were counted by haemocytometry . 
Joints show mean cell number ± s.e. mean (n=6); when error bars 
ire not seen thay are contained within symbols. * P< 0.05 denotes 
5 significant difference from untreated cells on that day.
theoretically should permit examination of the effects of drugs 
j which inhibit or stimulate growth and prevent the possibility of 
I a mitogenic effect being masked through maximal stimulation of 
, growth growth in 20% serum- supplemented DMEM.
I
The a1- a d r e n o c e p t o r  agonist, p h e n y l e p h r i n e  (O.lpM-lmM), was 
added twice daily after an initial 24 hour plating down period to 
cells grown in 10% serum- supplemented DMEM. No effect on cell 
numbers wa s  o b s e r v e d  a f t e r  4 d a y s  g r o w t h  at the l o w e r  
concentrations of phenylephrine (0.1-10pM) but cell numbers were
I increased at the h i g h e r  c o n c e n t r a t i o n s  (0.1 an d  ImM): the
|
increases in cell number were 17 ± 4% (n = 6) and 30 ± 6% (n=6), 
respectively (Figure 44) .
J  The a2- adrenoceptor agonist , clonidine (O.lpM-lmM), was added 
j twice daily after an initial 24 hour plating down period to cells 
I grown in 10% serum- supplemented DMEM. No effect on cell numbers 
| was observed after 4 days growth in clonidine concentrations of 
O.lpM to O.lmM, but at a concentration of ImM, cell numbers were 
, reduced by 73 ± 2% (n=6, Figure 45).
i
The unstable and non-selective p- adrenoceptor agonist, isoprena- 
line (30pM), was a d d e d  t w i c e  d a i l y  a f t e r  an i n i t i a l  24 h o u r  
Plating down period to cells grown in 10% serum- supplemented 
! DMEM but had no effect upon cell numbers after 4 days gr o w t h
i
! (Figure 46).
The effects of stable p- adrenoceptor agonists were then exam- 
lned- The selective p - adrenoceptor agonist, dobutamine (lOuM)
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Figure 44: Concentration- effect relationship showing the effects 
of phenylephrine on proliferation of rat ASMC. Rat ASMC were 
seeded at a density (SD) of 1.3 x 104 cells/ c m 2 in 10% serum- 
supplemented DMEM. Cells received either no drug (C) or phenyle­
phrine (O.lpM- ImM) added twice daily after an initial 24 hour 
plating down period. The cells were allowed to grow for 4 days 
aud then counted by haemocytometry . Bars show mean cell number ± 
se. mean (n=6). * P< 0.05; ** P< 0.005; denotes a significant 
difference from untreated cells.
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Figure 45: Concentration- effect relationship showing the effects 
of clonidine on proliferation of rat ASMC. Rat ASMC were seeded 
at a density (SD) of 1.4 x 104 cells/ c m 2 in 10% serum- supple­
mented DMEM. Clonidine (O.lpM- ImM) was added twice daily after 
an initial 24 hour plating down period. The cells were allowed to 
Srow for 4 days and then counted by haemocytometry • Bars show 
mean cell numbers ± s.e. mean (n=6). *** P< 0.005 denotes a 
significant difference from untreated cells.
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Figure 46: Effects of isoprenaline, dobutamine, and salbutamol on 
the proliferation of rat ASMC. Rat ASMC were seeded at a density 
i (SD) of 1.4 x 104 cells/ c m 2 in 10% serum- supplemented DMEM and 
received either isoprenaline (30pM, IPR) r dobutamine (lOpM, DOB), 
or salbutamol (lOpM, SAL) added twice daily after an initial 24 
hour plating down period. The cells were allowed to grow for 4 
hays and then counted by haemocytometry . Bars show the mean cell 
number ± s.e. mean (n=6). ** P< 0.005 denotes a significant 
hifference from untreated cells.
and the selective p 2- adrenoceptor agonist, salbutamol (lOpM), 
were added twice d a ily after an initial 24 hour p l a t i n g  down 
period to cells g r o w n  in 10% s e r u m - s u p p l e m e n t e d  DMEM. T h e s e  
analogues reduced cell numbers after 4 days growth by 13 ± 3%
(n=6) and 21 ± 4% (n=6), respectively (Figure 46). It is likely 
therefore that activation of a - adrenoceptors stimulates and p- 
adrenoceptors inhibits proliferation of rat ASMC.
6.2. EFFECTS OF CYCLIC AMP ON PROLIFERATION OF RAT ASMC 
It is known that the effector pathway for p- adrenoceptor activa­
tion is via activation of adenylate cyclase (Watson & Abbott, 
1989 ). It was possible that the reduction in cell numbers induced 
by dobutamine and s a l b u t a m o l  was m e d i a t e d  by an i n c r e a s e  in 
cellular cyclic AMP content. In keeping with this, increasing 
cellular c y c l i c  A M P  c o n t e n t  has b e e n  r e p o r t e d  to red u c e  DN A  
synthesis by human ASMC cultured from atherosclerotic lesions 
(Tertov et a l . , 1984). This suggests that cyclic AMP may have a
role in regulating the growth of vascular smooth muscle c e l l s . 
The effects of various agents which increase cyclic AMP content 
by activation of adenylate cyclase or by inhibiton of the cyclic 
AMP specific phosphodiesterase were therefore examined on the 
Proliferation of rat ASMC.
jjjl. Effects of dibutyryl cyclic AMP
membrane permeant analogue of cyclic AMP, dibutyryl cyclic 
AMP (30pM-lmM) , was added twice daily after an initial 24 hour 
Plating down period to cells grown in 10% serum- supplemented 
M^EM. This analogue had no effect on cell numbers after 4 days 
9r°wth at a lower concentration of 30pM, but reduced cell numbers
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at the higher concentrations of lOOpM and ImM by 29 ± 3% (n=6) 
and 66 ± 2% (n=6)# respectively (Figure 47). Even at the highest 
! concentration (ImM), dibutyryl cyclic AMP failed to stimulate 
trypan blue uptake (Figure 48).
6.2.2. Effects of forskolin
The activator of adenylate cyclase, forskolin (30pM), when added 
twice daily after an initial 24 hour plating down period to cells 
grown in 20% serum- supplemented DMEM, produced a marked reduc­
tion in cell numbers compared with untreated cells throughout an 
8 day period: an inhibition of 57 ± 2% (n=6) was observed at day 
8 (Figure 49). The ability of forskolin to reduce cell numbers 
was observed over the c o n c e n t r a t i o n  range lpM to lOOpM: the
maximum reduction obtained after 4 days growth at lOOpM was 90 ± 
1% (n=6, Figure 50). The inactive analogue, dideoxy forskolin 
(lpM-30pM) lacked the ability of forskolin to reduce cell numbers 
I when assessed after 4 days growth (Figure 50). The solvent for 
forskolin and d i d e o x y  f o r s k o l i n ,  DMS O  (0.1%), r e d u c e d  cell 
numbers by i t s e l f  but o n l y  b y  less t h a n  10%. It is l i k e l y  
therefore that the ability of forskolin to reduce cell numbers 
results from activation of adenylate cyclase and the subsequent 
increase in cellular cyclic AMP c o n t e n t .
jj-3. Effects of M & B 22948 and rolipram
Oscular smooth muscle is known to contain three phosphodiester­
ase isozymes: two cyclic GMP phosphodiesterases, one continuously 
active (Type V) a n d  the o t h e r  s t i m u l a t e d  by the c a l c i u m -  
calmodulin complex (Type I), and a cyclic AMP phosphodiesterases 
(Type iv) (Lugnier et al., 1986; Schoeffter et a l . , 1987 ). The
98
Figure 47: Concentration- effect relationship showing the ability 
of dibutyryl cyclic AMP (DBcAMP) to inhibit proliferation of rat 
ASMC. Rat ASMC were seeded at a density (d D  ) of 1.3- 1.6 x 10A 
cells/ cm2 in 10% serum- supplemented DMEM.
, (A) Cells received either no drugs ( ■ ■  ) or DBcAMP (30pM,E5H).
(3) Cells received either no drugs ( H I )  or DBcAMP (1 0 0 p M f E S  ).
(c) Cells received either no drugs ( ) or DBcAMP (ImM,GOB )•
Drugs were added twice daily after an initial 24 hour plating
fown period. Cells were allowed to grow for 4 days and then
counted by haemocytometry • Bars show mean cell number ± s.e.
tofian (n=6). *** p< 0.0005 denotes a significant difference from
^treated c e l l s .
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Figure 48: Effects of forskolin (FOR), dibutyryl cyclic AMP 
(DBcAMP) and 8 bromo cyclic GMP (8Br cGMP) on trypan blue uptake 
by rat ASMC. Rat ASMC were seeded at a density of 1.2 x 104 
cells/ cm2 in 10% serum- supplemented DMEM with the exception of 
forskolin- treated cells which were grown in 20% normal serum- 
supplemented DMEM. Cells received either no drugs (C), FOR 
UOyM), DBcAMP (ImM) and 8Br cGMP (ImM), added twice daily after 
an initial 24 hour plating down period. The cells were allowed to 
Srow for 4 days and then treated with trypan blue solution (0.1% 
v/v in 0.9% N a C l ) for 30 minutes. Bars show mean ± s.e. mean 
Percentage of cells taking up trypan blue (n=6).
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Figure 49: Effects of forskolin (FOR) on the proliferation of rat 
ASMC. Rat ASMC were seeded at a density of 1.4 x 104 cells/ cm 
in 20% serum- supplemented DMEM and received either no drug (o) 
or forskolin (30pM, • ), added twice daily after an initial 24 
hour plating down period. At the time points indicated, the cells 
were counted by haemocytometry . Points show mean cell numbers 
(t=6); all s.e. means are contained within the symbols.
** P< 0.005 denotes a significant difference from untreated cells 
that d a y .
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Figure 50: Concentration- effect curves showing the ability of 
forskolin but not of the inactive dideoxy forskolin to inhibit 
proliferation of rat ASMC. Rat ASMC were seeded at a density of 
1.2 x 104 cells/ c m 2 in 20% serum- supplemented DMEM. Forskolin 
(l[iM- lOOpM, •), dideoxy forskolin (lpM- 30pM, o) and DMSO (0.1% 
v/v, ■) were added twice daily after an initial 24 hour plating 
fown period. The cells were allowed to grow for 4 days and then 
counted by haemocytometry . Results are expressed as the mean ± 
s-e. mean reduction (%) in cell numbers when compared with 
^treated cells (n=6); when error bars are not seen they are 
contained within symbols. * P< 0.05; ** P< 0.005; denotes a 
sflgnificant difference from untreated cells.
cyclic GMP phosphodiesterases are inhibited by M & B 22948 and 
the cyclic A M P  p h o s p h o d i s t e r a s e  is i n h i b i t e d  s e l e c t i v e l y  by 
rolipram.
To examine further the possibility that forskolin reduced cell 
numbers via an increase in cellular cyclic AMP, the effects of 
rolipram and M & B 22948 were examined alone and in the combina­
tion with forskolin.
Rolipram (30pM), when added twice daily after an initial 24 hour 
plating down period to cells grown in 20% serum- supplemented 
DMEM, produced a reduction 37 ± 2% (n=6) in cell numbers after 4 
days growth and potentiated the inhibitory effect of forskolin 
(lOpM) from 32 ± 4% to 57 ± 4% (n=6, Figure 51).
M & B 22948 (30pM), when added twice daily after an initial 24 
hours plating down period to cells grown in 20% serum- s u p p l e ­
mented DMEM produced a reduction in cell numbers after 4 days 
growth of 26 ± 5% and 48 ± 5% (n=6) in two seperate experiments 
(Figure 52), but did not p o t e n t i a t e  the a b i l i t y  of f o r s kolin 
(lOpM) to reduce cell numbers after 4 days growth. In fact , M & 
B 22948 appeared to reverse the ability of forskolin to reduce 
cell numbers (Figure 52).
The potentiating action of rolipram further supports the concept 
°f cyclic AMP being an inhibitor of proliferation of rat ASMC.
Effects of histamine 
V  receptor activation normally results in the activation of
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Figure 51: Effects of rolipram on the antiproliferative action of 
forskolin on rat ASMC. Rat ASMC were seeded at a density (SD) of 
14 x 104 cells/ c m 2 in 20% serum- supplemented DMEM and received 
either no drug (C), forskolin (lOpM, FOR), rolipram (30pM, ROL), 
ora combination of FOR and ROL. Drugs were added twice daily 
after an initial 24 hour plating down period. The cells were 
allowed to grow for 4 days and then- counted by haemocytometry .
Bars show the mean cell numbers ± s.e. mean (n=6).
** 0.005 denotes a significant difference from untreated
Cells, or, between groups joined with a bracket.
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Figure 52: Effects of M & B 22948 on the ability of forskolin to 
inhibit proliferation of rat ASMC. Rat ASMC were seeded (SD) at a 
density of 1.4 x 104 cells/ c m 2 (top panel) or 1.2 x 104 cells/ 
cm2 (bottom panel) in 20% serum- supplemented DMEM and received 
either no drugs (C), forskolin (lOpM, FOR), M & B  22948 (30pM), 
ora combination of FOR and M & B  22948. Drugs were added twice 
daily after an initial 24 hour plating down period. The cells 
were allowed to grow for 4 days and then counted by haemocytome- 
tty\ Bars show mean cell numbers ± s.e. mean (n=6).
* P< 0.05; ** P< 0.005; denotes a significant difference from 
untreated cells, or, between groups joined with a bracket.
a d e n y l a t e  cyclase (Hill, 1990 ). The possibility that histamine 
night inhibit proliferation of rat ASMC in culture through eleva­
tion of cyclic AMP content was therefore examined.
Histamine (lpM-lmM), when added twice daily after an initial 24 
hour plating down period to cells grown in 10% serum- supplement­
ed DMEM, r e d u c e d  cell n u m b e r s  in a c o n c e n t r a t i o n -  d e p e n d e n t  
manner: the maximum reduction after 4 days growth in ImM hista­
mine was 44 ± 2% (n=6, Figure 53).
The possibility that histamine inhibited proliferation of rat 
ASMC through activation of H 2- receptors was examined by investi­
gating the effect of cimetidine, an H 2- antagonist. Cimetidine 
(lOpM), when added twice daily after an initial 24 hour plating 
down period to cells grown in 10% serum- supplemented DMEM had no 
effect by itself on cell numbers after 4 days growth, but blocked 
the ability of histamine (lOpM) to reduce cell numbers (Figure 
54 ) .
5.3. EFFECTS OF CYCLIC GMP ON PROLIFERATION OF RAT ASMC 
It has recently been reported that nitrovasodilators, which ele­
vate levels of cyclic GMP, inhibit rat aortic smooth muscle cell 
growth in culture (Garg & Hassid, 1989). These workers further 
suggested that EDRF (identified as nitric oxide), the active 
Principle generated by the nitrovasodilators, might be an endoge­
nous regulator of smooth muscle cell proliferation in the arteri- 
al wall.
Ihe effects of the v a r i o u s  a g e n t s  w h i c h  i n c r e a s e  c y c l i c  GMP
100
50 -i
£
UJ
QQ
1 40-
Z
J
J
u
0 30-
z
p 20-
0
D
G
LJ
K 10- 
X
***
- 7 -6 - 5 - 4 - 3 -2
LOG ( HISTAMINE ) M
Figure 53: Concentration- effect curve showing the ability of 
histamine to inhibit proliferation of rat A S M C . Rat ASMC were 
seeded at a density of 1.2 x 104 cells/ c m 2 in 10% serum- supple­
mented DMEM. Histamine (lpM- ImM) was added twice daily after an 
initial 24 hour plating down period. The cells were allowed to 
?row for 4 days and then counted by haemocytometry . The results 
expressed as the mean ± s.e. mean reduction (%) of cell 
numbers compared with untreated cells (n=6). *** P< 0.0005 d e ­
notes a significant difference from untreated cells.
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Figure 54: The ability of cimetidine to reverse the inhibitory 
action of histamine on rat ASMC proliferation. Rat ASMC were 
seeded at a density (SD) of 1.4 x 104 cells/ cm2 in 10% serum- 
supplemented DMEM and received either no drug (C), histamine 
(10pM, HIS), cimetidine (10pM, CIM), or a combination of HIS and 
CIM. Drugs were added twice daily after an initial 24 hour plat­
ing down period. The cells were allowed to grow for 4 days and 
than counted by haemocytometry • Bsirs show mean cell numbers i 
s'6- mean (n=6). * P < >0.05; ** P< 0.005; denotes a significant 
difference from untreated cells, or, between groups joined with a
bracket.
content were therefore examined on the proliferation of rat ASMC. 
These age n t s  i n c l u d e d  s t i m u l a n t s  of s o l u b l e  and p a r t i c u l a t e  
guanylate cyclase and an inhibitor of the cyclic GM? phosphodies­
terases .
6.3.1. Effects of 8 bromo cyclic GMP and atriopeptin II 
The membrane permeant analogue of cyclic GMP, 8 bromo cyclic GMP 
(O.lpM-lmM) was added twice daily after an initial 24 hour plat­
ing down period to cells grown in 10% serum- supplemented DMEM. 
It had no effect on cell numbers after 4 days growth at the 
lower concentrations of 0 . lpM and O.lmM, but reduced cell n u m ­
bers by 17 ± 3% (n=6, Figure 55) at the higher concentration of 
ImM. Even at the concentration of ImM, however, 8 bromo cyclic 
GMP failed to increase trypan blue uptake (Figure 48). The atrial 
natriuretic factor, a t r i o p e p t i n  II (O.lpM), w h i c h  a c t i v a t e s  
particulate guanylate cyclase, was added twice daily after an 
initial 24 hour plating down period to cells grown in 20% serum- 
supplemented DMEM. It had no effect on cell numbers when assessed 
throughout an 8 day growth period (Figure 56).
6-3.2. Effects of glyceryl trinitrate and sodium nitroprusside 
The nitrovasodilators, glyceryl trinitrate (O.luM-lmM) and sodium 
nitroprusside ( l p M - l m M ) ,  w h i c h  a c t i v a t e  s o l u b l e  g u a n y l a t e  
cyclase, were added twice daily after an initial 24 hours plating 
hown p eriod to cells g r o w n  in 10% se r u m -  s u p p l e m e n t e d  DMEM. 
Glyceryl trinitrate had no effect on cell numbers after 4 days 
Growth in concentrations up to O.lmM, but at ImM, cell numbers 
Were reduced by 17 ± 1% (n = 6, Figure 57). Sodium nitroprusside 
tad no effect on cell numbers at concentrations of luM to O.lmM,
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Figure 55: Concentration- effect relationship showing the ability 
of 8 bromo cyclic GMP to inhibit proliferation of rat ASMC. Rat 
ASMC were seeded at a density ( I— I) of 1.3- 1.6 x 104 cells/ c m 2 
in 10% serum- supplemented DMEM.
(A) Cells received either no drug ), or 8 bromo cyclic GMP
(FOpM, E S  ). (B) Cells received either no drug ( )  , or 8 bromo 
cyclic GMP (lOOpM, ESI ) . (C) Cells received either no drug ( H  )/ 
or 8 bromo cyclic GMP (ImM, E H  ) .
Orugs were added twice daily after an initial 24 hour plating 
iown period. Cells were allowed to grow for 4 days and then 
'•ounted by haemocytometry • Bars show mean cell numbers i s.e. 
®ean (n=6). *** p< 0.0005 denotes a significant difference from 
^treated c e l l s .
2.0 n
o 1.6-
E  1.4-
£
W  1-2 “OQ
I- 1.0-
J 0.8-
o 0.6- 
0 .4 -
°*2n
o.ol
0 1 2 3 4 5 6 7 8
TIME ( DAYS )
Figure 56: Effects of atriopeptin II on the proliferation of rat 
ASMC. Rat ASMC were seeded at a density of 1.4 x 104 cells/ c m 2 
in 20% serum- supplemented DMEM and received either no drug (o), 
or, atriopeptin II (O.lpM, A). Drugs were added twice daily after 
an initial 24 hour plating down period. At the time points indi­
cated, the cells were counted by haemocytometry. Points show mean 
ceU  numbers ± s.e. mean (n=6); when error bars are not seen they 
are contained within s y m b o l s .
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Figure 57: Concentration- effect relationship showing the effects 
of glyceryl trinitrate on proliferation of rat ASMC. Rat ASMC 
were seeded at a density (SD) of 1.4 x 104 cells/ c m 2 (A) and 1.4 
X 104 cells/ c m 2 (B) in 10% serum- supplemented DMEM and received 
either no drug (C), glyceryl trinitrate (0.lpM- lOOpM, GTN, A) or 
GTN (ImM, B) . Drugs were added twice daily after an initial 24 
hour plating down period. The cells were allowed to grow for 4 
days and then counted by haemocytometry • Bars show mean cell 
numbers ± s.e. mean (n=6). ** P< 0.005 denotes a significant 
difference from untreated cells.
but reduced cell numbers at concentrations between O.lmM and ImM: 
the maximum r e d u ction after 4 days growth was 107 ± 1% (n=6,
Figure 58) .
6.3.3. Effects of haemoglobin and M & B 22948 on the ability of 
sodium nitroprusside to inhibit proliferation of rat ASMC 
In an attempt to determine if the ability of sodium nitroprusside 
to inhibit smooth m uscle cell p r o l i f e r a t i o n  was m e d i a t e d  by 
nitric oxide- induced activation of soluble guanylate cyclase, 
the effects of haemoglobin and M & B 22948 were examined. Haemo­
globin binds nitric oxide with high affinity thereby preventing 
it from activating soluble guanylate cyclase, and M & B 22948 
inhibits cyclic GMP phosphodiesterase isozymes.
Haemoglobin (20pM) when added twice daily after an initial 24 
hours plating down period to cells grown in 10% serum- su p p l e ­
mented DMEM had no effect on cell numbers after 4 days growth 
(data not shown). Furthermore, the sodium nitroprusside (0.lmM- 
lmM) induced reduction in cell numbers was not inhibited by the 
addition of haemoglobin (20pM, Figure 59).
M & B 22948 (30pM), when added twice daily after an initial 24 
hours plating down period to cells grown in 10% serum- s u p p l e ­
mented DMEM r educed cell numbers by 33 ± 2% (n = 6, Figure 59) 
after 4 days growth. The sodium nitroprusside (O.lmM-ImM) induced 
Eduction in cell numbers was not, however, potentiated following 
the addition of M & B 22948 (30pM, Figure 59).
These results suggested that the reduction in cell numbers m -
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Figure 58: Concentration- effect curve showing the ability of 
sodium nitroprusside to inhibit proliferation of rat ASMC. Rat 
ASMC were seeded at a density of 1.5 x 104 cells/ c m 2 in 10% 
serum- supplemented DMEM. Sodium nitroprusside (lpM- ImM) was 
added twice daily after an initial 24 hour plating down period.
The cells were allowed to grow for 4 days and then counted by 
haemocytometry The results are expressed as the mean ± s.e.
Nean reduction (%) of cell number when compared with untreated 
cells (n=6-12); when error bars are not seen they are contained 
within symbols. **-p< 0.005 denotes a significant difference from
entreated cells.
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Figure 59: Effects of M & B 22948 and haemoglobin on the antipro­
liferative action of sodium nitroprusside on rat ASMC. Rat ASMC 
were seeded at a density of 1.4 x 104 cells/ c m 2 in 10% serum- 
supplemented DMEM and received either no drug, haemoglobin (20pM, 
lata not shown), M  & B 22948 (30pM, A), sodium nitroprusside 
(lOOpM- ImM, o), a combination of sodium nitroprusside and haemo­
globin (•), or a combination of sodium nitroprusside and M  & B 
22948 ( A ) .  Drugs were added twice daily after an initial 24 hour 
Plating down period. Cells were allowed to grow for 4 days and 
then counted by haemocytometry • The results are expressed as 
^an + s.e. mean reduction (%) of cell numbers compared with 
untreated cells (n=6); when error bars are not seen they are 
contained within the symbols. ** P< 0.005 denotes a significant 
difference from sodium nitroprusside treated cells.
duced by sodium nitroprusside was unrelated to stimulation of 
soluble gua n y l a t e  cyclase, and resulted from a non- specific 
action. The possibility that the ability of sodium nitroprusside 
inhibited proliferation by a cytotoxic action was investigated by 
examining the a c c u m u l a t i o n  of the v i tal stain, t r y p a n  blue. 
Sodium nitroprusside (0.I m M - l m M ), over the same concentration 
range that inhibits proliferation, increased the accumulation of 
trypan blue in a c o n c e n t r a t i o n  effect manner: at the highest
concentration dose (ImM) almost all the cells accumulated trypan 
blue (Figure 60).
6.3.4. Effect of methaemoglobin on the ability of sodium nitro­
prusside to inhibit proliferation of rat ASMC
An alternative m e c h a n i s m  by w h i c h  sodium n i t r o p r u s s i d e  could 
produce its antiproliferative actions on rat ASMC is through the 
production of c y a n i d e .  The e f f e c t  of the o x i d i s e d  f o r m  of 
haemoglobin, methaemoglobin, which binds to cyanide was therefore 
examined.
Methaemoglobin (5pM) was added twice daily after an initial 24 
hour plating down period to cells grown in 10% serum- supplement­
ed DMEM, had no effect by itself on cell numbers after 4 days 
9^owth. F u r t h e r m o r e ,  the s o d i u m  n i t r o p r u s s i d e  ( 0 . I m M - l m M ) - 
induced r e d u c t i o n  in cell n u m b e r s  was not i n h i b i t e d  by the 
addition of m e t h a e m o g l o b i n  (5pM, F i g u r e  61). G e n e r a t i o n  of 
cyanide from the hydrolysis of sodium nitroprusside is unlikely 
therefore to contribute to the antiproliferative action.
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Figure 60: Effects of sodium nitroprusside on trypan blue uptake 
by rat ASM C . Rat ASMC were seeded at a density of 1.2 X 104 
cells/ cm2 in 10% serum- supplemented DMEM. Cells received either 
no drug (C), or sodium nitroprusside (O.lmM- ImM), added twice 
daily after an initial 2 4  hour plating down period. The cells 
w&re allowed to grow for 4  days and then treated with trypan blue 
solution (0.1% v/v in 0.9% NaCl) for 30 minutes. Bars show mean ± 
s-e. mean percentage of cells taking up trypan blue (n=6). ** P < 
0.005 denotes a significant difference from untreated cells.
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Figure 61: Effects of methaemoglobin on the antiproliferative 
action of sodium nitroprusside on rat ASMC. Rat ASMC were seeded 
at a density of 1.3 x 104 cells/ c m 2 in 10% serum- supplemented 
DMEM and received either no drug, methaemoglobin (5 p M , A  ), sodium 
nitroprusside (lOOpM- ImM, o), or a combination of sodium nitro­
prusside and methaemoglobin (•). Drugs were added twice daily 
after an initial 24 hour plating down period. Cells were allowed 
to grow for 4 days and then counted by haemocytometry • '^^ ie 
results are expressed as mean ± s.e. mean reduction (%) of cell 
numbers compared with untreated cells (n=6); when error bars are 
tot seen they are contained within the s y m b o l s .
6.3.5. Effects of N G-Nitro L- arginine
It has recently been reported that vascular smooth muscle cells 
generate low but m e a s u r a b l e  q u a n t i t i e s  of a l abile r e l a x i n g  
factor which possesses pharmacological and chemical properties 
similiar to those of EDRF (Wood et a l ., 1990). The possibility
that this endogenous factor has a role in controlling the prolif­
eration of rat ASMC in culture was investigated by examining the 
effects of N G-nitro L- arginine (L-NOARG). L-NOARG is a potent 
competitive inhibitor of the synthesis of nitric oxide from L- 
arginine and acts by inhibiting the converting enzyme, nitric 
oxide synthase (Rees et a l . , 1989; 1990).
L-NOARG (50pM) when added twice daily after an initial 24 hour 
plating down period to cells grown in 10% serum- supplemented 
DMEM, increased cell numbers by 17 ± 4% (n=6, Figure 62) after 4 
days growth. It is possible therefore that L-NOARG increases cell 
numbers by inactivation of nitric oxide synthase.
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■igure 62: Effects of N G- nitro L- arginine on the proliferation 
of rat ASMC. Rat ASMC were seeded at a density (SD) of 1.3 x 104
:ells/ cm2 in 10% serum- supplemented DMEM. Cells received either
'o drug (C),or L- NOARG (50pM) added twice daily after an initial
^hour plating down period. Cells were allowed to grow for 4
:jys and then counted by haemocytometry . Bars show the mean cell
:^ ers ± s.e. mean (n=6). * P< 0.05 denotes a significant dif-
^ence from untreated c e l l s .
DISCUSSION
7.1. PHOSPHODIESTERASE SUBTYPES IN PIG AORTIC ENDOTHELIAL CELLS
It is likely that as in other cells, cyclic nucleotides play a 
role as second messengers in endothelial cells. Several early 
studies demonstrated that the endothelium responded to certain 
vasoactive s u b s t a n c e s  i n c l u d i n g  c a t e c h o l a m i n e s ,  h i s t a m i n e ,  
acetylcholine, prostaglandins and angiotensin II by the elevation 
of either c y c l i c  A M P  or c y c l i c  GMP content. This o c c u r e d  in 
endothelial cells cultured from a variety of sources including 
rabbit and bovine aortae and human umbilical vein (Buonassisi & 
Venter, 1976; S c h a f e r  et a 1 ., 1980; M a k a r s k i ,  1981). M o r e
recently, atrial n a t r i u r e t i c  peptides, n i t r o v a s o d i l a t o r s  and 
adenosine have been shown to elevate cyclic AMP or cyclic GMP 
content in endothelial cells cultured from bovine and pig aortae 
and human umbilical vein (Goldman et al., 1983; Brotherton, 1986; 
Leitman & Murad, 1986; Martin et al., 1988b; Schini et a l ., 1988; 
Legrand et a l ., 1989; 1990). T h e s e  s t u d i e s  d e m o n s t r a t e  that
soluble and particulate guanylate cyclase and adenylate cyclase 
are present in vascular endothelial cells.
Several v a s c u l a r  r e s p o n s e s  have been s hown to be u n d e r  the 
influence of cyclic nucleotides, for example, elevation of cyclic 
AMP and cyclic GMP content may stimulate angiotensin converting 
enzyme activity (Krulewitz & Fanburg, 1986), and thromboxane A 2 
synthesis (Fuller & Worthington, 1984), respectively. An early 
report described inhibition of prostacyclin production resulting 
from elevation of cyclic AMP content following treatment with the 
Phosphodiesterase inhibitor, IBMX (Brotherton & Hoak, 1982). This 
inclusion has bee n  revised, however, s ince s u b s e q u e n t  w o r k  
indicated that the IBMX- i n d u c e d  i n h i b i t i o n  of p r o s t a c y c l i n
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production was the result of a cyclic AMP- independent action of 
the inhibitor (Brotherton et a l ., 1982). The elevation of cyclic 
AMP content induced by prostacyclin in endothelial cells has been 
demonstrated to inhibit the release of EDRF (Shimokawa et al.,
1988) .
Furthermore, the e l e v a t i o n  of c y c l i c  GMP c o n t e n t  by a t r i a l  
natriuretic factor or by the membrane permeant analogue of cyclic 
GMP, 8 b r o m o  c y c l i c  GMP, has b e e n  d e m o n s t r a t e d  to i n h i b i t  
agonist- induced release of EDRF from rabbit aorta (Evans et a l ., 
1988 ; H o g a n  e t a 1 . , 1989 ) an d  f r o m  c u l t u r e d  b o v i n e  a o r t i c
endothelial cells (Busse et a l . , 1988). Recent studies indicate
that the inhibitory effect of cyclic GMP on EDRF release may be 
mediated through inhibition of calcium fluxes and IP3 formation 
in response to EDRF rel e a s i n g  agents (Rapoport, 1986; Lang & 
Lewis, 1991).
The control of vascular permeability has also been demonstrated 
to be under the influence of cyclic nucleotides. Elevation of 
cyclic AMP content has an inhibitory action on the transfer of 
albumin across monolayers of endothelial cells cultured from pig 
aortic (Gudgeon & Martin, 1989), human umbilical vein (Yamada et 
il-, 1990) and bovine pulmonary artery (Stelzner et a l . , 1989).
There are, however, conflicting reports on the ability of cyclic 
GMP to i n h i b i t  p e r m e a b i l i t y .  E l e v a t i o n  of c y c l i c  GMP has no 
effect on a l b u m i n  t r a n s f e r  a c r o s s  m o n o l a y e r s  of p i g  a o r t i c  
endothelial cells (Gudgeon & Martin, 1989), but inhibits transfer 
across human umbilical vein endothelial cells (Yamada et a l . , 
^90), respectively. It has been suggested that cyclic AMP and
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cyclic GMP m e d i a t e  t h e i r  e f f e c t s  by the p h o s p h o r y l a t i o n  of 
cytoskeletal proteins via cyclic AMP- or cyclic GMP- dependent 
protein kinases (Stelzner et a l ., 1989; Yamada et a l ., 1990).
In view of t hese i m p o r t a n t  i n t r a c e l l u l a r  a c t i o n s  of cyc l i c  
nucleotides, it is essential to understand how their activities 
are regulated. Cyclic nucleotides are known to be inactivated by 
phosphodiesterase (P D E ) enzymes (Thompson & Appleman, 1971), but 
until recently little was known of the properties of PDE subtypes 
in vascular endothelial cells.
7.1.1. Purification and characterization of PDE activities in pig 
aortic endothelial cell homogenates
The inactivation of cyclic AMP and cyclic GMP is catalysed by 
cyclic nucleotide PDE. At least five distinct isozyme families
exist with more than 20 different enzymes now recognised (Beavo &
Reifsnyder, 1990). The five families are as follows: calcium/
calmodulin- dependent PDE (Type I), cyclic GMP- stimulated PDE 
(Type II), cyclic GMP- i n h i b i t e d  PDE (Type III), cyclic AMP- 
specific PDE (Type IV) and a cyclic GMP- specific PDE (Type V). 
These i s o z y m e s  are f o u n d  to be d i f f e r e n t i a l l y  e x p r e s s e d  and 
regulated in different tissues and cell types. For example, the 
calcium/ calmodulin- dependent PDE (Type I) is located at high 
concentrations in the dendrites of Purkinje cells and cortical
Pyramidal cells of the rat brain (Kincaid et a l . , 1987 ), whereas
the cyclic G M P - . specific PDE (Type V) is most abundant form in 
the retina (Hurwitz et a l . , 1985).
The following study of the PDE subtypes in pig aortic endothelial
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cell homogenates was carried out in collaboration with Dr. J. E. 
Souness, Rhone- Poulenc Ltd., in his Dagenham laboratory.
The hydrolytic activity of the particulate and soluble fraction 
from PAEC h o m o g e n a t e s  was exa m i n e d .  It was f o u n d  that b o t h  
contained equal hydrolytic activity for cyclic AMP and cyclic 
GMP. Furthermore, their activities were not influenced by the 
addition of c a l c i u m  (2mM)/ c a l m o d u l i n  (10 u n i t s /  ml). This 
indicates that the calcium/ calmodulin- dependent PDE (Type I) is 
absent f r o m  e n d o t h e l i a l  cells. The p u r i f i c a t i o n  a n d 
characterization of the PDE subtypes present in PAEC was carried 
out by a p p l y i n g  the s u p e r n a n t a n t  (soluble) f r a c t i o n  of P A E C 
homogenates to a DEAE- Trisacyl chromatography.
The first peak of PDE activity eluted hydrolysed both cyclic AMP 
and cyclic GMP. Upon addition of cyclic GMP (lpM), the hydrolysis 
of cyclic AMP was stimulated two- fold, thus indicating that this 
first i s o z y m e  is a l l o s t e r i c a l l y  r e g u l a t e d  by c y c l i c  GMP. 
Furthermore, as obser v e d  w i t h  crude homogenates, addit i o n  of 
calcium (2mM) and calmodulin (0.5 unit/ ml) did not augment the 
hydrolysis of c y c l i c  GMP. The f i r s t  p e a k  w a s  t h e r e f o r e  
characterized as Type II according to the criteria of Beavo & 
Feifsnyder (1990).
The second peak eluted was a PDE which selectively hydrolysed 
cyclic AMP and v/as neither stimulated nor inhibited by cyclic 
Again addition of calcium (2mM) and calmodulin (0.5 units/ 
did not augment the hydrolysis of cyclic AMP. This enzyme 
was therefore characterized as Type IV PDE according to Beavo &
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Reif snyder ( 1990 )
PAEC therefore contain two PDE isozymes, a cyclic AMP- specific 
PDE (Type IV) and a cyclic GMP- stimulated PDE (Type II). These 
findings are in agreement with those of Lugnier & Schini (1990) 
who demonstrated the presence of the same two PDE activites in 
cultured bovine aortic endothelial cells. One small difference 
between these two studies was that for bovine aortic endothelial 
cell homogenates, the majority of the hydrolytic activity for 
both cyclic nucleotides was found in the cytosolic fraction (more 
than 80%), whereas in our study, the percentages for soluble and 
particulate were 58% and 42%, respectively.
7.1.2. Selectivity of phosphodiesterase inhibitors on the cyclic 
GMP- stimulated PDE and on the cyclic AMP- specific PDE 
An examination of the selectivity of various inhibitors on the 
isozymes p r e s e n t  in PAEC h o m o g e n a t e s  was also carr i e d  out in 
collaboration with Dr. J. E. Souness, Rhone- Poulenc Ltd., in his 
Dagenham laboratory.
It was found that M & B 22948, a selective inhibitor of Type 1 
DDE in smooth muscle, was a weak inhibitor of both PDE isozymes. 
Similiarly, SK & F 94120, a selective inhibitor of the cylic GMP- 
inhibited PDE (Type III), also exhibited only weak inhibitory 
activity against the two PDE isozymes. It was found, however, 
that dipyridamole and trequinsin, two non- selective inhibitors, 
Potently inhibited both isozymes whereas, rolipram was found to 
selectively inhibit the cyclic AMP- specific PDE. These observa­
tions were similiar to those reported in cultured bovine aortic
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endothelial cells homogenates (Lugnier & Schini, 1990). In there, 
M & B 22948 was a weak inhibitor of both isozymes, trequinsin and 
dipyridamole potently inhibited both isozymes, and rolipram was 
found a selective inhibitor of the cyclic AMP- specific PDE.
The first o b j e c t i v e  of this p r o j e c t  was to i n v e s t i g a t e  the 
functional roles of each of the two PDE isozymes in regulating 
the c e l l u l a r  c y c l i c  A M P  an d  c y c l i c  GMP c o n t e n t .  T h i s  was
attempted b y  e x a m i n i n g  the e f f e c t s  of the i n h i b i t o r s ,  
dipyridamole, t r e q u i n s i n  and rolipram, on b a s a l  and a g o n i s t  
stimulated content of cyclic AMP and cyclic GMP. All these and 
subsequent experiments were carried out in Glasgow.
7.1.3. Cyclic GMP content of PAEC
It was found that p r i m a r y  cultures of pig aortic en d o t h e l i a l  
cells had a basal cyclic GMP content of 59.1 ± 5.7 fmol pg DNA'1 
(n=34). Furthermore, haemoglobin and L- NMMA, which selectively 
block the activation of soluble guanylate cyclase by binding to 
EDRF (Martin e;t al . , 1985 ) and by i n h i b i t i n g  E D R F  s y n t h e s i s
(Palmer et a l . , 1988a; Rees et a l . , 1989; 1990 ), respectively,
were found to reduce the basal intracellular level of cyclic GMP.
canavanine, w h i c h  i n h i b i t s  n i t r i c  o x ide s y n t h a s e  in the
macrophage (Hibbs et a l . , 1987a) has been proposed to inhibit the 
synthesis of EDRF in rabbit aorta (Schmidt et a l . , 1988), but
this has been disputed (Rees et a l . , 1989). L- canavanine did
n°t, however, reduce the basal intracellular level of cyclic GMP 
content of PAEC. T h e s e  o b s e r v a t i o n s  s u g g e s t  that the b a s a l  
lntracel l u l a r  l e v e l  of c y c l i c  GMP is d e t e r m i n e d  by the
sPontaneous p r o d u c t i o n  of E D R F  by the e n d o t h e l i a l  c e l l s
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themselves. This finding is consi s t e n t  with previous studies 
demonstrating that in the isolated aorta of the rat and rabbit, 
the b a s a l  l e v e l  of c y c l i c  GMP is r e l a t e d  to s p o n t a n e o u s  
production of EDRF by the endothelial cells (Rapoport & Murad, 
1983 ; Martin et a l . , 1986a; 1986b).
In PAEC bradykinin increased the intracellular cyclic GMP content 
through stimulation of EDRF production as previously described 
(Martin et a 1 . , 1988b) . T h i s  i n c r e a s e  w a s  a b o l i s h e d  by
pretreating the cells with either haemoglobin or L- NMMA, but L- 
canavanine had no effect. From these findings it is clear that 
synthesis of EDRF determines the cyclic GMP content of PAEC, and 
this is inhibited by L-NMMA but not L- canavanine.
7.1.4. Role of the cyclic GMP- stimulated PDE in PAEC 
It was likely that the cyclic GMP- stimulated PDE present in PAEC 
played an important regulatory role in c o n t r o l l i n g  cyclic GMP 
content, since it was the one capable of hydrolysing this cyclic 
nucleotide.
In keeping with this, the non- selective inhibitor, dipyridamole, 
which had p r e v i o u s l y  bee n  f o u n d  to i n h i b i t  the c y c l i c  GMP- 
stimulated PDE in cell homogenates, induced a large increase in 
intracellular cyclic GMP content. This pe a k e d  w i t h i n  5 to 10 
ninutes and then declined rapidly but remained elevated above 
control levels for a prolonged period. Several recent studies 
have indicated that efflux of cyclic nucleotides from cells might 
act together with phosphodiesterase enzymes to regulate cellular 
cyclic nucleotide content (Goldman e t a l . , 1983; Schini e t a l .  ,
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1989). D i p y r i d a m o l e  is k n o w n  to b l o c k  the a c t i o n s  of the 
nucleoside transporter protein in numerous cell types, including 
erythrocytes (Plagemann & Waffendin, 1988), endothelial cells 
(Pearson et a l . , 1978 ) and sarcoma 180 cells (Cabral et a l . ,
1984). It was p o s s i b l e  t h e r e f o r e  that d i p y r i d a m o l e  caused an 
elevation of cyclic GMP content in PAEC by blocking the efflux of 
this molecule from the cell and not by inhibiting the cyclic GMP- 
stimulated PDE. This was not the case, however. In u n t r e a t e d  
cells there was a small steady leakage of cyclic GMP into the 
bathing m e d i u m  w i t h  time. Ra t h e r  than b l o c k i n g  this leak, as 
would have b e e n  e x p e c t e d  if the n u c l e o s i d e  t r a n s p o r t e r  was 
blocked, d i p y r i d a m o l e  e l e v a t e d  the cyclic GMP content of the 
bathing medium. Furthermore, this increase occured only after the 
intracellular increase had been established.
Thus, it is a l m o s t  c e r t a i n  t h a t  d i p y r i d a m o l e  i n c r e a s e s  
intracellular cyclic GMP content by inhibiting the cyclic GMP- 
stimulated PDE and not the efflux of the cyclic nucleotide from 
the cells. The m a g n i t u d e  of the rise in c y c l i c  GMP c o n t e n t  
stimulated by d i p y r i d a m o l e  s u g g e s t s  a r a p i d  i n t r a c e l l u l a r  
hydrolysis of this cyclic nucleotide in PAEC. The elevation of 
cyclic G M P  c o n t e n t  wa s  l i k e l y  to h a v e  r e s u l t e d  f r o m  the 
activation of soluble guanylate cyclase by EDRF since both the 
rises in intracellular and extracellular content were abolished 
following pretreatment with haemoglobin.
Trequinsin, which had previously been found to inhibit the cyclic 
GMP- stimulated PDE in cell homogenates was also observed to 
eievate intracellular cyclic GMP content. This peaked after 15
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minutes, fell t h e r e a f t e r ,  but r e m a i n e d  e l e v a t e d  a b o v e  b a sal 
levels for a prolonged period. This increase, like that induced 
by d i p y r i d a m o l e ,  wa s  a b o l i s h e d  by p r e t r e a t m e n t  w i t h  
haemoglobin.
It is c l e a r  t h e r e f o r e  that in P A E C  the rises in c y c l i c  GMP 
content following treatment with the PDE inhibitors, dipyridamole 
and trequinsin, were dependent upon the activation of soluble 
guanylate cyclase by EDRF synthesised by the endothelial cells 
themselves. Rolipram, which in cell homogenates had previously 
been found to inhibit only the cyclic AMP- specific PDE, had no 
effect on the i n t r a c e l l u l a r  c y c l i c  GMP c o n t e n t .  This, as 
expected, confirms that the cyclic AMP- specific PDE has no role 
in regulating the intracellular cyclic GMP content of PAEC.
The time course of the rise in cyclic GMP content stimulated by 
dipyridamole or trequinsin was complex: it reached a peak then 
fell to a plateau after roughly 15 minutes. It was possible that 
the inhibitors, dipyridamole and trequinsin, had a short duration 
of action, but as will be seen later, this was not the case. An 
alternative explanation, however, is that high intracellular 
concentrations of c y c l i c  GMP m i g h t  p o t e n t i a l l y  i n h i b i t  the 
production of EDRF. Recent studies have demonstrated that atrial 
natriuretic factor and 8 bromo cyclic GMP,each reduce agonist- 
induced release of EDRF in the rabbit aorta and ear artery (Busse 
?t__al. , 1988; E v a n s  et al., 1988; H o g a n  et a l , 1989 ). T h e s e  
observations s u g g e s t  the p r e s e n c e  of a n e g a t i v e  f e e d b a c k  
Mechanism controlling the production of EDRF.
IlL-5- Role of the c y c l i c  GMP- s t i m u l a t e d  PDE in r e g u l a t i n g
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agonist- induced increases in cyclic GMP content in PAEC
Nitrovasodilators stimulate soluble guanylate cyclase through 
production of nitric oxide (Arnold et a l . , 1977 ; Katsuki et a l . , 
1977 ; Craven & De Rubertis, 1978 ). These agents induce increases 
in the i n t r a c e l l u l a r  cyclic GMP content of en d o t h e l i a l  cells 
cultured from a variety of sources including pig aorta and human 
umbilical vein (Brotherton, 1986 ; Ma r t i n  et a l . , 1988b). The
increases in i n t r a c e l l u l a r  c y c l i c  GMP c o n t e n t  s t i m u l a t e d  by 
glyceryl t r i n i t r a t e  and s o d i u m  a z ide are b l o c k e d  f o l l o w i n g  
pretreatment w i t h  e i t h e r  m e t h y l e n e  blue or h a e m o g l o b i n ,  two 
agents k n o w n  to i n h i b i t  the s t i m u l a t i o n  of s o l u b l e  but not 
particulate guanylate cyclase by EDRF (Martin et al., 1988b). In 
contrast, in b o v i n e  a o r t i c  e n d o t h e l i a l  c ells, s o d i u m  
nitroprusside induced only a small increase in cyclic GMP content 
(Schini et a l . , 1988). These workers suggested that the observed 
differences may be related to species variation, vascular origin 
of cells or t i m e  s p e n t  in c u l t u r e .  It has b e e n  s h o w n  t h a t  
endothelial cells r e s p o n s i v e n e s s  declines wit h  time spent in 
culture (Ager & Martin, 1983; Pearson et a l . , 1983; Needham et 
al-, 1987 ) .
In the present study, sodium nitroprusside was found to increase 
both the intracellular and extracellular (i.e. the Kreb's bathing 
®edium) c o n t e n t  of c y c l i c  GMP. E x a m i n i n g  the e f f e c t s  of 
Inhibiting the cyclic GMP- stimulated PDE with dipyridamole on 
the sodium nitroprusside- induced rise in cyclic GMP content was 
complicated b y  the f i n d i n g  t h a t  the PDE i n h i b i t o r  i t s e l f  
Simulated an increase. This, as described previously, peaked 
within a few minutes then fell to a lower sustained level after
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around 35 m i n u t e s , p o s s i b l y  t h r o u g h  a n e g a t i v e  f e e d b a c k  
inhibition of EDRF production. After this time, however, the PDE 
still appeared to be inhibited since subsequent stimulation with 
sodium nitroprusside resulted in augmented increases in cyclic 
GMP content.
The effects of inhibiting the cyclic GMP stimulated PDE were also 
examined on the increase in cyclic GMP content s t i m u l a t e d  by 
activation of particulate guanylate cyclase. In these experiments 
the PAEC were pretreated with haemoglobin to prevent activation 
of soluble guanylate cyclase by the spontaneous produced EDRF. It 
was found that the atrial natriuretic factor, atriopeptin II, 
which a c t i v a t e s  p a r t i c u l a t e  g u a n y l a t e  cyclase, e l e v a t e d  the 
intracellular cyclic GMP content in PAEC. The effect of atriopep­
tin II wa s  c o n c e n t r a t i o n  d e p e n d e n t .  T h e s e  f i n d i n g s  are in 
agreement with those of several earlier studies describing the 
ability of atrial natriuretic peptides to increase the cyclic GMP 
content of bovine aortic, human umbilical vein and pig aortic 
endothelial ceils (Leitman & Murad, 1986; Schini et a l . , 1988;
Brotherton, 1986; Martin et a l ., 1988b). In one of these studies, 
it was o b s e r v e d  that the a t r i o p e p t i n  II- induced increase in 
intracellular c y c l i c  GMP c o n t e n t  was a s s o c i a t e d  w i t h  a time 
dependent effJ.ux of this c y c l i c  n u c l e o t i d e  into the b a t h i n g  
tedium (Schini et al., 1988). This reinforces the suggestion that 
regulation of cyclic nucleotide content of endothelial cells is 
controlled by a' combination of hydrolysis and efflux (Schini et 
, 1989) .
was f o u n d  t h a t  the n o n -  s e l e c t i v e  PD E  i n h i b i t o r s ,
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dipyridamole an d  t r e q u i n s i n ,  e a c h  e n h a n c e d  the a b i l i t y  of 
atriopeptin II to increase the intracellular cyclic GMP content 
of PAEC. In contrast, the selective inhibitor of the cyclic AMP- 
specific PDE, rolipram, had no effect on the a t r i o p e p t i n  II- 
induced increase in intracellular cyclic GMP content.
These findings show that in PAEC the cyclic GMP- stimulated PDE 
controls basal cyclic GMP content and following stimulation of 
either soluble or particulate guanylate cyclase. They further 
show that the o t h e r  e n z y m e  p r e s e n t  in PAEC, the c y c l i c  AMP - 
specific PDE has no role in r e g u l a t i n g  e i t h e r  the b a s a l  or 
agonist- stimulated increases in cyclic GMP content.
7.1.6. Role of the cyclic AMP- specific PDE in PAEC 
Our e x p e r i m e n t s  w i t h  cell h o m o g e n a t e s  s h o w e d  that b o t h  PDE 
isozymes present in PAEC, the cyclic AMP- specific PDE and the 
cyclic GMP- stimulated PDE, had the ability to hydrolyse cyclic 
AMP (Souness et al., 1990). The importance of the cyclic AMP- 
specific PDE (Type IV) in regulating the cyclic AMP content of 
intact PAEC was i n v e s t i g a t e d  by e x a m i n i n g  the effects of the 
selective inhibitor of this enzyme, rolipram.
The activator of adenylate cyclase, forskolin (Seaman & Daly, 
1981) , was found to have no effect on the intracellular cyclic 
AMP content at a concentration of lOpM but at 30pM, an elevation 
w^ s o b s e r v e d .'R o l i p r a m  e l e v a t e d  the i n t r a c e l l u l a r  cyclic AMP 
content by itself and enhanced the forskolin- induced increase. 
This result is in agreement with previous studies reporting the 
ahility of for s k o l i n  and p r o s t a c y c l i n  to elevate e n d o t h e l i a l
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cyclic AMP concent and of cyclic AMP PDE inhibitors to enhance 
these rises (Leitman et a l . , 1986; Martin et a l . , 1988b). These
findings show that the cyclic AMP- specific PDE regulates basal 
and agonist- stimulated cyclic AMP content in PAEC.
7.1.7. Role of the c y c l i c  GMP- s t i m u l a t e d  PDE in r e g u l a t i n g  
cyclic AMP content in PAEC
Our studies with cell homogenates showed that cyclic AMP could be 
hydrolysed by the cyclic GMP- stimulated PDE (Souness et a l ., 
1990). It was possible, therefore, that this PDE acted together 
with the c y c l i c  A M P -  s p e c i f i c  PDE to c o n t r o l  c y c l i c  A M P  
hydrolysis in PAEC. This was difficult to determine, however, 
since no selective inhibitor of this PDE isozyme was available.
The non- selective inhibitor, dipyridamole, which inhibits both 
the cyclic GMP- stimulated PDE and cyclic AMP- specific PDE in 
cell h o m o g e n a t e s ,  wa s  f o u n d  to h a v e  no e f f e c t  on the 
intracellular cyclic AMP content at a concentration of 25pM, but 
at lOOpM, an elevation was observed. Furthermore, dipyridamole 
(25pM and lOOpM) was found to enhance isoprenaline- (a p- adreno­
ceptor agonist) and forskolin- induced increases in intracellular 
cyclic AMP content. Whether these rises occurred by inhibition of 
the cyclic GMP- stimulated PDE, the cyclic AMP- specific PDE, or 
both could not be determined.
Ij. 8. Conclusion
conclusion, p i g  a o r t i c  e n d o t h e l i a l  cells c o n t a i n  two PDE 
activities, a cyclic GMP- stimulated PDE (Type II) and a cyclic 
s p e c i f i c  PDE (Type IV). The c y c l i c  GMP- s t i m u l a t e d  PDE
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isozyme actively participates in the regulation of the intracel­
lular content of cyclic GMP under basal conditions and following 
stimulation of both soluble and particulate guanylate cyclase. 
The cyclic AMP- specific PDE participates only in the regulation 
of the i n t r a c e l l u l a r  c y c l i c  A M P  content, since it lacks the 
ability to hydrolyse cyclic GMP. The cyclic GMP- stimulated PDE 
might have an a d d i t i o n a l  role in r e g u l a t i n g  the c y c l i c  AM P  
content, but definite proof of this must await the development of 
a selective inhibitor of this enzyme.
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8.1. PROLIFERATION OF PAEC IN CULTURE
The objective of this part of the study were to investigate the 
effects of PKC activation by phorbol esters and of cyclic nucleo­
tides on the proliferation of pig aortic endothelial cells in 
culture.
8.1.1. Effects of PKC activation on the proliferation of endothe- 
lial cells
The calcium- phospholipid dependent protein kinase, PKC, has been 
shown to play a role in signal transduction during several cellu­
lar responses including proliferation (Nishizuka, 1986). Basic 
FGF is a potent mitogen for endothelial cells and its ability to 
activate PKC has been previously demonstrated in many cell types. 
In Swiss 3T3 fibroblasts, induction of diacylgycerol formation 
and PKC activation was observed during the mitogenic response to 
basic FGF (Tsuda et a l . , 1985 ). In contrast, basic FGF was found 
'o be mitogenic via a PKC- independent pathway in hamster fibro­
blasts (Magnaldo et a l . , 1986 ). This was shown to be the case
since basic FGF lacked the a b i l i t y  to induce a c c u m u l a t i o n  of 
inositol trisphosphate and activate PKC.
Recently, however, it has been reported that the mitogenic activ- 
:tY of basic FGF and of a structurally related mitogen, human 
•lepatoma- derived growth factor (Klagsbrun et a l . , 1986; Presta
i!_al. , 1986), in endothelial cells is, at least in part, related 
bo their ability to activate PKC. The response to these growth 
fectors was blocked following pretreatment either with phorbol 
ssters, which initially stimulate then down- regulate PKC, or a 
inhib itor. This was seen in several endothelial cell types
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including bovine cerebral cortex capillary (Daviet et a l ., 1990), 
bovine a d r e n a l  c a p i l l a r y  ( D o c t r o w  & Folkman, 1987) and in a 
transformed foetal bovine aortic endothelial cell line (Presta et 
al., 1989a) .
The importance of PKC activation in the proliferation of endothe­
lial cells has been further e l u c i d a t e d  by the use of p horbol 
esters. They have been shown to have differing actions on the 
proliferation of endothelial cells from different species and 
vascular origin. An inhibition of proliferation has been reported 
for endothelial cells obtained from human aorta (Hoshi et a l ., 
1988b) and bovine adrenal capillary (Doctrow & Folkman, 1987). In 
contrast, a stimulation of proliferation has been observed in 
endothelial cells obtained from bovine cerebral cortex capillary 
(Daviet et a l . , 1989; 1990) and in a transformed foetal bovine
aortic cell line (Presta et al., 1989a). No effect was observed 
on p r o l i f e r a t i o n  of e n d o t h e l i a l  cells o b t a i n e d  f r o m  f o e t a l  
bovine aorta (Presta et a l . , 1989a), human omental microvascula­
ture (Dupuy et a l ., 1989), bovine aorta (Doctrow & Folkman, 1987) 
and bovine adrenal capillary (Morris et a l ., 1988). Activation of 
pKC, therefore, plays an important role in the mitogenic response 
of endothelial cells .
iil-2. Effect of PKC activation by PMA on the proliferation of 
i^ EC as assessed by haemocytometry
In view of the above conflicting reports on the effects of phor- 
bol esters on proliferation of endothelial cells, the effects of 
phorbol 12-myristate 13-acetate (PMA) was examined on PAEC. It 
found that PMA significantly inhibited the proliferation of
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PAEC in serum- containing medium over a period of 1 to 8 days . 
This finding is therefore in agreement with those of Hoshi et al. 
(1988b) and Doctrow & Folkman (1987 ). The inhibition of growth is 
unlikely to have resulted from a non- selective cytotoxic action 
since p l a t i n g  e f f i c i e n c y  and cell v i a b i l i t y ,  as a s s e s s e d  by 
uptake of the vital stain trypan blue was unaffected by PMA. This 
is in agreement with previous reports demonstrating that phorbol 
esters have no effect on either plating efficiency or viability 
of endothelial cells (Doctrow & Folkman, 1987; Hoshi et a l . , 
1988b) . The inhibition of proliferation by PMA was observed to be 
concentration- dependent and appeared to be due to the activation 
of PKC since the inactive p h o r b o l  ester, 4a- p h o r b o l -  12,13- 
didecanoate, lacked antiproliferative activity.
The activation of PKC by PMA was further investiagted by examin­
ing the effects of a PKC inhibitor, staurosporine (Tamaoki et 
al. , 1986 ). It was found that s t a u r o s p o r i n e  inh i b i t e d  serum- 
induced proliferation of PAEC throughout a 8 day period, but, 
failed to block the antiproliferative effects of PMA.
Recent studies have indicated the presence of multiple PKC iso­
zymes in many cell types (Coussens et a l ., 1986; Nishizuka, 1988; 
Rarago & Nishizuka, 1990). Different PKC isozymes have also been 
identified in PAEC (Uratsuji & DiCorleto, 1988). Why staurospo- 
hne blocks the se r u m -  i n d u c e d  p r o l i f e r a t i o n  of P A E C  is not 
clear. it is possible that it inhibits proliferation of PAEC by 
locking the a c t i v a t i o n  of a PKC i s o z y m e ( s )  i n v o l v e d  in the 
s&rum- induced mitogenic response. Alternatively, as staurospo- 
rine has been shown to be a non- selective inhibitor it may be
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acting by a PKC- independent mechanism. For example, staurospo­
rine inhibits not only PKC but also several other protein k i ­
nases, including tyrosine protein kinase, cyclic AMP- dependent 
protein kinase and calcium/ calmodulin- dependent protein kinase 
(Riiegg & Burgess, 1989).
The failure of s t a u r o s p o r i n e  to b l o c k  the a n t i p r o l i f e r a t i v e  
activity of PMA in PAEC is surprising. If PMA does act by stimu­
lating PKC, as seems likely from the lack of effect of the inac­
tive phorbol ester, 4a- phorbol- 12,13- didecanoate, it is neces­
sary to propose that PMA activates PKC isozyme(s) that is insen­
sitive to blockade by staurosporine. There are, however, no other 
reports of the effects of PKC inhibitors on the antiproliferative
effects of PMA on endothelial cells.
It has been shown, however, that in endothelial cell types where 
phorbol esters stimulate proliferation that staurosporine and 
another inhibitor, H-7, each block this stimulation. This has 
been seen in transformed foetal bovine aortic (Presta et a l . , 
1989a) and bovine cerebral cortex capillary (Daviet et a l . , 1989;
1990) endothelial cells. It is possible, therefore, that where 
phorbol esters inhibit proliferation, this occurs by stimulation 
°f a subt y p e ( s )  of PKC that is i n s e n s i t i v e  to s t a u r o s p o r i n e  
whereas when stimulation of proliferation is seen, this occurs by 
stimulation of an isozyme(s) that is sensitive to inhibition.
Lie 3 • Effect of PMA on p r o l i f e ration of PAEC as a s s e s s e d  by
[iOcthymidine incorporation
a study of the effects of PMA on the proliferation of PAEC, as
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assessed by [ JH ] - t h y m i d i n e  i n c o r p o r a t i o n  into DNA, an e a r l y  
stimulation of proliferation was observed followed by an inhibi­
tion (Uratsuji & DiCorleto, 1988). This d u a l i s t i c  action was 
considered by these authors to reflect the ability of phorbol 
esters to stimulate then down- regulate PKC. In the experiments 
discussed thus far where cell numbers was the index of prolifera­
tion, no early stimulation of proliferation was observed follow­
ing treatment of PAEC with PMA. This lack of an early stimulation 
might have resulted because within the first time point examined, 
(48 hours), there had been a complete down- regulation and there­
fore disappearance of PKC activity. Uratsuji & DiCorleto (1988) 
had p r e v i o u s l y  d e m o n s t r a t e d  a c o m p l e t e  d i s a p p e a r a n c e  of PKC 
activity f o l l o w i n g  t r e a t m e n t  of PAE C  for 24 h o urs w i t h  PM A 
(200nM) . Measurement of [3H]-thymidine incorporation represents a 
more sensitive index of proliferation, so experiments were r e ­
peated using this technique to see if an early stimulation was 
observed with PMA in PAEC.
It was found that serum- induced stimulation of [ 3H]-thymidine 
incorporation by PAEC was concentration- dependent. Moreover, it 
was demonstrated that PMA significantly reduced [3H]-thymidine 
incorporation in 0%, 4% and 20% serum- containing medium after an 
18 hour incubation period. Even at the earlier time points exam­
ined (4, 8 and 12 hours), PMA was found to induce only inhibition 
[3H]-thymidine incorporation into PAEC with no stimulatory 
Phase.
The p k c  inhibitor, staurosporine (lOnM), was found to have no 
effect on serum- induced incorporation of [3H]-thymidine into
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PAEC after an 18 hour incubation period, but at the higher con­
centration of lOOnM, an inhibition of incorporation was observed. 
This contrasts slightly with the results from the haemocytometric 
experiments where staurosporine (lOnM) inhibited serum- induced 
proliferation of PAEC over a period of 4 to 8 days. The possibil­
ity that this discrepancy resulted from the different incubation 
periods employed in the two experiments is supported by a recent 
report demonstrating that staurosporine inhibits the prolifera­
tion of rabbit aortic smooth muscle cells only after a 24 hour 
incubation period (Matsumoto et a l . , 1989).
In agreement with the earlier haemocytometric experiments, stau­
rosporine at b o t h  c o n c e n t r a t i o n s  (10 and lOOnM) was w i t h o u t  
effect on the PMA- induced inhibition of [3H]-thymidine incorpo­
ration by PAEC over the range of serum concentrations (1%, 4% and 
20%). This as has already been discussed, may be explained by PMA 
inhibiting proliferation by activating an isozyme of PKC that is 
insenstive to blockade by staurosporine. It is not clear why the 
early stimulation of [3H]-thymidine incorporation reported previ­
ously (Uratsuji & DiCorleto, 1988) could not be reproduced in 
this study despite experimental conditions being similiar. In 
this study, passage 1 PAEC only were used, whereas in the earlier 
study, PAEC between passage 4 and 13 were used. No other explana­
tion for the di f f e r e n c e s  r e p o r t e d  in the two studies appears 
obvious.
These results, utilising two independent methods ( haemocytometry 
and [3H]-thymidine incorporation), suggest that activation of PKC 
Powerfully inhibits the proliferation of PAEC.
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3.1.4. Possible mechanisms by which phorbol esters mediate their
antiproliferative action on PAEC
;t is g e n e r a l l y  a c c e p t e d  t h a t  PKC e x e r t s  its a c t i o n s  on 
proliferation through changes in the phosphorylation state of 
proteins (reviewed in Takai et a l . , 1985 ; Nishizuka, 1986). This 
leads subsequently to altered expression of growth factors and 
oncogenes (Bikfalvi et a l . , 1990; Murphy et a l . f 1988; Black-
shear, 1988; Colotta et a l . , 1988; Reuse et a l . , 1990 ) and the
down- r e g u l a t i o n  of g r o w t h  f a c t o r  r e c e p t o r s  (Hoshi et al . , 
1988b) . The possibility that PMA inhibits proliferation of PAEC 
by alternative mechanisms was considered.
3.1.5. Oxygen- derived free radicals
PMA is known to stimulate the production of destructive, oxygen- 
derived free radicals by endothelial cells (Matsubara & Ziff, 
1986 ), and these could potentially contribute to the antiprolif­
erative action. In k e e p i n g  w i t h  this p o s s i b i l i t y ,  p a r a q u a t ,  
another agent known to generate free radicals (Minakami et a l . , 
1990 ) was found to inhibit proliferation of PAEC in a concentra­
tion- dependent manner. At the highest concentration examined of 
1®M, the antiproliferative effect was associated with detachment 
rf cells and uptake of the vital stain, trypan blue. This is in 
:ontrast to the actions of PMA where inhibition of proliferation 
occurred with no evidence of cytotoxicity.
furthermore, combined treatment with two agents which act extra- 
:eUularly to remove superoxide anions and hydrogen peroxide, 
^peroxide dismutase and catalase, respectively, had no effect 
3n prol i f e r a t i o n  or the a n t i p r o l i f e r a t i v e  a c t i o n s  of P M A  or
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paraquat. The p o s s i b i l i t y  that both PMA and pa r a q u a t  medi a t e 
their actions by the intracellular generation of radicals which 
cannot be removed by exogenous superoxide dismutase and catalase 
vas considered. An earlier study had already indicated that the 
antiproliferative action of paraquat on E. coli was mediated via 
intracellular generation and this was unaffected by superoxide 
dismutase and catalase (Minakami et a l . , 1990). It was found in
PAEC that two lipid soluble agents known to act as intracellular 
radical scavangers, vitamin E and B H T , each had no effect by 
themselves on proliferation or on the antiproliferative action of 
PMA, but both reversed the antiproliferative action of paraquat. 
This demonstrates that the intracellular production of oxygen- 
derived free radicals is responsible for the antiproliferative 
actions of paraquat in PAEC. In contrast, it is unlikely that the 
generation of oxygen- derived free radicals contributes signifi­
cantly to the ability of PMA to inhibit proliferation of PAEC.
3.1.6. Cyclic nucleotides
An interaction between phorbol esters and cyclic nucleotides has 
ceen previously reported. In an interleukin- dependent T cell 
une, age n t s  w h i c h  e l e v a t e  the c e l l u l a r  c y c l i c  A M P  c o n t e n t  
inhibit phorbol 12,13- dibutyrate- induced growth (Goto et a l . , 
*988). Furthermore, PMA- induced contraction of vascular smooth 
muscle in the r a b b i t  ear a r t e r y  is r e v e r s e d  by e l e v a t i o n  of 
:yclic AMP content (Rasmussen et a l . , 1984). However, it was
'Ound that neither of the membrane permeant analogues, dibutyryl 
:yclic AMP and 8 bromo cyclic GMP, had any effect on the ability 
PMA to i n h i b i t  the p r o l i f e r a t i o n  of PAEC. U s i n g  the m o r e  
Ssnsitive index of proliferation, dibutyryl cyclic AMP had no
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effect by itself, and was found to be without effect on the PMA- 
induced i n h i b i t i o n  of [ 3H ] - t h y m i d i n e  i n c o r p o r a t i o n  in t h ese 
cells.
These findings show that neither the production of oxygen- d e ­
rived free radicals nor an interaction with cyclic nucleotides is 
likely to contribute to the antiproliferative actions of PMA on 
PAEC. It is likely that the antiproliferative action of PMA on 
PAEC is mediated by the phosphorylation of unidentified proteins.
8.2. EFFECTS OF CYCLIC NUCLEOTIDES ON CELLULAR PROLIFERATION 
Cyclic nucleotides have been shown to act as intracellular m e s ­
sengers in the regulation of proliferation of a variety of cell 
types (Friedman, 1981). Cyclic AMP has been found to have either 
a growth inhibitory or growth stimulatory action: inhibition of
proliferation was observed with BHK 21/13 hamster cells, HeLa 
cells, human normal fibroblasts, rat thymic- and B- lymphocytes 
(Burk, 1968; Ryan & Heidrick, 1968; MacManus & Whitfield, 1969; 
Hollenburg & Cuatrecasas, 1975 ; Muraguchi et a l . , 1984), whereas 
stimulation of proliferation was observed in mammary epithelial 
cells, hepatocytes and Swiss 3T3 fibroblasts (Yang et a l . , 1980; 
McGowan et a l ., 1981; Rozengurt et a l ., 1983b; O'Neill et a l .,
1985). The effects of cyclic AMP on cellular proliferation are 
therefore strictly dependent on the cell type being examined.
jj_»2.1. Effect of elevated cyclic AMP content on the proliferation 
of_PAEC
This study showed that when cell numbers were counted, the m e m ­
brane p e r m e a n t  analogue of cyclic AMP, d i b u t y r y l  cyclic AMP,
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orofoundly inhibited the proliferation of PAEC in serum- contain­
ing medium du r i n g  an e x t e n d e d  p e r i o d  in culture (8 days). In 
contrast, in shorter experiments (18 hours) where [3H]-thymidine 
incorporation was m e a s u r e d ,  d i b u t y r y l  c y c l i c  A M P  a p p a r e n t l y  
failed to inhibit proliferation. It is possible that this d i s ­
crepancy results from the different incubation periods employed 
in the two experiments .
The finding that dibutyryl cyclic AMP inhibits proliferation is 
in agreement w i t h  Lei t m a n  et al. ( 1986 ) who found a similiar  
inhibition of proliferation on bovine aortic endothelial cells. 
Furthermore, Leitman et al. (1986) demonstrated that the inhibi­
tion of proliferation of bovine aortic endothelial cells did not 
result from a cytotoxic action since treatment with forskolin, 
cyclic AMP PDE inhibitors or dibutyryl cyclic AMP did not in­
crease the release of lactate dehydrogenase.
Slevation of c y c l i c  AMP c o n t e n t  does not, howev e r ,  i n h i b i t  
proliferation of all endothelial cell types. In bovine coronary 
cicrovascular (Meininger & Granger, 1990), foetal bovine aortic 
(Presta et a l . , 1989a) and human dermal microvascular (Davidson & 
forasek, 1981) endothelial cells, elevation of cyclic AMP content 
has been shown to stimulate proliferation.
^2-2. Effect of elevated cyclic GMP content on the proliferation 
of_pAEC
Jnlike for cyclic AMP, the effects of cyclic GMP on cellu l a r  
proliferation are less well documented. It has been reported, 
however, that elevated levels of cyclic GMP inhibit the prolif­
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e ra t io n  of rat glomerular mesangial cells in culture (Johnson et 
al., 1988 ). Furthermore, one previous study found that membrane 
oermeant analogues of cyclic GMP have only a slight inhibitory 
effect on the proliferation of bovine aortic endothelial cells 
(Leitman et a l . , 1986).
Endothelial cells contain both soluble and particulate forms of 
guanylate c y c l a s e  (Brothe r t o n ,  1986; L e i t m a n  & Murad, 1986 ; 
Martin et a l . , 1988b; Schini et al., 1988). In endothelial cells, 
as in other cell types (Arnold et a l ., 1977; K atsuki et a l .,
1977 ), the soluble form of gua n y l a t e  cyclase is a c t i v a t e d  by
nitrovasodilators, such as s odium n i t r o p r u s s i d e  (Brotherton,
1986 ; Schini et a l . , 1988) or glyceryl trinitrate (Martin et a l . , 
1988b) or even by the endothelial cell's own EDRF (Martin et a l . , 
1988b) and the p a r t i c u l a t e  f o r m  can be s t i m u l a t e d  by a t r i a l  
natriuretic factors (Brotherton, 1986; Leitman & Murad, 1986; 
Martin et a l . , 1988b; Schini et a l . , 1988).
h this study it was found that stimulation of soluble guanylate 
nyclase by glyceryl trinitrate, sodium nitroprusside or bradyki- 
tin, which stimulates EDRF production, had no effect on prolif- 
®nation of PAEC in culture. Activation of particulate guanylate 
:yclase by the atrial natriuretic peptide, atriopeptin II also 
nad no effect on the p r o l i f e r a t i o n  of PAEC. Furthermore, the 
^ibrane permeant analogue of cyclic GMP, 8 bromo cyclic GMP, was 
also without effect on proliferation of PAEC. These observations
:nitially suggested that cyclic GMP had no effect on the prolif-
9ration of P A E C .
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:his turned out, however, not to be the case, since haemoglobin 
and methylene blue, two agents known to lower endothelial cell 
cyclic GMP content by inhibiting the ability of spontaneously 
released EDRF to stimulate soluble guanylate cyclase (Martin et 
al., 1985; 1988b), each inhibited the proliferation of PAEC in
serum- containing medium in c u l t u r e .
;n the case of haemoglobin, the inhibition was of the order of 
20 - 40 % and was specific, since it was reversed by the addition 
of agents which elevate intracellular cyclic GMP content i.e. 
sodium nitroprusside, atriopeptin II or the membrane permeant 
analogue, 8 bromo cyclic GMP. The a b i l i t y  of these agents to 
reverse the antiproliferative effect of haemoglobin, but to have 
no stimulating effects in the absence of haemoglobin is difficult 
to explain. One possible explanation is that a certain level of 
cyclic GMP, generated by the endogenous production of EDRF, is 
required to e x e r t  an a l l - o r - n o n e  p e r m i s s i v e  a c t i o n  on cell 
growth. According to this scheme, elevating cyclic GMP content 
further cannot increase the permissive action. Only by reducing 
the cyclic GMP content e.g. by using haemoglobin can the permis­
sive action be inferred. Further work is required, however, to 
test this hypothesis.
to contrast to haemoglobin, the inhibitory effect of methylene 
slue on proliferation was not reversed by sodium nitroprusside, 
toriopeptin II or 8 bromo cyclic GMP. It is likely, therefore, to 
seflect an action unrelated to guanylate cyclase inhibition. It 
:s possible that the antiproliferative action of methylene blue 
3n PAEC is due to its ability to produce oxygen- derived free
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radicals ( M a r s h a l l  et a l . , 1988 ). This e x p l a n a t i o n  w o u l d  be
consistent w i t h  the e a r l i e r  o b s e r v a t i o n s  in this s t u d y  that 
paraquat, an agent known to generate free radicals, p o t e n t l y  
inhibits the proliferation of PAEC.
EDRF is now recognised to be nitric oxide (Palmer et al., 1987), 
and its biosynthetic pathway has been identified. L- arginine is 
the physiological precursor from which EDRF is produced by the 
action of the enzyme, n i t r i c  o x i d e  s y n t h a s e  ( Palmer et al . , 
1988a; Schmidt et a l . , 1988; Rees et a l . , 1989). The L- arginine 
analogue, N G- m o n o m e t h y l  L- a r g i n i n e  (L- N M M A ) i n h i b i t s  the 
synthesis of nitric oxide by inhibiting the enzyme, nitric oxide 
synthase, but its enantiomer, D- N M M A  is c o m p l e t e l y  inactive 
(Rees et a l . , 1989; 1990).
In this study the possibility that EDRF exerts a permissive role 
in controlling proliferation of PAEC was investigated by examin­
ing the actions of L- NMMA on proliferation. It was found, howev­
er, that although L- NMMA did inhibit proliferation of PAEC in 
culture, this property was one shared with the inactive D- iso- 
merf D- NMMA. This would suggest that both L- NMMA and D- NMMA 
exerts their antiproliferative actions on PAEC via a mechanism 
independent of EDRF.
In conclusion, the i n h i b i t o r y  e f f e c t  of h a e m o g l o b i n  and its 
reversal following elevation of cyclic GMP content suggests that 
SDrf exerts a permissive action in regulating the proliferation 
of PAEC in c u l t u r e  t h r o u g h  s t i m u l a t i o n  of s o l u b l e  g u a n y l a t e  
cyclase. It remains to be determined whether or not EDRF exerts
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such a permissive effect on proliferation of endothelial cells 
from all species and vascular sites.
It has been observed that there is reduced release of EDRF by 
aortas from humans and animals in atherosclerosis (Guerra et a l . , 
1989 ). This impaired release of EDRF may augment the development 
of the atherosclerotic lesion by several mechanisms. Firstly, 
EDRF has b e e n  s h o w n  to p o s s e s s  anti- t h r o m b o t i c  p r o p e r t i e s  
(Radomski et a 1 ., 1987a; 1987b; 1987c; H awkins et a l ., 1988;
Sneddon & Vane, 1988). Its loss might, therefore, promote the 
aggregation and adhesion of platelets to the vessel wall. The 
localised release of platelet mitogens, including PDGF, could 
therefore stimulate the migration and proliferation of the under­
lying smooth muscle cells. Secondly, EDRF has been proposed to 
inhibit smooth muscle proliferation (Garg & Hassid, 1989), and so 
reduced production of this agent might lead to enhanced prolifer­
ation. Thirdly, as already discussed, EDRF may play a permissive 
role in c o n t r o l l i n g  e n d o t h e l i a l  cell p r o l i f e r a t i o n .  R e d u c e d  
production of EDRF in atherosclerosis might reduce the rate of 
re- endothelialization of denuded or damaged areas. This would 
permit greater adhesion of platelets to the exposed underlying 
collagen.
jjj-3. Role of PDE isozymes in regulating proliferation of PAEC 
Two p d e isozymes, a cyclic GMP- stimulated PDE (Type II) and a 
^clic AMP -  s p e c i f i c  PDE (Type IV), are f o u n d  in p i g  a o r t i c  
endothelial cells and have been demonstrated to play a role in 
re?ulating the intracellular cyclic AMP and cyclic GMP content 
'Souness et a l . , 1990; this study). The effects of inhibitors of
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these PDE isozymes on cyclic nucleotide content has been d i s ­
cussed earlier (Chapter 7). The effects of these inhibitors were 
examined on the proliferation of PAEC in culture.
It was found that the non- selective PDE inhibitor, dipyridamole, 
which elevates the intracellular cyclic AMP and cyclic GMP con­
tent (this study), i n h i bited the p r o l i f e r a t i o n  of pig aortic 
endothelial cells in s e r u m -  c o n t a i n i n g  medium. H a e m o g l o b i n  
blocked the a b i l i t y  of d i p y r i d a m o l e  to raise the c y c l i c  GMP 
content by blocking the actions of EDRF (Figure 13) but did not 
inhibit the reduction in proliferation. It is likely, therefore, 
that the antiproliferative action of dipyridamole is mediated by 
the increase in i n t r a c e l l u l a r  c o n t e n t  of c y c l i c  A M P  and not 
cyclic GMP. This result is in agreement with an earlier study 
demonstrating that elevation of cyclic AMP content by cyclic AMP 
PDE inhibitors inhibits the proliferation of bovine aortic e n ­
dothelial cells in culture (Leitman et a l ., 1986).
Since dipyridamole inhibits the two PDE isozymes located in PAEC 
it is not possible to conclude if one or both of these enzymes 
has the ability to regulate the cell's growth by controlling the 
cyclic AMP content. To answer this definitely requires the devel­
opment of selective inhibitors of each of the PDE isozymes.
Ill-4. Conclusion
to conclusion, this part of the study shows that pho r b o l  12- 
ayristate 13- acetate (PMA) powerfully inhibits the proliferation 
of Pig aortic endothelial cells in serum- containing medium. This 
totiproiiferative action of PMA was not mediated by the stimulat­
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ed production of oxygen- derived free radicals or an interaction 
with cyclic nucleotides, and is likely to have resulted from PKC- 
stimulated p h o s p h o r y l a t i o n  of as yet u n i d e n t i f i e d  pro t e i n s .  
Furthermore, c y c l i c  AMP was f o u n d  to i n h i b i t  p r o l i f e r a t i o n ,  
whereas cyclic GMP was found to have a permissive role on the 
proliferation of pig aortic endothelial cells.
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9.1. PROLIFERATION OF RAT AORTIC SMOOTH MUSCLE CELLS IN CULTURE
The objectives of this part of the study were to investigate the 
effects of PKC activation by phorbol esters, and of cyclic n u ­
cleotides on the proliferation of rat aortic smooth muscle cells 
in culture.
Smooth m u s c l e  cells located w i t h i n  the blood vessel wall are 
responsible for maintaining the vascular tone via contraction and 
relaxation. These cells upon examination are found to contain 
large amounts of thick and thin myofilaments and are described to 
be in the contractile phenotype (Chamley- Campbell et a l ., 1979). 
As well as maintaining vascular tone, smooth muscle cells play a 
role in wound repair, but abnormal migration and proliferation 
can lead to the development of several vascular diseases, for 
example, atherosclerosis. In this condition, the cells are o b ­
served to undergo a phenotypic transformation: they lose their 
contractile machinery and the ability to contract, and now con­
tain large amounts of rough endoplasmic reticulum, free ribosomes 
and Golgi a p p a r t u s . Furthermore, the cells b ecome capable of 
synthesizing and secreting an extracellular matrix. All of these 
changes prepare the cells for proliferation. This state is d e ­
scribed as the synthetic phenotype (Chamley- Campbell et a l . , 
1979 ) .
Freshly isolated smooth muscle cells are observed to undergo this 
phenotypic transformation after 5 to 6 days in culture before 
they proliferate in response to serum. Cells that have undergone 
tess than five cell d o u blings will return to the c o n t r a c t i l e  
Phenotype upon reaching confluency, but if they have undergone
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more than five, the cells will remain permanently in the synthet­
ic phenotype (Chamley- Campbell et a l ., 1981).
9.1.1. Serum- dependent proliferation of rat ASMC in culture 
Adult smooth muscle cells have been shown to secrete a PDGF- like 
growth factor and possess cell surface receptors to this mitogen 
thus making them responsive to it (Walker et a l . , 1986; Seifert
et a l ., 1984; S j o l a n d  et a l ., 1988). P r o l i f e r a t i o n  of h u m a n
aortic smooth muscle cells has been found to be dependent on the 
presence of PDGF (Fager et a l . , 1988). These cells did not grow
in plasma- derived serum or serum- supplemented medium in the 
presence of an antiserum to PDGF (Fager et al., 1988). Further­
more, PDGF has been observed to be a potent mitogen for bovine 
aortic (Banskota et al., 1989 ) and rat aortic (Tomita et al., 
1987 ; Takagi e t a l . , 1988; Abell et al., 1989; Kihara et a l . ,
1989; M a j a c k  et a l ., 1990) s m o o t h  m u s c l e  cells. P D G F  is no w
regarded as the main m i t o g e n  pres e n t  in serum (Seppa et a l . , 
1982 ) .
Upon examining the effects of serum on proliferation of rat ASMC 
in this study, it was found that proliferation was stimulated in 
a concentration- dependent manner over a period of 11 days. This 
result is in agreement with previous studies where an increase in 
serum concentration produced a corresponding increase in either 
Cell numbers or [3H]-thymidine incorporation in bovine aortic 
(Uonzon et a l . , 1985) and rat aortic (Kihara et a l . , 1989) smooth 
muscle cells. Furthermore, monkey and rat ASMC maintained in the 
absence of serum or in a low concentrations of serum (0.5 - 2%) 
will survive for a p e r i o d  of days but p r o l i f e r a t e  only at a
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greatly reduced rate (Chamley- Campbell et a l . , 1979; Jonzon et
al., 1985; this study). The growth dependence of smooth muscle 
cells on the presence of PDGF is further demonstrated by the fact 
that cultured smooth muscle cells lack the ability to grow in 
plasma- supplemented medium (Ross et a l . , 1974; Fager et a l . ,
1988). This is in contrast to cultured endothelial cells which 
can proliferate equally well in either serum- or plasma- supple­
mented m e d i u m  ( K a z l a u s k a s  & D i C o r l e t o ,  1985). It is l i k e l y  
therefore that serum contains growth factors which are mitogenic 
for rat ASMC in culture. This not only includes PDGF (Tomita et 
al. , 1987; Takagi et a l . , 1988; Abell et a l . , 1989; Majack et
al. , 1990 ), but other p l a t e l e t -  d e r i v e d  m i t o g e n s  such as EGF
(Owen, 1985; Tomita et a l ., 1987; Takagi et al., 1988) and TFG0 
(Majack et a l . , 1990).
9.1.2. Effects of PKC activation on proliferation of rat ASMC 
The mitogenic response to PDGF in rat and rabbit aortic smooth 
muscle cells was r e d u c e d  s i g n i f i c a n t l y  by p r e t r e a t m e n t  w i t h  
either phorbol esters, or a PKC inhibitor, H-7 (Kariya et a l . , 
1987a; Tagaki et a l . , 1988). This suggests that PKC may play a 
regulatory role in the response of smooth muscle cells to PDGF. 
Not all findings are c o n s i s t e n t  wit h  this, however, since no 
reduction in PDGF- induced mitogenesis was observed in rat ASMC 
Pretreated with another PKC inhibitor, polymixin B (Kihara et 
!!•, 1989) .
The role of PKC a c t i v a t i o n  in the p r o l i f e r a t i o n  of vascular 
smooth muscle cells has been further investigated by examining
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the effects of phorbol esters. An inhibition of proliferation has 
been reported for smooth muscle cells obtained from rat aorta 
(Kihara et a l . , 1989 ) and rabbit aorta (Kariya et a l . , 1987b;
Fukumoto et a l ., 1988). In contrast, a stimulation of prolifera­
tion has been o b s e r v e d  for s mooth m u scle cells o b t a i n e d  from 
bovine pulmonary artery and aorta (Dempsey et a l ., 1990; Doctrow 
& Folkman, 1987 ), rat aorta (Owen, 1985 ; Takagi et a l . , 1988), 
and rabbit aortic (Kariya et a l . , 1987a). The ability of PMA to
either stimulate or inhibit the proliferation of rat and rabbit 
ASMC was found to be dependent on the culture conditions employed 
(Owen, 1985; Takagi et a l . , 1988; Kihara et al., 1989; Kawahara 
et a l ., 1988). Inhibition of proliferation was observed when the 
cells were cultured in 10% whole blood serum, whereas, stimula­
tion was observed in serum- free or plasma- derived serum- sup­
plemented medium.
It was found in this study, however, PMA had no effect on proli­
feration of rat ASMC grown in either low or high concentrations 
of serum throughout a twelve day period. At this moment, there 
is no clear explanation why PMA lacked activity on rat ASMC grown 
in conditions that favou r e d  inhibiton of p r o l i f e r a t i o n  (high 
serum concentrations) or stimulation of proliferation (low serum 
concentrations) .
jjl.3. Effects of adrenoceptor activation on proliferation of rat 
ASMC
Circulating' catecholamines have been reported to be a major risk 
factor in the d e v e l o p m e n t  of a t h e r o s c l e r o s i s  in a n i m a l s  and 
humans (Helin et al., 1970; Kones, 1979; Kukreja et a l . , 1981).
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Abnormal migration and proliferation of vascular smooth muscle 
cells are early events occurring during the development of an 
atherosclerotic lesion and catecholamines are known to modulate 
the proliferation of vascular smooth muscle cells through inter­
actions with specific adrenergic receptors.
Blaes & Boissel (1983), Bauch et a l . (1987) and Bell & Madri
(1989) reported that catecholamines had a stimulatory effect on 
smooth m u s c l e  cell p r o l i feration, and that this requi r e d  the 
presence of serum. It has been proposed that adrenoceptor activa­
tion acts synergistically with growth factors present in serum to 
stimulate proliferation of smooth muscle cells (Nakaki et a l . , 
1989). Furthermore, it was reported that noradrenaline, an adre­
noceptor agonist, produced a biphasic effect on proliferation of 
rat aortic smooth muscle cells in 10% serum- containing medium  
(Nakaki et a l ., 1989). These workers proposed that the stimulato­
ry and inhibitory effects of noradrenaline on proliferation were 
mediated through different receptors, with stimulation through 
c^ - and inhibition through P 2- adrenoceptors. Furthermore, it was 
proposed that expression of the adrenergic signal- transduction 
systems depended on cell density and number of cell doublings: in 
smooth m u s c l e  cells seeded at low density, a 1- a d r e n o c e p t o r  
stimulation predominated resulting in stimulation of prolifera­
tion, whereas in cells seeded at a higher density or in cells of 
high passage number, p - adrenoceptor stimulation predominated 
resulting in inhibition of proliferation. These findings may be 
evidence of' the existence of a subtle negative feedback m echa­
nism regu l a t i n g  the growth of smooth mus c l e  cells w i t h i n  the 
S e r i a l  wall.
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c^ - adrenoceptor activation has been demonstrated to stimulate 
the proliferation of several other cells types in culture, in­
cluding 3T3 cells, b o v i n e  a o r t i c  e n d o t h e l i a l  cells and rat 
hepatocytes (Sherline & Mascardo, 1984; Cruise et a l ., 1985). It 
was found in the present study that the a x- adrenoceptor agonist, 
phenylephrine, stimulated the proliferation of rat ASMC in 10% 
serum- supplemented medium. This stimulation was observed to be 
concentration dependent over the range of 0. ImM to ImM and p r o ­
duced a maximum increase in cell numbers of 30 ± 6%. It is known 
that a 1- adrenergic receptor activation induces phosphatidylino- 
sitol h y d r o l y s i s  (Watson & Abbott, 1989). This results in an 
accumulation of two second messengers, diacylglycerol, which is 
the endogenous activator of protein kinase C (Bell, 1986) and 
inositol t r i s p h o s p h a t e , which stimulates the release of stored 
calcium (Putney, 1987; Rana & Hokin, 1990). Calcium influx is 
also stimulated through receptor- operated and voltage operated 
channels (Benham & Tsien, 1987). From the present study, it is 
impossible to state which o n e (s ) of the second messengers are 
involved in the mitogenic response of phenylephrine.
Although the a - adrenoceptor agonist, phenylephrine, stimulated 
proliferation in serum- containing medium the a 2- adrenoceptor 
agonist, clonidine had no such effect. It is likely, therefore, 
that the action of phenyephrine found in this study did indeed 
result from activation of a 1- adrenceptors.
in this study, it was found that the non- selective p- adrenocep­
tor agonist, isoprenaline, was without effect on the prolifera­
tion of rat ASMC whereas the selective p :- and p 2- adrenoceptor
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agonists, dobutamine and salbutamol, respectively, both inhibited 
proliferation. Nakaki et a l . (1989) found, however, that isopren- 
aline was more potent than dobutamine and salbutamol. A possible 
explaination for the difference in effects of isoprenaline b e ­
tween this study and that of Nakaki et a l . (1989) may be related
to the e x p e r i m e n t a l  p r o t o c o l  emp l o y e d .  N a k a k i  et a l . (1989)
examined the effect of isoprenaline on rat ASMC in serum- free 
medium by measuring [3H]-thymidine incorporation over a 24 hour 
incubation period. In the present study, the effect of isoprena­
line was examined over a period of 4 days by counting cell num­
bers grown in serum- supplemented medium. It is possible that 
within this time the inhibitory effect of isoprenaline had been 
masked by the growth stimulatory action of serum. Alternatively, 
the lack of effect of isoprenaline could have reflected its short 
half- life. Nevertheless, both studies agree that p 2- adrenocep­
tor stimulation inhibits the proliferation of rat ASMC in c u l ­
ture .
It is known that p- adrenoceptor activation leads to stimulation 
of adenylate cyclase and increases in cellular cyclic AMP content 
(Watson & Abbott, 1989). It is likely therefore that dobutamine 
and salbutamol inhibited proliferation of rat ASMC by elevating 
cyclic AMP content. Further evidence that cyclic AMP inhibits the 
Proliferation of vascular smooth muscle cells is suggested by the 
effects of adenosine and prostaglandins.
Wenosine and certain of its analogues acting via A 1 or A 2 recep- 
tQrs have been shown to have a dualistic effect on the prolifera- 
lion of rat aortic smooth muscle cells (Jonzon et a l . , 1985). It
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was p r o p o s e d  that the s t i m u l a t o r y  and i n h i b i t o r y  e f f e c t s  of 
adenosine and its a n a l o g u e s  w e r e  m e d i a t e d  t h r o u g h  d i f f e r e n t  
receptors, with stimulation through A x~ and inhibition through 
I- receptors, respectively (Jonzon et a l . , 1985). A 2- receptor
activation is known to involve activation of adenylate cyclase 
and elevation of cyclic AMP content (Watson & Abbott, 1989), 
whereas A :- r e c e p t o r  a c t i v a t i o n  i n h i b i t s  the s t i m u l a t i o n  of 
adenylate cyclase (Watson & Abbott, 1989). It is possible that 
adenosine, which is present in plasma following metabolism of ATP 
by many cell types (Gordon, 1986), could prevent proliferation of 
smooth muscle cells in the arterial wall by activation of A 2- 
receptors, and therefore prevent or inhibit the development of 
atherosclerosis .
Furthermore, several prostaglandins (PGEi; P G D 2 and P G I 2) have 
been shown to inhibit serum- induced DNA synthesis in smooth 
muscle cells obtained from rat aorta (Nilsson & Olsson, 1984) and 
human aorta (Tertov et a l . , 1984). This inhibitory effect may be 
related to the ability of prostaglandins to elevate cyclic AMP 
content (Nilsson & Olsson, 1984). p- adrenoceptor agonists might 
also hav e  p o t e n t i a l  a n t i -  a t h e r o s c l e r o t i c  a c t i o n s  t h r o u g h  
inhibition of smooth muscle proliferation.
jj. EFFECTS OF CYCLIC NUCLEOTIDES ON PROLIFERATION OF RAT ASMC 
9j.l. Effects of cyclic AMP on proliferation of rat ASMC 
in keeping with the concept of an inhibitory effect of cyclic 
AMP, it was found in the present study that the membrane permeant 
analogue of this cyclic nucleotide, dibuytryl cyclic AMP, and the 
stimulator of adenylate cyclase, forskolin (Seaman & Daly, 1981),
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both profoundly inhibited the proliferation of rat ASMC in serum- 
containing medium. The inhibitions of proliferation induced by 
dibutyryl cyclic AMP or forskolin were observed to be concentra­
tion- dependent. These results are in a g r e ement wit h  several 
studies demonstrating that membrane permeant analogues of cyclic 
AMP, or forskolin or cyclic AMP PDE blockers inhibit the prolif­
eration of rat brain microvascular (Kempski et a l ., 1987), rabbit 
aortic (Fukumoto et a l . , 1988) and human aortic (Tertov et a l . , 
1984) smooth muscle cells in culture. The antiproliferative ac­
tions of dibutyryl cyclic AMP and forskolin in this study were 
found not to result from a cytotoxic effect as assessed by the 
vital stain, trypan blue. Furthermore, the antiproliferative 
action of forskolin was clearly due to activation of adenylate 
cyclase since the inactive forskolin analogue, dideoxy forskolin 
and the solvent, DMSO, both lacked the antiproliferative action 
of forskolin.
To further examine if the forskolin- induced inhibiton of prolif­
eration was m e d i a t e d  via an e l e v a t i o n  of ce l l u l a r  cyclic AMP 
content, the effects of two PDE inhibitors were examined. Smooth 
muscle cells f r o m  rat, b o v i n e  and h u m a n  a o r t a s  are k n o w n  to 
contain three PDE activities, two cyclic GMP PDEs (one continu­
ously active [Type V ] , the other stimulated in the presence of 
calmodulin and calcium [Type I]), and a cyclic AMP- specific PDE 
(Type IV)(Lugnier et al., 1986; Schoeffter et a l ., 1987). Inhibi­
tion of the cyclic GMP PDE isozymes by M & B 22948 and of the 
cyclic AMP PDE by rolipram has been previously shown to result in 
increases in smooth muscle cell cyclic GMP and cyclic AMP c o n ­
tent , r e s p e c t i v e l y  (Lugnier et a l . , 1986; S c h o e f f t e r  et a l . ,
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1987 )
In this study, the selective cyclic AMP PDE inhibitor, rolipram, 
was f o und to i n h i b i t  p r o l i f e r a t i o n  of rat A S M C  by itself in 
serum- containing medium and to potentiate the forskolin- induced 
inhibition of proliferation. This strengthens the concept that 
forskolin mediates its antiproliferative actions via an elevation 
of intracellular cyclic AMP content. Furthermore, M & B 22948, 
the selective cyclic GMP PDE inhibitor, was found to inhibit the 
proliferation of rat ASMC by itself in serum- containing medium. 
Whether this inhibition of proliferation resulted from an accumu­
lation of c y c l i c  GMP is not clear. H o w e v e r ,  in two s e p e r a t e  
experiments M & B 22948 was observed to reverse the antiprolifer­
ative actions of forskolin on rat ASMC. There is no clear expla­
nation for this action at the present time.
Histamine, an important mediator of inflammation (Killackey et 
al., 1986; M o v a t , 1987 ) is primarily secreted from mast cells,
basophils and the platelets of certain species, and possibly from 
endothelial cells (Riley & West, 1966; G r a h a m  et al . , 1955;
Saxena et a l . , 1989). Histamine is known to produce relaxation of 
smooth muscle through H 2- receptor- linked activation of adeny­
late cyclase and resultant increases in intracellular cyclic AMP 
intent (reviewed by Hill, 1990). The possibility that histamine 
well as possessing vasodilator activity might have a role in 
tissue gr o w t h  and repair has been reported. Support for this 
suggest ion c omes f r o m  s e v e r a l  s t u d i e s  w h e r e  the a c t i v i t y  of 
bistidine decarboxylase, the enzyme which synthesizes histamine 
‘rom histadine, was elevated in a number of rapidly proliferating
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tissues (Ishikawa et a l ., 1970; Watenabe et a l ., 1981; Barthol- 
eyns & Fozard, 1985). Furthermore, histamine has been reported 
to stimulate the proliferation of human microvascular endothelium 
(Marks et a l . , 1986) and bovine aortic endothelium (Bell & Madri,
1989). The growth stimulatory effect was mediated via H x- recep­
tors as the H 3~ antagonist, c l e m a s t i n e  fumarate, s e l e c t i v e l y  
blocked this mitogenic response (Marks et a l ., 1986).
In the present study, it was found that histamine inhibited the 
proliferation of rat A S M C  in s e r u m -  c o n t a i n i n g  m edium. This 
antiproliferative action of histamine was observed to be concen­
tration- dependent and appeared due to activation of H 2- recep­
tors since it was blocked by the H 2~ antagonist, cimetidine. It 
is therefore possible that histamine (secreted by mast cells, 
basophils, platelets or endothelial cells) could play a role in 
inhibiting the proliferation of smooth muscle cells in the arte­
rial wall thus preventing the development of atherosclerosis.
In summary, it is likely that the inhibiton of proliferation of 
rat ASMC produced by forskolin, cyclic AMP PDE inhibitors, hista­
mine and p- a d r e n o c e p t o r  agoni s t s  resulted from e l e v a t i o n  of 
cyclic AMP c o n t e n t .
jj2.2. Effects of cyclic GMP on proliferation of rat ASMC 
Recent evidence has been accumulating that cyclic GMP acts as the 
intracellular mediator generated by several vasodilators. These 
include EDRF, recently identified as nitric oxide (Palmer et a l .,
1987), atrial natriuretic peptides and the n i t r o v a s o d i l a t o r s , 
stch as sodium nitroprusside and glyceryl trinitrate (Rapoport &
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Murad, 1983; L i n c o l n  & F i s h e r -  Simpson, 1984; G r a c e  et a l .,
1988). As discussed earlier, histamine (this study), adenosine 
(Jonzon et a l . , 1985 ), p- a d r e n o c e p t o r  agonists (this study;
Nakaki et a l ., 1989) and prostaglandins (Nilsson & Olssen, 1984; 
Tertov et a l . , 1984) possess not only vasodilator properties,
but have also been shown to inhibit the proliferation of smooth 
muscle cells in culture by elevating the intracellular cyclic AMP 
content. By analogy, therefore, it was possible that agents which 
relaxed vascular smooth muscle by elevating cyclic GMP content 
might also be able to inhibit the p r o l i f e r a t i o n  of v a s c u l a r  
smooth muscle cells.
It was found in the pres e n t  s t udy that a t r i o p e p t i n  II, w h i c h  
activates particulate guanylate cyclase (Leitman & Murad, 1986), 
had no effect on the proliferation of rat ASMC in serum- contain­
ing medium. This is in contrast to earlier studies indicating 
that atrial natriuretic factor inhibits the proliferation of rat 
and ra b b i t  A S M C  i n d u c e d  by e i t h e r  P D G F  or w h o l e  b l o o d  s e r u m  
(Abell et a l ., 1989; Kariya et a l ., 1989). The d i f f e r e n c e  in
results may be related to the experimental procedure used. In the 
studies of Abell et al. (1989) and Kariya et a l . (1989), [3H ]—
thymidine incorporation after 24 hours was used as the index of 
proliferation. In this study, however, cell numbers throughout a 
8 day period were counted with 48 hours as the first time point 
examined. It is p o s s i b l e  that w i t h i n  the 48 hours the g rowth 
inhibitory effects of AP II had been m a s k e d  by the m i t o g e n i c  
actions of serum.
Nitrovasosdilators stimulate soluble guanylate cyclase through
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production of nitric oxide (Arnold et al., 1977; Katsuki et a l ., 
1977; Craven & De Rubertis, 1978). In this study, the two nitro- 
vasodilators, glyceryl trinitrate and sodium nitroprusside were 
each found to inhibit the proliferation of rat ASMC in serum- 
containing medium. The i n h i b i t o r y  effect of these agents was 
observed only at high concentrations i.e. ImM for glyceryl trini­
trate and 0.1 - ImM for sodium nitroprusside. These concentra­
tions are 100-1000 times greater than those required for relaxa­
tion of vascular smooth muscle (Lincoln & Fisher-Simpson, 1984;
Martin et a l . , 1986b; Grace et al., 1988). The antiproliferative 
effect of sodium nitroprusside and glyceryl trinitrate, t h e r e ­
fore, may be unrelated to the ability of these agents to elevate 
cyclic GMP c o n t e n t .
The effector molecule generated from the nitrovasodilators is 
nitric oxide (Arnold et al., 1977 ; Katsuki et a l . , 1977: Craven & 
De Rubertis, 1978). Nitrovasodilators can mimic therefore the 
actions of endogenously produced EDRF, which has been identified 
as nitric oxide (Palmer et al., 1987). It had been previously 
shown t h a t  s e v e r a l  n i t r o v a s o d i l a t o r s  i n c l u d i n g  s o d i u m  
nitroprusside, S- nitroso- N- acetylpenicillamine and isosorbide 
dinitrate, inhibited the proliferation of rat and rabbit aortic 
smooth muscle cells in culture (Garg & Hassid, 1989; Kariya et 
si., 1989). On the basis of the actions of nitrovasodilators it 
was suggested by Garg & Hassid (1989) that EDRF released from 
sndothelial cells may act as an endogenous regulator of smooth 
Muscle cell growth within the arterial wall.
 ^ recent s t u d y  d e m o n s t r a t e d  t h a t  s m o o t h  m u s c l e  c e l l s  of
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endothelium- d e n u d e d  rings of bovine i n t r a p u l m o n a r y  arterial 
produce low but measurable quantities of a labile relaxing factor 
possessing pharmacological and chemical properties similiar to 
those of EDRF (Wood et a l ., 1990). On the scheme of Garg & Hassid 
(1989), it was possible that this smooth muscle- derived EDRF 
also had a regulatory role in controlling proliferation of smooth 
muscle cells w i t h i n  the a r t e r i a l  wall. In k e e p i n g  w i t h  this 
hypothesis, it was found in the present study that N G- nitro L- 
arginine, a competitive inhibitor of nitric oxide synthase, the 
enzyme that forms nitric oxide from L- arginine, stimulated the 
proliferation of rat A S M C  by 17 ± 4% in se r u m -  c o n t a i n i n g  
medium. The stimulation is more likely to have resulted from a 
non- s e l e ctive action, however, since as will be seen later, 
haemoglobin, which inhibits the action of nitric oxide, did not 
share this property.
Recently, a t h i r d  p o t e n t i a l  s o u r c e  of n i t r i c  o x i d e  has b e e n  
identified that could regulate smooth muscle proliferation in the 
arterial wall. It has been demonstrated that macrophages have the 
ability to generate nitric oxide from the terminal guanidino 
nitrogen atom(s) of L- arginine (Hibbs et a l ., 1987b; Stuehr et 
al. , 1989; Kwon et a l . , 1990; Tayeh & Marietta, 1990). M a c r o ­
phages secrete much higher quantities of nitric oxide than en- 
dothel ial cells, and such quantities are clearly cytotoxic for 
foany cell types (Hibbs et a l ., 1987a; D r a p i e r  & Hibbs, 1988; 
KrOncke et a l . , 1991). It is possible, therefore, that nitric 
oxide inhibits the proliferation of smooth muscle cells not by 
Simulating soluble guanylate cyclase, but by a cytotoxic action, 
^is is supported by the observation made in the present study
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that s o d i u m  n i t r o p r u s s i d e  i n d u c e d  a c c u m u l a t i o n  of the v i tal  
stain, trypan blue, in the same concentration range over which it 
inhibited proliferation: at the highest concentration examined
i.e. ImM almost all the smooth muscle cells accumulated trypan 
blue. In sharp contrast to the present study Garg & Hassid (1989) 
reported that the antiproliferative actions of the nitrovasodila­
tors on rat ASMC were not due to cytotoxicity assessed by release 
of l a c t a t e  d e h y d r o g e n a s e ,  s t a i n i n g  w i t h  t r y p a n  blu e  or cell 
detachment. These work e r s  a s s e s s e d  c y t o t o x i c i t y  only after a 
short incubation time (20 hours) whereas in the present study the 
cytotoxic effects were evident after 24 hours.
A p o s s i b l e  e x p l a n a t i o n  for the c y t o t o x i c  a c t i o n s  of s o d i u m  
nitroprusside is that one of its d e g r a d a t i o n  p r o d u c t s  is the 
metabolic poison, cyanide. This a p p e a r e d  not to be the case, 
however, since in this study, it was found that the addition of 
methae m o g l o b i n , w h i c h  binds cyanide (Stadie, 1920; Drab k i n  & 
Austin, 1935) did not reverse the antiproliferative action of 
sodium nitroprusside.
Haemoglobin has been shown to bind nitric oxide avidly (Martin et 
al. , 1985). However, in this study, the antiproliferative action 
of sodium nitroprusside was not reversed by haemoglobin at con­
centrations up to 20pM. Garg & Hassid (1989), however, showed 
that at 50pM, inhibition was reversed. It is likely that a high 
concentration of h a e m o g l o b i n  was r e q u i r e d  to b i n d  the large 
quantities’of nitric oxide generated by the high concentration of 
sodium nitroprusside. Furthermore, the a b i l i t y  of s u p e roxide 
dismutase to potentiate the actions of the nitrovasodilator in
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inhibiting proliferation of smooth muscle (Garg & Hassid, 1989) 
is consistent with inhibition being mediated by nitric oxide. 
Superoxide anions have previously been shown to destroy nitric 
oxide ( G r y g l e w s k i  et a l ., 1986; R u b a n y i  & V a n h o u t t e ,  1986a;
1986b) .
Although it is likely that nitric oxide is responsible for the 
nitrovasodilator- induced inhibition of smooth muscle prolifera­
tion, it is not clear if stimulation of soluble guanylate cyclase 
is involved. In the present study, 8 bromo cyclic GMP at a high 
concentration of ImM did inhibit proliferation of rat ASMC wit h ­
out increasing uptake of trypan blue , thus confirming a previous 
report on rabbit ASMC (Kariya et al., 1989) It is not certain, 
however, if the inhibiton was m e d i a t e d  by cyclic GMP p r o t e i n  
kinase, or a non- specific action.
Other e v i d e n c e  s u g g e s t i n g  that sodium n i t r o p r u s s i d e  inhibits 
proliferation by a cyclic GMP- independent mechanism is that the 
cyclic GMP PDE inhibitor, M & B 22948, did not potentiate the 
action of sodium nitroprusside. A recent study reported that the 
antiproliferative action of several nitrovasodilators, including 
sodium nitroprusside in Balb/ c3T3 fibroblasts is mediated by a 
cyclic GMP- independent m e c hanism (Garg & Hassid, 1990). These 
cells are known to lack soluble guanylate cyclase. Furthermore, 
citric oxide has recently been shown to induce several cyclic 
GMP- independent responses, including decreased cytosolic free 
calcium in Balb c/3T3 cells (Garg & Hassid, 1991) and ADP- ri- 
kosylation of a 39 kDa protein in platelets (Briine & Lapetina,
1989). These effects suggest the exi s t e n c e  of an a l t e r n a t i v e
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signalling transduction pathway for nitric oxide. In the study of 
Garg & Hassid (1990), the antiproliferative action of the nitro­
vasodilators appeared not to be due to cytotoxicity as assessed 
by release of lactate dehydrogenase, staining with trypan blue or 
cell detachment. These workers assessed cytotoxicity after 24 
hours, but after 4 days treatment with the nitrovasodilator, S- 
nitroso- N- acetylpenicillamine, increased cell detachment was, 
clearly e v i d e n t .
It is possible, therefore, that high concentrations of nitric 
oxide can inhibit p r o l i f e r a t i o n  by a cyclic GMP- independent 
transduction m e c h a n i s m ,  bu t  the m a r g i n  for s a f e t y  b e f o r e  
cytotoxicity is seen is very small. It is unlikely, therefore, 
that EDRF acts as an endogenous regulator of smooth muscle cell 
growth in the arterial wall.
9.2.3. Conclusion
In conclusion, this part of the study shows that activation of 
protein kinase C by phorbol esters has no effect on the prolifer­
ation of rat aortic smooth muscle cells in culture. Furthermore, 
elevation of cyclic AMP content inhibits the proliferation of 
these cells w i t h o u t  evide n c e  of cytotoxicity. The effects of 
elevating cyclic GMP were less clear. 8 bromo cyclic GMP does 
inhibit smooth muscle proliferation at high concentrations but 
the inhibition of proliferation induced by sodium nitroprusside 
was p r o b a b l y  m e d i a t e d  by a cyclic GMP- in d e p e n d e n t  c y t otoxic
a c t i o n .
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Appendix I. Purification of Endothelial Cell PDEs
PAEC (100- 150 million) grown in 250 ml culture flasks (Nunclon) 
were washed three times with ice- cold phosphate- buffered saline 
b e f o r e  b e i n g  s c r a p p e d  f r o m  the s u r f a c e  an d  r e m o v e d  to a 
centrifuge tube (50 ml). The cells were then centrifuged at 2000 
g for 5 minutes and, after the phosphate- buffered saline had 
been removed, the pellet was stored at - 7 0 °C until required.
The cell pellet was homogenized in 6 vol. of Tris/ HCl 20 mM, pH 
7.5 containing magnesium acetate 2 mM, dithiothreitol 1 mM, EDTA' 
5 mM and aprotinin (2000 units/ ml) with a Dounce h o m o g e n i z e r .; 
The homogenate was then centrifuged at 105000 g for 60 m i n u t e s 5 
and the supernatant (20 ml) applied to a DEAE- Trisacryl column 
(7 cm X 0.9 cm) pre- equilibrated with column buffer (Tris/ HCl 
20 mM, magnesium acetate 2 mM, dithiothreitol 1 mM, N a- tosyl- L- 
lysychloromethane hydrochloride 20pM, pH 7.5). The column was 
washed with two successive linear gradients of NaCl (0- 150 mM in 
80 ml and 150- 400 mM in 70 ml) in column buffer; 2 ml fractions 
were collected, assayed, and for short term storage at -20°C, 
ethylene glycol was added to a final concentration of 30% (v/v). 
Assays on the pooled peak fractions were performed within 48 hr 
after homogenization of the c e l l s .
Appendix II. Measurement of PDE Activity
PDE activity was determined by the two- step radioisotope method
p r e v i o u s l y  d e s c r i b e d  by T h o m p s o n  et al . ( 1979 ). The reaction
m i x t u r e  c o n t a i n e d  T r i s /  HCl 20 mM, pH 8.0, M g C l 2 10 mM, 2- 
mercaptoethanol 4 mM and bovine serum albumin 0.05 mg/ ml. The 
concentration of substrate (cyclic [3H] AMP or cyclic [3H] GMP) 
was lpM.
IC 50 v a l u e s  ( c o n c e n t r a t i o n  w h i c h  p r o d u c e d  50% i n h i b i t i o n  of 
substrate hydrolysis) for the compounds examined were determined 
from c o n c e n t r a t i o n -  response curves, in w h i c h  concen t r a t i o n s  
ranged from 0 . lpM to 1 m M . Three concentration responses were
generated for each inhibitor examined.
